Pipeline Watchlist

Company Pipelines

Recent additions

14 days
CYBN
Cybin Inc.

HLP003

Mental health / Phase 3 / Adjunctive treatment of Major Depressive Disorder (MDD)

helus.com
CVAC
CureVac N.V.

UPEC FimH ferritin nanoparticle mRNA vaccine candidate

Infectious disease / Preclinical / urinary tract infections caused by uropathogenic E. coli

curevac.com
CVAC
CureVac N.V.

COVID-19/influenza combination mRNA vaccine candidate

Infectious disease / Phase 1/2 / COVID-19 and influenza

curevac.com
CVAC
CureVac N.V.

sqNSCLC shared-antigen cancer precision immunotherapy candidate

Oncology / IND/CTA filed / squamous non-small cell lung cancer

curevac.com

Companies

Novartis AG

novartis.com
62assets
  • LutatheraAAA601 / Lutathera / SSTR / Radioligand therapy / Oncology: Solid Tumors
    Gastroenteropancreatic neuroendocrine tumorsPhase 3Supplementary; filing 2028GEPNET, pediatricsPhase 2
  • 177Lu-NeoBAAA603 / GRPR / Radioligand therapy / Oncology: Solid Tumors
    Breast cancerPhase 1Multiple solid tumorsPhase 2Lead; filing >= 2029
  • AAA614FAP / Radioligand therapy / Oncology: Solid Tumors
    Solid tumorsPhase 2Lead
  • PluvictoAAA617 / Pluvicto / PSMA / Radioligand therapy / Oncology: Solid Tumors
    Oligometastatic prostate cancerPhase 3Supplementary; filing >= 2029Metastatic hormone sensitive prostate cancer (mHSPC)RegistrationSupplementary
  • 225Ac-PSMA-617AAA817 / PSMA / Radioligand therapy / Oncology: Solid Tumors
    Metastatic castration-resistant prostate cancer (mCRPC)Phase 3Supplementary; filing >= 2029post Lu Metastatic castration-resistant prostate cancer (mCRPC)Phase 3Lead; filing 2028
  • ScemblixABL001 / Scemblix / BCR-ABL / Inhibitor / Oncology: Hematology
    Chronic myeloid leukemia, pediatricsPhase 2Supplementary; filing 2027
  • CosentyxAIN457 / Cosentyx / IL17A / Inhibitor / Immunology
    Polymyalgia rheumaticaRegistrationSupplementary; filing 2026
  • AimovigAMG334 / Aimovig / CGRPR / Antagonist / In-market Brands and Global Health
    Migraine, pediatricsPhase 3Supplementary; filing 2028
  • AMO959DNA PK / Inhibitor / Oncology: Solid Tumors
    Prostate cancerPhase 1Lead
  • MayzentBAF312 / Mayzent / S1P1,5 receptor modulator / Neuroscience
    Multiple sclerosis, pediatricsPhase 3Supplementary; filing 2027
  • VijoyceBYL719 / Vijoyce / PI3K-alpha / Inhibitor / Oncology: Solid Tumors
    Lymphatic malformationsPhase 3Supplementary; filing >= 2029
  • farabursenCYX082 / MIR17 / Inhibitor / Cardiovascular, Renal and Metabolic
    Autosomal dominant polycystic kidney diseasePhase 1Lead
  • pelabresibDAK539 / BET / Inhibitor / Oncology: Hematology
    MyelofibrosisPhase 3Lead; filing 2026
  • DFT383CTNS gene delivery / Neuroscience
    CystinosisPhase 1Lead
  • DII235siRNA targeting Lp(a) MRNA / Cardiovascular, Renal and Metabolic
    CVRR-Lp(a)Phase 2Lead; filing >= 2029
  • del-braxDWH213 / siRNA DUX4 knockdown / Neuroscience
    Facioscapulohumeral muscular dystrophyPhase 3Lead; filing 2028
  • tulmimetostatDZR123 / EZH1, EZH2 / Inhibitor / Oncology: Solid Tumors
    Metastatic prostate cancerPhase 1Solid tumors & lymphomasPhase 2Lead
  • ECI830CDK2 / Inhibitor / Oncology: Solid Tumors
    Breast cancerPhase 1Lead
  • EDI048CpPI(4)K / Inhibitor / In-market Brands and Global Health
    CryptosporidiosisPhase 2Lead
  • EDK060Lead Indication / Neuroscience
    Charcot-Marie-Tooth diseasePhase 1
  • ESP359DLL3 / Radioligand therapy / Oncology: Solid Tumors
    Solid tumorsPhase 1Lead
  • del-desiranEWF980 / siRNA DMPK knockdown / Neuroscience
    Myotonic dystrophy type 1Phase 3Lead; filing 2027
  • EYU688NS4B / Inhibitor / In-market Brands and Global Health
    Dengue feverPhase 2Lead
  • zigakibartFUB523 / Anti-APRIL / Cardiovascular, Renal and Metabolic
    IgA nephropathyPhase 3Lead; filing 2027
  • 177Lu-NNS309FXX489 / FAP / Radioligand therapy / Oncology: Solid Tumors
    Solid tumorsPhase 1Lead
  • GCJ904Lead Indication / Oncology: Solid Tumors
    Solid tumorsPhase 1
  • GHZ339Lead Indication / Immunology
    Atopic dermatitisPhase 2filing >= 2029
  • GIA632IL-15 mAb / Immunology
    Atopic dermatitisPhase 2Lead; filing >= 2029VitiligoPhase 2Supplementary; filing >= 2029
  • GXV813M4 / Agonist / Neuroscience
    SchizophreniaPhase 2Lead
  • HJB647Lead Indication / Cardiovascular, Renal and Metabolic
    Heart failurePhase 1
  • votoplamHTT227 / Huntingtin modulator / Neuroscience
    Huntington’s diseasePhase 3Lead; filing >= 2029
  • INE963Plasmodium falciparum / Inhibitor / In-market Brands and Global Health
    MalariaPhase 2Lead
  • IPX643Lead Indication / Immunology
    Inflammation-driven diseasesPhase 1
  • ITU512HbF inducing agent / In-market Brands and Global Health
    Sickle cell diseasePhase 1Lead
  • luxdegalutamideJSB462 / Androgen receptor protein degrader / Oncology: Solid Tumors
    Metastatic hormonal sensitive prostate cancerPhase 2Metastatic castration resistant prostate cancerPhase 2Lead; filing >= 2029
  • cipargaminKAE609 / PfATP4 / Inhibitor / In-market Brands and Global Health
    Malaria, uncomplicatedPhase 2Supplementary; filing >= 2029Malaria severePhase 2Lead; filing >= 2029
  • LeqvioKJX839 / Leqvio / siRNA (regulation of LDL-C) / Cardiovascular, Renal and Metabolic
    CVRR (primary prevention)Phase 3Supplementary; filing >= 2029CVRR (secondary prevention)Phase 3Supplementary; filing 2027
  • Ganaplacide + lumefantrineKLU156 / Non-artemisinin plasmodium falciparum / Inhibitor / In-market Brands and Global Health
    Malaria, uncomplicatedPhase 3Lead; filing 2026
  • del-zotaKPE179 / PMO mediated exon 44 skipping / Neuroscience
    Duchenne muscular dystrophyPhase 2Lead; filing 2026
  • FabhaltaLNP023 / Fabhalta / CFB / Inhibitor / Neuroscience / Cardiovascular, Renal and Metabolic / Oncology: Hematology / Others
    Generalized myasthenia gravisPhase 3Supplementary; filing 2027C3 glomerulopathy, pediatricsPhase 3IgAN, pediatricsPhase 3
  • RhapsidoLOU064 / Rhapsido / BTK / Inhibitor / Immunology
    Chronic spontaneous urticaria, pediatricsPhase 3Hidradenitis suppurativaPhase 3Supplementary; filing 2027Chronic inducible urticaria (CINDU)Phase 3Supplementary; filing 2026
  • remibrutinibLOU064 / BTK / Inhibitor / Neuroscience
    Multiple sclerosis, secondary progressivePhase 3Supplementary; filing >= 2029Myasthenia gravisPhase 3Supplementary; filing 2028Multiple sclerosis, relapsing remittingPhase 3Supplementary; filing 2027
  • LTP001SMURF1 / Inhibitor / Cardiovascular, Renal and Metabolic
    Idiopathic pulmonary fibrosisPhase 2Pulmonary arterial hypertensionPhase 2Lead; filing >= 2029
  • LXE408Proteasome / Inhibitor / In-market Brands and Global Health
    ChagasPhase 2Visceral leishmaniosisPhase 2Lead; filing >= 2029
  • abelacimabMAA868 / FXI / Inhibitor / Cardiovascular, Renal and Metabolic
    Atrial fibrillationPhase 3Lead; filing 2028
  • MAS825IL18 Inhibitor, IL1B / Immunology
    Still’s diseasePhase 2Lead
  • NIO752Tau antisense oligonucleotide / Neuroscience
    Alzheimer’s diseasePhase 1Progressive supranuclear palsyPhase 1Lead
  • OJR520Lead Indication / Cardiovascular, Renal and Metabolic
    CKDPhase 1
  • KesimptaOMB157 / Kesimpta / CD20 / Antagonist / Neuroscience
    Multiple sclerosis, new dosing regimenPhase 3Supplementary; filing 2027Multiple sclerosis, pediatricsPhase 3Supplementary; filing 2026
  • PAC001Anti-IL-6 mAb / Cardiovascular, Renal and Metabolic / Others
    ASCVD pacibekitugPhase 2Lead; filing >= 2029Thyroid eye disease (TED) pacibekitugPhase 2
  • PIT565Anti-CD19, Anti-CD2, Anti-CD3 / Immunology
    Systemic lupus erythematosusPhase 1Rheumatoid arthritisPhase 1
  • RydaptPKC412 / Rydapt / Multi-targeted kinase / Inhibitor / In-market Brands and Global Health
    Acute myeloid leukemia, pediatricsPhase 2Supplementary; filing 2027
  • PKN605HDAC6 / Inhibitor / Cardiovascular, Renal and Metabolic
    Atrial FibrillationPhase 2Lead
  • QCZ484Lead Indication / Cardiovascular, Renal and Metabolic
    HypertensionPhase 2filing >= 2029
  • AtecturaQMF149 / Atectura / LABA + ICS / In-market Brands and Global Health
    Asthma, pediatricsPhase 3Supplementary; filing >= 2029
  • AdakveoSEG101 / Adakveo / P-selectin / Inhibitor / In-market Brands and Global Health
    Sickle cell disease, pediatricsPhase 3Supplementary; filing >= 2029
  • TIN816ATP modulator / Cardiovascular, Renal and Metabolic
    Acute kidney injuryPhase 2Lead
  • pelacarsenTQJ230 / ASO targeting Lp(a) / Cardiovascular, Renal and Metabolic
    CVRR (secondary prevention) in patients with elevated Lp(a)Phase 3Lead; filing 2026
  • ianalumabVAY736 / BAFF-R inhibitor, ADCC-mediated B-cell depletor / Immunology / Oncology: Hematology
    Lupus NephritisPhase 3Supplementary; filing 2028Systemic lupus erythematosus (SLE)Phase 3Supplementary; filing 2028Systemic sclerosisPhase 2Supplementary; filing 2028
  • VHB937TREM2 stabilizer and activator / Neuroscience
    Amyotrophic lateral sclerosisPhase 2Lead; filing >= 2029Alzheimer's diseasePhase 2Supplementary; filing >= 2029
  • YMI024Lead Indication / Cardiovascular, Renal and Metabolic
    CVRRPhase 1
  • rapcabtagene autoleucelYTB323 / CD19 CAR-T / Immunology / Neuroscience / Oncology: Hematology
    Rheumatoid arthritis and severe, refractory Sjögren’s diseasePhase 1Systemic sclerosisPhase 2Supplementary; filing >= 2029MyositisPhase 2Supplementary; filing >= 2029

AbbVie

abbvie.com
37assets
  • ABBV-8736ABBV-8736 / TREM1 / Biologic / Immunology
    Crohn's DiseasePhase 2
  • TavapadonD1/D5 partial agonist / Small molecule / Neuroscience
    Parkinson's DiseaseSubmitted
  • ABBV-525ABBV-525 / MALT1 / Small molecule / Oncology
    Hematologic TumorsPhase 1
  • Telisotuzumab vedotinABBV-399 / EMRELIS / c-Met / Antibody-drug conjugate / Oncology
    Non-Small Cell Lung CancerApprovedUS
  • EpcoritamabGen3013 / EPKINLY/TEPKINLY / CD3, CD20 / Bispecific antibody / Oncology
    Relapsed/Refractory DLBCLApprovedUSEURelapsed/Refractory Follicular LymphomaApprovedRelapsed/Refractory CLLPhase 2
  • ABBV-466 (Skyrizi + ABBV-382)ABBV-466 / SKYRIZI / IL-23 + anti-a4b7 mAb / Biologic combination / Immunology
    Crohn's DiseasePhase 2
  • BudigalimabABBV-181 / PD1 / Biologic / Oncology
    Solid and Hematologic TumorsPhase 2
  • ABBV-701ABBV-701 / TL1A / Biologic / Immunology
    Inflammatory Bowel DiseasePhase 1
  • ABBV-932ABBV-932 / DRD2/DRD3 modulator / Small molecule / Neuroscience
    Bipolar DepressionPhase 2Generalized Anxiety DisorderPhase 2
  • ABBV-9832 (Lutikizumab + Ravagalimab)ABBV-9832 / IL-1a/1b + CD40 antagonist / Biologic combination / Immunology
    Rheumatoid ArthritisPhase 2
  • ABBV-6628ABBV-6628 / C5 / Biologic / Eye Care
    Geographic AtrophyPhase 1
  • ABBV-619ABBV-619 / CD19 / Biologic/CAR-T / Immunology
    Autoimmune diseasesPhase 1
  • LivmoniplimabABBV-151 / GARP-TGF-beta1 / Biologic / Oncology
    Hepatocellular CarcinomaPhase 2Solid TumorsPhase 2Non-Small Cell Lung CancerPhase 2
  • Armour ThyroidArmour Thyroid / T3T4 / Biologic / Other Specialties
    HypothyroidismPhase 3
  • ABBV-319ABBV-319 / CD19 / Biologic ADC / Immunology
    Sjogren's diseasePhase 1Systemic Lupus ErythematosusPhase 1
  • ABBV-722ABBV-722 / LPAR1 / Small molecule / Immunology
    Idiopathic Pulmonary FibrosisPhase 1Systemic SclerosisPhase 1
  • ABBV-142ABBV-142 / LPAR1 / Biologic / Immunology
    Idiopathic Pulmonary FibrosisPhase 1
  • ABBV-324ABBV-324 / Biologic ADC / Oncology
    Solid TumorsPhase 1
  • ABBV-295ABBV-295 / Long-Acting Amylin Analog / Large molecule / Other Specialties
    ObesityPhase 1
  • SurzetoclaxABBV-453 / BCL-2 / Small molecule / Oncology
    Relapsed/Refractory Multiple MyelomaPhase 1
  • ABBV-2002ABBV-2002 / PAR-2 / Biologic / Neuroscience
    MigrainePhase 2
  • IcalcaprantABBV-1354 / KOR antagonist / Small molecule / Neuroscience
    Bipolar DepressionPhase 2Major Depressive DisorderPhase 2
  • ABBV-1042ABBV-1042 / M4 receptor / Small molecule / Neuroscience
    Bipolar ManiaPhase 1
  • Surabgene LomparvovecABBV-RGX-314 / VEGF / Gene therapy / Eye Care
    wet AMD (subretinal)Phase 3wet AMD (suprachoroidal)Phase 2Diabetic Retinopathy (suprachoroidal)Phase 2
  • UbrogepantUBRELVY / CGRP receptor / Small molecule / Neuroscience
    Menstrual MigrainePhase 3
  • ABBV-2001ABBV-2001 / BCMA, CD38, CD3 / Biologic trispecific T-cell engager / Oncology
    Relapsed/Refractory Multiple MyelomaPhase 1
  • Pivekimab SunirinePVEK / CD123 / Biologic ADC / Oncology
  • Mirvetuximab soravtansineELAHERE / FR-alpha / Biologic ADC / Oncology
    Platinum-Resistant Ovarian CancerApprovedPlatinum-Sensitive Ovarian CancerPhase 3
  • AtogepantQULIPTA / CGRP receptor / Small molecule / Neuroscience
    Acute MigraineSubmittedOUSMenstrual MigrainePhase 3OUS
  • EmraclidineM4 PAM / Small molecule / Neuroscience
    SchizophreniaPhase 2PsychosisPhase 1
  • UpadacitinibABT-494 / RINVOQ / JAK1 / Small molecule / Immunology
    Alopecia AreataSubmittedUSEUHidradenitis SuppurativaPhase 3Systemic Lupus ErythematosusPhase 3
  • ABBV-166 (Skyrizi + Lutikizumab)ABBV-166 / SKYRIZI / IL-23 + IL-1a/1b / Biologic combination / Immunology
    Psoriatic ArthritisPhase 2
  • ABBV-848ABBV-848 / IRAK4 / Small molecule / Immunology
    Rheumatoid ArthritisPhase 1
  • ABBV-706ABBV-706 / SEZ6 / Biologic ADC / Oncology
    First Line Small Cell Lung CancerPhase 2Relapsed/Refractory Small Cell Lung CancerPhase 3Neuroendocrine NeoplasmsPhase 1
  • ABBV-1480ABBV-1480 / PD-1, VEGF / Biologic bispecific antibody / Oncology
    Solid TumorsPhase 1
  • LutikizumabABT-981 / IL-1a/1b / Biologic / Immunology
    Hidradenitis SuppurativaPhase 3
  • GemibotulinumtoxinAGemibotA / SNAP-25 / Biologic / Neuroscience
    Ventral Hernia RepairPhase 2

AstraZeneca PLC

astrazeneca.com
32assets
  • camizestrant + CDK4/6ingSERD + CDK4/6i / small molecule combination / Oncology
    1L HR+ HER2- ESR1m advanced breast cancerPhase IIISubmitted
  • camizestrant + palbociclibngSERD + CDK4/6i / small molecule combination / Oncology
    1L HR+ HER2- advanced breast cancerPhase III
  • camizestrant +/- abemaciclibngSERD + CDK4/6i / small molecule combination / Oncology
    adjuvant HR+ HER2- early breast cancerPhase III
  • camizestrantngSERD / small molecule / Oncology
    adjuvant switch HR+ HER2- early breast cancerPhase III
  • AZD0120AZD0120 / CD19/BCMA CAR-T / cell therapy / Oncology/Rare Disease/Respiratory & Immunology
    relapsed/refractory multiple myelomaPhase IIINew to Phase IIIamyloid light-chain amyloidosisPhase Isystemic lupus erythematosusPhase I
  • puxitatug samrotecanB7-H4 TOP1i ADC / antibody-drug conjugate / Oncology
    2-3L B7-H4+ endometrial cancerPhase III
  • rilvegostomigPD-1/TIGIT bispecific mAb / bispecific antibody / Oncology
    HCC; biliary tract; NSCLC; gastric cancerPhase III
  • saruparibPARP1 inhibitor / small molecule / Oncology
    prostate cancer; breast cancerPhase III
  • sonesitatug vedotinCLDN18.2 MMAE ADC / antibody-drug conjugate / Oncology
    CLDN18.2+ gastric cancerPhase III
  • surovatamigAZD0486 / CD19/CD3 T-cell engager / bispecific antibody / Oncology/Respiratory & Immunology
    1L elderly DLBCL; follicular lymphomaPhase IIIB-cell driven autoimmune diseasePhase I
  • torvutatug samrotecanAZD5335 / anti-FRα TOP1i ADC / antibody-drug conjugate / Oncology
    ovarian cancerPhase III
  • volrustomigPD-1/CTLA-4 bispecific mAb / bispecific antibody / Oncology
    cervical cancer; HNSCC; NSCLC; mesotheliomaPhase IIIcolorectal cancer; NSCLC; other solid tumoursPhase II
  • balcinrenone/dapagliflozinMR antagonist/modulator + SGLT2 inhibitor / small molecule combination / Cardiovascular, Renal and Metabolism
    heart failure with CKDPhase IIICKDPhase II
  • baxdrostataldosterone synthase inhibitor / small molecule / Cardiovascular, Renal and Metabolism
    hypertensionPhase IIIAcceptedprimary aldosteronismPhase III
  • baxdrostat/dapagliflozinaldosterone synthase inhibitor + SGLT2 inhibitor / small molecule combination / Cardiovascular, Renal and Metabolism
    CKD; prevention of heart failurePhase III
  • laroprovstatPCSK9 inhibitor / small molecule / Cardiovascular, Renal and Metabolism
    dyslipidaemiaPhase III
  • WainuaWainua / ligand-conjugated antisense / antisense oligonucleotide / Cardiovascular, Renal and Metabolism
    ATTRv-PNPhase IIILaunchedATTR CMLCM
  • zibotentan/dapagliflozinendothelin A receptor antagonist/SGLT2 inhibitor / small molecule combination / Cardiovascular, Renal and Metabolism
    CKD with high proteinuriaPhase III
  • elecoglipronoral GLP-1 receptor agonist / small molecule / Cardiovascular, Renal and Metabolism
    T2D/chronic weight managementPhase II
  • AZD6234AZD6234 / peptide / peptide / Cardiovascular, Renal and Metabolism
    chronic weight management in overweight or obesityPhase II
  • tozorakimabIL-33 mAb / monoclonal antibody / Respiratory & Immunology
    COPDPhase IIIsevere viral lower respiratory tract diseasePhase IIIasthmaPhase II
  • TezspireTezspire / TSLP mAb / monoclonal antibody / Respiratory & Immunology
    severe uncontrolled asthmaPhase IIILaunchedChinaeosinophilic esophagitis; COPD; nasal polypsLCM
  • SaphneloSaphnelo / type I IFN receptor mAb / monoclonal antibody / Respiratory & Immunology
    systemic lupus erythematosusPhase IIILaunchedChinacutaneous lupus erythematosus; SLE SCLCM
  • anselamimabfibril-reactive mAb / monoclonal antibody / Rare Disease
    amyloid light-chain amyloidosisPhase IIISubmitted
  • cliramitugtransthyretin depleter / large molecule / Rare Disease
    transthyretin amyloid cardiomyopathyPhase III
  • efzimfotase alfanext generation TNSALP ERT / enzyme replacement therapy / Rare Disease
    hypophosphatasiaPhase III
  • eneboparatideparathyroid hormone receptor 1 / large molecule / Rare Disease
    hypoparathyroidismPhase III
  • gefurulimabanti-C5 dual-binding nanobody / nanobody / Rare Disease
    generalised myasthenia gravisPhase IIISubmitted
  • KavigaleKavigale / SARS-CoV-2 LAAB / long-acting antibody / Infectious Disease
    prevention of COVID-19Phase IIILaunched
  • AZD0292AZD0292 / pseudomonas Psl-PcrV bispecific mAb / bispecific antibody / Infectious Disease
    bronchiectasisPhase II
  • AZD5148AZD5148 / anti-Clostridioides difficile TcdB mAb / monoclonal antibody / Infectious Disease
    reduction of C. diff recurrencePhase II
  • AZD7760AZD7760 / S. aureus virulence factors / mAb combination / Infectious Disease
    prevention of Staph aureus infectionPhase II

Amgen Inc.

amgenpipeline.com
30assets
  • erenumab-aooeAIMOVIG / CGRP receptor / Monoclonal antibody / Neuroscience
    Pediatric migraineInvestigational
  • blinatumomabBLINCYTO / CD19 x CD3 / BiTE molecule / Hematology/Oncology; Inflammation
    Newly diagnosed B-cell precursor acute lymphoblastic leukemiaInvestigationalRelapsed/refractory acute lymphoblastic leukemia, subcutaneous administrationPhase 2InvestigationalSystemic lupus erythematosus with and without nephritisInvestigational
  • dazodalibepCD40L / Fusion protein / Rare Disease
    Sjögren’s diseaseInvestigational
  • romosozumab-aqqgEVENITY / Sclerostin / Monoclonal antibody / Bone
    Pediatric osteogenesis imperfectaInvestigational
  • tarlatamab-dlleIMDELLTRA / DLL3 x CD3 / BiTE molecule / Hematology/Oncology
    Small cell lung cancer, limited-stage and extensive-stage settingsInvestigationalSmall cell lung cancer, combination studiesInvestigationalSmall cell lung cancer, subcutaneous administrationPhase 1Investigational
  • pegloticaseKRYSTEXXA / Uric acid / PEGylated uricase / Rare Disease
    Uncontrolled gout, subcutaneous administration with methotrexateInvestigational
  • sotorasibLUMAKRAS / KRAS G12C / Small molecule / Hematology/Oncology
    KRAS G12C-mutated metastatic colorectal cancer, first line combinationInvestigationalPreviously treated advanced KRAS G12C-mutated non-small cell lung cancerInvestigationalNewly diagnosed advanced KRAS G12C-mutated NSCLC, combinationInvestigational
  • maridebart cafraglutideAMG 133 / MariTide / GLP-1 receptor; GIP receptor / Antibody-peptide conjugate / Cardiometabolic; Diabetes
    ObesityInvestigationalCardiovascular risk reduction in ASCVD with obesity or overweightInvestigationalHeart failure events and cardiovascular risk reduction in HFpEF/HFmrEF with obesityInvestigational
  • romiplostimNPLATE / Thrombopoietin receptor / Peptibody / Hematology/Oncology
    Chemotherapy-induced thrombocytopeniaInvestigational
  • olpasiranAMG 890 / Lp(a) / siRNA / Cardiometabolic
    Atherosclerotic cardiovascular diseaseInvestigational
  • apremilastOTEZLA / PDE4 / Small molecule / Inflammation
    Juvenile psoriatic arthritisInvestigationalPediatric Behcet’s diseaseInvestigational
  • etelcalcetidePARSABIV / Calcium-sensing receptor / Peptide / Nephrology
    Pediatric secondary hyperparathyroidism in CKD receiving hemodialysisInvestigational
  • evolocumabREPATHA / PCSK9 / Monoclonal antibody / Cardiometabolic
    Hypercholesterolemia in high cardiovascular risk without prior MI or strokeInvestigational
  • avacopanTAVNEOS / C5aR1 / Small molecule / Rare Disease
    Pediatric ANCA-associated vasculitisInvestigational
  • teprotumumab-trbwTEPEZZA / IGF-1R / Monoclonal antibody / Rare Disease
    Thyroid eye disease, subcutaneous administrationInvestigational
  • tezepelumab-ekkoTEZSPIRE / TSLP / Monoclonal antibody / Inflammation
    Chronic obstructive pulmonary diseaseInvestigationalEosinophilic esophagitisInvestigational
  • xaluritamigAMG 509 / STEAP1 x CD3 / XmAb bispecific T-cell engager antibody / Hematology/Oncology
    Prostate cancerInvestigationalEwing sarcomaInvestigational
  • ABP 206ABP 206 / PD-1 / Monoclonal antibody biosimilar / Hematology/Oncology
    Investigational biosimilar to OPDIVO (nivolumab)Investigational biosimilar
  • ABP 234ABP 234 / PD-1 / Monoclonal antibody biosimilar / Hematology/Oncology
    Investigational biosimilar to KEYTRUDA (pembrolizumab)Investigational biosimilar
  • ABP 692ABP 692 / CD20 / Monoclonal antibody biosimilar / Inflammation
    Investigational biosimilar to OCREVUS (ocrelizumab)Investigational biosimilar
  • daxdilimabILT7 / Monoclonal antibody / Rare Disease
    Dermatomyositis and anti-synthetase inflammatory myositisInvestigationalDiscoid lupus erythematosusInvestigational
  • inebilizumabUPLIZNA / CD19 / Monoclonal antibody / Inflammation
    Systemic lupus erythematosus with nephritisInvestigational
  • carfilzomibKYPROLIS / Proteasome / Small molecule / Hematology/Oncology
    Pediatric acute lymphoblastic leukemiaInvestigational
  • AMG 104AMG 104 / TSLP / Monoclonal antibody Fab / Inflammation
    AsthmaInvestigational
  • AMG 732AMG 732 / IGF-1R / Monoclonal antibody / Rare Disease
    Thyroid eye diseaseInvestigational
  • AMG 355AMG 355 / CCR8 / Monoclonal antibody / Hematology/Oncology
    Advanced solid tumor malignanciesInvestigational
  • AMG 410AMG 410 / Small molecule / Hematology/Oncology
    Solid tumorsInvestigational
  • AMG 436AMG 436 / Small molecule / Hematology/Oncology
    Advanced solid tumor malignanciesInvestigational
  • AMG 513AMG 513 / Cardiometabolic
    ObesityInvestigational
  • AMG 691AMG 691 / Monoclonal antibody / Inflammation
    AsthmaInvestigational

Novo Nordisk A/S

novonordisk.com
30assets
  • Glucose sensitive insulinNN1845 / Analogue / Diabetes
    Type 1 and 2 diabetesPhase 1
  • Ventus NLRP3iNN6022 / NLRP3 / Inhibitor / Diabetes
    CVDPhase 1
  • siRNA GalXC-GYS2siRNA / Diabetes
    siRNA GalXC-GYS2Phase 1
  • CNPCNP / Analogue / Diabetes
    Heart failurePhase 1
  • Amylin 355Analogue / Obesity
    ObesityPhase 1
  • Amylin 1213Analogue / Obesity
    ObesityPhase 1
  • SLC25A5SLC25A5 / siRNA / Obesity
    MASHPhase 1
  • Inno8Antibody fragment / Rare Blood Disorders
    HaemophiliaPhase 1
  • Subcutaneous ZenagamtideGLP-1 / amylin / Co-agonist / Diabetes / Obesity
    Subcutaneous ZenagamtidePhase 2ObesityPhase 2
  • Monlunabant in DKDCB1 receptor / Small molecule / Diabetes
    Diabetic Kidney Disease (DKD)Phase 2
  • Oral ZenagamtideGLP-1 / amylin / Co-agonist / Diabetes / Obesity
    DiabetesPhase 2ObesityPhase 2
  • CDR132LmiR-132 / Antisense oligonucleotide / Diabetes
    Heart failure with reduced ejection fraction (HFrEF)Phase 2
  • UBT251 (GGG tri-agonist)Obesity
    ObesityPhase 2
  • TripleGLP1 / GIP / amylin / Tri-agonist / Obesity
    ObesityPhase 2
  • MonlunabantINV-202 / CB1 receptor / Small molecule / Obesity
    ObesityPhase 2
  • NDecEPI01 / Rare Blood Disorders
    Sickle cell disease / An oral combination of decitabine and tetrahydrouridine. Project is developed in collaboration with EpiDestiny.Phase 2
  • EtavopivatRare Blood Disorders
    ThalassemiaPhase 2
  • CagriSema in T2DNN9388 / Analogue / Diabetes
    Type 2 diabetesPhase 3
  • Ziltivekimab ASCVDNN6018 / Diabetes
    Atherosclerotic cardiovascular disease (ASCVD) with chronic kidney disease (CKD) and inflammationPhase 3
  • CoramitugPRX004 / Diabetes
    ATTR CardiomyopathyPhase 3
  • Ziltivekimabin HFpEFDiabetes
    Heart failure with preserved ejection fraction (HFpEF)Phase 3
  • Ziltivekimab AMIDiabetes
    Acute Myocardial infarction (AMI)Phase 3
  • CagrilintideAnalogue / Obesity
    ObesityPhase 3
  • Efruxifermin in MASHFGF21 / Analogue / Obesity
    MASHPhase 3
  • Etavopivat (Sickle Cell Disease)Small molecule / Rare Blood Disorders
    Sickle Cell DiseasePhase 3
  • IcosemaNN1535 / Analogue / Diabetes
    Type 2 diabetes / A combination of GLP-1 analogue semaglutide and insulin icodec intended for once-weekly treatment.Filed
  • Insulin icodecNN1436 / Analogue / Diabetes
    DiabetesFiled
  • CagriSemaNN9898 / Analogue / Obesity
    ObesityFiled
  • Semaglutide 7.2 mgAnalogue / Obesity
    ObesityFiled
  • DenecimigMim8 / Inhibitor / Rare Blood Disorders
    Haemophilia A with or without inhibitors / A next generation FVIII mimetic bispecific antibody for subcutaneous prophylaxis of haemophilia A regardless of inhibitor status.Filed

GSK

gsk.com
26assets
  • ArexvyArexvy / RSV F protein / Recombinant protein, adjuvanted vaccine / Infectious diseases
    RSV adults (50-59 years of age at increased risk)Phase III/Registration
  • gepotidacinGSK2140944 / Bacterial topoisomerase inhibitor / Small molecule / Infectious diseases
    Urogenital gonorrhoeaPhase III/Registration
  • bepirovirsenGSK3228836 / HBsAg / Antisense oligonucleotide / Infectious diseases
    Chronic HBV infectionPhase III
  • BexseroBexsero / MenB / Recombinant protein, OMV vaccine / Infectious diseases
    Meningitis B (infants US)Phase III/RegistrationUS
  • MenABCWY vaccineGSK3536819 / Meningococcal ABCWY / Recombinant protein, OMV, conjugated vaccine / Infectious diseases
    Meningococcal diseasePhase III/Registration
  • Nucala (mepolizumab)Nucala / IL-5 / Monoclonal antibody / Respiratory/Immunology
    COPD with eosinophilic phenotypePhase III/Registration
  • depemokimabGSK3511294 / IL-5 / Monoclonal antibody / Respiratory/Immunology
    Asthma with type 2 inflammationPhase III/RegistrationChronic rhinosinusitis with nasal polypsPhase III/RegistrationEGPAPhase III
  • camlipixantGSK4523199 / P2X3 / Small molecule antagonist / Respiratory/Immunology
    Refractory chronic coughPhase III
  • linerixibatGSK2330672 / IBAT / Small molecule / Respiratory/Immunology
    Cholestatic pruritus in primary biliary cholangitisPhase III
  • Blenrep (belantamab mafodotin)GSK2857916 / Blenrep / BCMA / Antibody-drug conjugate / Oncology
    Relapsed/refractory multiple myelomaPhase III/Registration
  • Jemperli (dostarlimab)Jemperli / PD-1 / Monoclonal antibody / Oncology
    Endometrial cancerPhase III/RegistrationRectal cancer (dMMR)Phase IINon-small cell lung cancerPhase III
  • Zejula (niraparib)Zejula / PARP / Small molecule / Oncology
    Ovarian cancerPhase III/Registration
  • belrestotugGSK4428859 / TIGIT / Monoclonal antibody / Oncology
    NSCLC and other solid tumorsPhase III
  • GSK5764227GSK5764227 / B7-H3 / Antibody-drug conjugate / Oncology
    Extensive-stage small-cell lung cancerPhase IIIAdvanced GI solid tumorsPhase I/II
  • cobolimabGSK4069889 / TIM-3 / Monoclonal antibody / Oncology
    Non-small cell lung cancerPhase II/III
  • GSK4532990GSK4532990 / HSD17B13 / RNA interference / Opportunity driven
    NASH/MASHPhase II
  • GSK4172239GSK4172239 / DNMT1 / Small molecule inhibitor / Opportunity driven
    Sickle cell diseasePhase I
  • GSK3882347GSK3882347 / FimH / Small molecule antagonist / Infectious diseases
    Uncomplicated UTIPhase I
  • GSK3923868GSK3923868 / PI4K beta / Small molecule inhibitor / Infectious diseases
    Rhinovirus diseasePhase I
  • GSK3965193GSK3965193 / PAPD5/PAPD7 / Small molecule inhibitor / Infectious diseases
    Chronic HBV infectionPhase I
  • GSK2556286GSK2556286 / Mtb cholesterol-dependent / Small molecule inhibitor / Infectious diseases
    TuberculosisPhase I
  • GSK3772701GSK3772701 / P. falciparum whole cell / Small molecule inhibitor / Infectious diseases
    MalariaPhase I
  • GSK4024484GSK4024484 / P. falciparum whole cell / Small molecule inhibitor / Infectious diseases
    MalariaPhase I
  • GSK3536867GSK3536867 / Salmonella typhoid + paratyphoid A / Bivalent conjugate vaccine / Infectious diseases
    Salmonella (typhoid + paratyphoid A)Phase I
  • latiglutenase / AMG 133-like programs
  • AGN-151586 / progranulin program (latozinemab)AL001 / Progranulin/sortilin / Monoclonal antibody / Opportunity driven
    Frontotemporal dementia with progranulin gene mutationPhase III

BeOne Medicines Ltd.

beonemedicines.com
26assets
  • ZanubrutinibBTK / Inhibitor / Hematologic Malignancies / Immunology & Inflammation
    Treatment-Naive Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaApprovedRelapsed/Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaApprovedRelapsed/Refractory Waldenström Macroglobulinemia and Treatment-Naïve Waldenström MacroglobulinemiaApproved
  • SonrotoclaxBCL2 / Inhibitor / Hematologic Malignancies
    Treatment-Naive Chronic Lymphocytic LeukemiaPhase 3Treatment-Naive Chronic Lymphocytic LeukemiaPhase 3Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaApproved
  • TislelizumabPD-1 / Monoclonal Antibody / Lung Cancers / Gastrointestinal Cancers / Other Cancers
    First-Line Extensive-Stage Small Cell Lung CancerApprovedFirst-Line Non-Squamous Non-Small Cell Lung CancerApprovedFirst-Line Squamous Non-Small Cell Lung CancerApproved
  • BGB-16673BTK Chimeric Degradation Activation Compound [CDAC] / Hematologic Malignancies / Immunology & Inflammation
    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 3Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 3Relapsed/Refractory Mantle Cell LymphomaPhase 2
  • BlinatumomabCD19 x CD3 / BiTE® [Bispecific T-Cell Engager] / Hematologic Malignancies
    Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (subcutaneous formulation)Phase 2
  • TarlatamabDLL3 x CD3 / BiTE® [Bispecific T-cell Engager] / Lung Cancers
    First-Line Extensive-Stage Small Cell Lung CancerPhase 3First-Line Extensive-Stage Small Cell Lung CancerPhase 3Second-Line Small Cell Lung CancerPhase 3
  • ZanidatamabHER2 Bispecific / Antibody / Gastrointestinal Cancers
    First-Line HER2 Positive Gastroesophageal AdenocarcinomaPhase 3Second-Line HER2 Positive Biliary Tract CancerApprovedFirst-Line HER2 positive Biliary Tract CancerPhase 3
  • BG-68501CDK2 / Inhibitor / Breast/Gynecologic Cancers
    Breast Cancer and Solid TumorsPhase 1
  • BGB-21447BCL2 / Inhibitor / Breast/Gynecologic Cancers
    Hormone Receptor Positive Breast CancerPhase 1
  • BGB-43395CDK4 / Inhibitor / Breast/Gynecologic Cancers
    Breast Cancer and Solid TumorsPhase 1
  • BGB-B455Claudin 6 x CD3 Bispecific / Antibody / Breast/Gynecologic Cancers
    Gynecologic and Solid TumorsPhase 1
  • BG-C9074B7-H4 Antibody Drug Conjugate / Breast/Gynecologic Cancers
    Breast Cancer and Solid TumorsPhase 1
  • BG-75202KAT6A/B / Inhibitor / Breast/Gynecologic Cancers
    Breast CancerPhase 1
  • BG-75098CDK2 Chimeric Degradation Activation Compound [CDAC] / Breast/Gynecologic Cancers
    Breast CancerPhase 1
  • BGB-B2033GPC3 x 4-1BB Bispecific / Antibody / Gastrointestinal Cancers
    Solid TumorsPhase 1
  • BG-C137FGFR2b Antibody Drug Conjugate / Gastrointestinal Cancers
    Gastrointestinal CancersPhase 1
  • BGB-53038Pan-KRAS / Inhibitor / Gastrointestinal Cancers
    Lung Cancers and GI CancersPhase 1
  • BG-C477CEA Antibody Drug Conjugate / Gastrointestinal Cancers
    Lung Cancers and GI CancersPhase 1
  • BG-C0902EGFR x MET x MET Antibody Drug Conjugate / Lung Cancers
    Lung Cancers and GI CancersPhase 1
  • BG-T187EGFR x MET x MET Trispecific / Antibody / Lung Cancers
    Lung Cancers and GI CancersPhase 1
  • BGB-58067MTA Cooperative PRMT5 / Inhibitor / Lung Cancers
    Lung Cancers and GI CancersPhase 1
  • BG-89894MAT2A / Inhibitor / Lung Cancers
    Lung Cancers and Solid TumorsPhase 1
  • BG-60366EGFR Chimeric Degradation Activation Compound [CDAC] / Lung Cancers
    Lung CancersPhase 1
  • BGB-26808HPK1 / Inhibitor / Gastrointestinal Cancers
    Solid Tumors/Pan- TumorPhase 1
  • XaluritamigSTEAP1 x CD3 Bispecific T-cell Engager (XmAb®) / Other Cancers
    Metastatic Castration-Resistant Prostate CancerPhase 1
  • BGB-45035IRAK4 Chimeric Degradation Activation Compound [CDAC] / Immunology & Inflammation
    Rheumatoid ArthritisPhase 2Skin DiseasesPhase 1

Alnylam Pharmaceuticals, Inc.

alnylam.com
24assets
  • NucresiranRNAi therapeutic / Transthyretin Amyloidosis (TTR)
    ATTR Amyloidosis with CardiomyopathyPhase 3hATTR Amyloidosis with PolyneuropathyPhase 3
  • ZilebesiranRNAi therapeutic / Cardiovascular
    HypertensionPhase 3REVERSIR HypertensionPhase 1
  • RapirosiranALN-HSD / HSD / RNAi therapeutic / Metabolic
    Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2
  • ALN-ANG3ALN-ANG3 / ANG3 / RNAi therapeutic / Metabolic
    Diabetic Kidney DiseasePhase 2
  • ALN-4324ALN-4324 / GRB14 / RNAi therapeutic / Metabolic
    Type 2 Diabetes MellitusPhase 1
  • ALN-2232ALN-2232 / ACVR1C / RNAi therapeutic / Metabolic
    Obesity & Weight ManagementPhase 1
  • ALN-PNPALN-PNP / PNP / RNAi therapeutic / Metabolic
    Non-Alcoholic Fatty Liver Disease (NAFLD)Phase 1
  • ALN-APOC3ALN-APOC3 / APOC3 / RNAi therapeutic / Metabolic
    DyslipidemiaPhase 1
  • ALN-CIDEBALN-CIDEB / CIDEB / RNAi therapeutic / Metabolic
    Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 1
  • Cemdisiran(+/- Pozelimab)RNAi therapeutic / Neuroscience/Other
    Myasthenia GravisPhase 3Geographic AtrophyPhase 3
  • MivelsiranALN-APP / APP / RNAi therapeutic / Neuroscience
    Cerebral Amyloid Angiopathy (CAA)Phase 2Alzheimer’s DiseasePhase 1
  • ALN-HTT02ALN-HTT02 / HTT / RNAi therapeutic / Neuroscience
    Huntington’s DiseasePhase 1
  • ALN-5288ALN-5288 / MAPT / RNAi therapeutic / Neuroscience
    Alzheimer’s DiseasePhase 1
  • ALN-SODALN-SOD / SOD1 / RNAi therapeutic / Neuroscience
    SOD1 Amyotrophic Lateral Sclerosis (ALS)Phase 1
  • ALN-SNCAALN-SNCA / SNCA / RNAi therapeutic / Neuroscience
    Parkinson’s DiseasePhase 1
  • Cemdisiran (+Pozelimab)RNAi therapeutic / Hematology
    Paroxysmal Nocturnal HemoglobinuriaPhase 3
  • ALN-6400ALN-6400 / PLG / RNAi therapeutic / Hematology
    Bleeding DisordersPhase 2
  • AG-236ALN-TMP / TMP / RNAi therapeutic / Hematology
    Polycythemia VeraPhase 1
  • ALN-CFBALN-CFB / CFB / RNAi therapeutic / Hematology
    Paroxysmal Nocturnal HemoglobinuriaPhase 1
  • Elebsiran (+Tobevibart)RNAi therapeutic / Other
    Hepatitis D Virus InfectionPhase 2
  • ALN-BCATALN-BCAT / BCAT / RNAi therapeutic / Other
    Hepatocellular CarcinomaPhase 1
  • ALN-4285ALN-4285 / RNAi therapeutic / Other
    Healthy VolunteersPhase 1
  • ALN-4915ALN-4915 / RNAi therapeutic / Other
    Healthy VolunteersPhase 1
  • ALN-F1202ALN-F1202 / RNAi therapeutic / Other
    Healthy VolunteersPhase 1

BioNTech SE

biontech.com
21assets
  • PumitamigPD-L1/VEGF-A / immunomodulator / Oncology
    Multiple solid tumors; NSCLC; SCLC; HCC; CRC; ES-SCLC; EGFRm NSCLC; glioblastoma; MPM; NEN; TNBC; PDACclinical
  • BNT325/DB-1305BNT325/DB-1305 / targeted therapy / Oncology
    Multiple solid tumorsclinical
  • BNT324/DB-1311BNT324/DB-1311 / targeted therapy / Oncology
    Multiple solid tumorsclinical
  • BNT321BNT321 / targeted therapy / Oncology
    Multiple solid tumors; HCC combinationclinical
  • Autogene cevumeranmRNA cancer immunotherapy / Oncology
    Adjuvant CRC; adjuvant PDACclinical
  • BNT116BNT116 / mRNA cancer immunotherapy / Oncology
    Advanced NSCLC; 1L advanced NSCLCclinical
  • BNT113BNT113 / HPV16 / mRNA cancer immunotherapy / Oncology
    1L HPV16+ HNSCCclinical
  • GotistobartCTLA-4 / immunomodulator / Oncology
    Metastatic NSCLC; metastatic CRPC; PROC; multiple solid tumorsclinical
  • BNT211BNT211 / cell therapy / Oncology
    Multiple solid tumorsclinical
  • BNT314/GEN1059BNT314/GEN1059 / immunomodulator / Oncology
    Multiple solid tumors; metastatic CRC combinationclinical
  • BNT329BNT329 / immunomodulator / Oncology
    Multiple solid tumorsclinical
  • BNT326/YL202BNT326/YL202 / targeted therapy / Oncology
    Multiple solid tumors; NSCLC combination; advanced/metastatic breast cancerclinical
  • BNT317BNT317 / immunomodulator / Oncology
    Multiple solid tumorsclinical
  • Trastuzumab pamirtecanHER2 / targeted therapy / Oncology
    Metastatic breast cancer; advanced/metastatic breast cancer combination; 2L endometrial cancer; multiple solid tumorsclinical
  • BNT162 + BNT161BNT162 + BNT161 / mRNA vaccine combination / Infectious diseases
    COVID-19-influenza combinationclinical
  • BNT163BNT163 / HSV / mRNA vaccine / Infectious diseases
    HSVclinical
  • BNT166BNT166 / Mpox / mRNA vaccine / Infectious diseases
    Mpoxclinical
  • BNT162BNT162 / COMIRNATY / SARS-CoV-2 / mRNA vaccine / Infectious diseases
    COVID-19Commercialmarketed
  • BNT351BNT351 / HIV / antibody mRNA / Infectious diseases
    HIVclinical
  • BNT164BNT164 / Tuberculosis / mRNA vaccine / Infectious diseases
    Tuberculosisclinical
  • BNT165BNT165 / Malaria / mRNA vaccine / Infectious diseases
    Malariaclinical

Gilead Sciences, Inc.

gilead.com
19assets
  • LenacapavirHIV capsid inhibitor / Long-acting injectable / Virology
    HIV Prevention (PrEP, PURPOSE 365)Phase 3HIV Treatment (in combinations)Phase 3HIV Treatment (with bNAbs)Phase 2
  • Bictegravir/lenacapavir oral combinationINSTI + capsid inhibitor / Oral / Virology
    HIV Treatment (virologically suppressed, ARTISTRY-1 & ARTISTRY-2)Phase 3
  • Islatravir/lenacapavir oral combinationLong-acting oral / Virology
    HIV Treatment (virologically suppressed, ISLEND-1 & ISLEND-2)Phase 3
  • Lenacapavir + teropavimab + zinlirvimabCapsid + bNAbs / Long-acting injectable / Virology
    HIV Treatment (virologically suppressed)Phase 2
  • GS-1720/GS-4182GS-1720/GS-4182 / INSTI/capsid inhibitor / Long-acting oral / Virology
    HIV Treatment (WONDERS-1 & -2)Phase 2
  • Teropavimab + zinlirvimabbNAbs / Broadly neutralizing antibodies / Virology
    HIV CurePhase 2
  • VesatolimodVirology
    HIV Cure (FRESH)Phase 2
  • SelgantolimodVirology
    HBV CurePhase 2
  • HepcludexHepcludex / Virology
    Chronic HDV with compensated liver disease (MYR301)FiledBLA pending (US); Approved (EU)USEU
  • EdecesertibInflammation
    Lupus (COSMIC)Phase 2
  • Tilpisertib fosmecarbilInflammation
    Inflammatory bowel disease (PALEKONA)Phase 2
  • α4β7 inhibitorα4β7 / Inflammation
    Inflammatory Bowel Disease (SWIFT)Phase 2
  • Sacituzumab govitecan-hziyAntibody-drug conjugate / Oncology
    1L metastatic triple-negative breast cancer (PD-L1-, ASCENT-03)FiledsBLA pendingUS1L metastatic triple-negative breast cancer (PD-L1+, with pembrolizumab, ASCENT-04)FiledsBLA pendingUSHigh risk adjuvant triple-negative breast cancer (with pembrolizumab, ASCENT-05)Phase 3
  • Axicabtagene ciloleucelCD19 CAR / Cell therapy / Oncology
    2L+ high-risk follicular lymphoma (ZUMA-22)Phase 31L high-risk large B-cell lymphoma (ZUMA-23)Phase 3
  • Brexucabtagene autoleucelCD19 CAR / Cell therapy / Oncology
    Pediatric acute lymphocytic leukemia/non-Hodgkin lymphoma (ZUMA-4)Phase 2
  • Anitocabtagene autoleucelCell therapy / Oncology
    2-4L relapsed/refractory multiple myeloma (iMMagine-3)Phase 34L+ relapsed/refractory multiple myeloma (iMMagine-1)FiledBLA pendingUS
  • KITE-363KITE-363 / CD19/CD20 bicistronic / Cell therapy / Oncology
    Relapsed/refractory diffuse large B-cell lymphomaPhase 1RMAT designationRheumatology (autoimmune)Phase 1
  • DenikitugGS-1811 / Oncology
    Advanced cancersPhase 1
  • Domvanalimab + zimberelimabAnti-TIGIT + anti-PD1 / Combination therapy / Oncology
    1L metastatic non-small cell lung cancer (with chemo, STAR-121)Phase 31L head and neck squamous cell carcinoma (VELOCITY-HNSCC)Phase 2

Ionis Pharmaceuticals, Inc.

ionis.com
19assets
  • ZilganersenION373 / GFAP / RNA-Targeted Therapeutic / Neurology
    Alexander DiseasePhase 1/3ActiveGlobal
  • ION582ION582 / UBE3A-ATS / RNA-Targeted Therapeutic / Neurology
    Angelman SyndromeClinicalActive
  • ION269ION269 / APP / RNA-Targeted Therapeutic / Neurology
    Alzheimer's DiseaseClinicalActive
  • ION717ION717 / PRNP / RNA-Targeted Therapeutic / Neurology
    Prion DiseaseClinicalActive
  • ION356ION356 / PLP1 / RNA-Targeted Therapeutic / Neurology
    Pelizaeus-Merzbacher DiseaseClinicalActive
  • ION859ION859 / LRRK2 / RNA-Targeted Therapeutic / Neurology
    Parkinson's DiseaseClinicalActive
  • ION464ION464 / SNCA / RNA-Targeted Therapeutic / Neurology
    Multiple System AtrophyClinicalActiveParkinson's DiseaseClinicalActive
  • ION440ION440 / MECP2 / RNA-Targeted Therapeutic / Neurology
    MECP2 Duplication SyndromeClinicalActive
  • OlezarsenApoC-III / RNA-Targeted Therapeutic / Cardiology
    Severe HypertriglyceridemiaClinicalActive
  • DonidalorsenPKK / RNA-Targeted Therapeutic / Specialty/Rare
    Hereditary AngioedemaClinicalActive
  • SapablursenTMPRSS6 / RNA-Targeted Therapeutic / Specialty/Rare
    Polycythemia VeraClinicalActive
  • UlefnersenFUS / RNA-Targeted Therapeutic / Neurology
    Amyotrophic Lateral SclerosisClinicalActive
  • TofersenSOD1 / RNA-Targeted Therapeutic / Neurology
    Amyotrophic Lateral Sclerosis (Presymptomatic SOD1)ClinicalActive
  • IONIS-MAPTRxBIIB080 / TAU / RNA-Targeted Therapeutic / Neurology
    Alzheimer's DiseaseClinicalActive
  • TominersenIONIS-HTTRx / HTT / RNA-Targeted Therapeutic / Neurology
    Huntington's DiseasePhase 2Active
  • ION306ION306 / SMN2 / RNA-Targeted Therapeutic / Neurology
    Spinal Muscular AtrophyClinicalActive
  • EplontersenTTR / RNA-Targeted Therapeutic / Cardiology
    Transthyretin-Mediated Amyloid CardiomyopathyPhase 3Active
  • ION904ION904 / Angiotensinogen / RNA-Targeted Therapeutic / Cardiology
    Treatment-Resistant HypertensionClinicalActive
  • BepirovirsenHepatitis B Virus / RNA-Targeted Therapeutic / Other Medicines
    Hepatitis B Virus InfectionPhase 3Active

Astellas Pharma Inc.

astellas.com
18assets
  • zolbetuximabIMAB362 / VYLOY / Claudin 18.2 / Antibody / Oncology
    Gastric and gastroesophageal junction adenocarcinoma, combo with pembrolizumab and chemotherapyFiledEuropeJapan
  • gilteritinibASP2215 / XOSPATA / FLT3 / Small molecule / Oncology
    Newly diagnosed acute myeloid leukemia with high intensity induction chemotherapyPhase 3Post-chemotherapy maintenance acute myeloid leukemiaPhase 3Post-hematopoietic stem cell transplant maintenance acute myeloid leukemiaPhase 3
  • enfortumab vedotinASG-22ME / PADCEV / Nectin-4 / Antibody-drug conjugate (ADC) / Oncology
    Cisplatin-eligible muscle-invasive bladder cancer, combo with pembrolizumabFiledEuropeUSCisplatin-ineligible muscle-invasive bladder cancer, combo with pembrolizumabFiledEuropeJapanBladder-sparing muscle-invasive bladder cancer, combo with pembrolizumabPhase 2
  • fezolinetantESN364 / VEOZAH / NK3 receptor / Small molecule / Women's Health
    Vasomotor symptoms due to menopausePhase 3ChinaVasomotor symptoms in breast cancer patients on adjuvant endocrine therapyPhase 2
  • zocaglusagene nuzaparvovecAT845 / GAA gene replacement / Gene therapy (AAV-based gene therapy) / Genetic Regulation
    Pompe diseasePhase 1
  • ASP2957ASP2957 / MTM1 gene replacement / Gene therapy (AAV-based gene therapy) / Genetic Regulation
    X-linked myotubular myopathyPhase 1
  • setidegrasibKRAS G12D / Small molecule degrader / Targeted Protein Degradation
    Pancreatic ductal adenocarcinomaPhase 3
  • ASP7317ASP7317 / Retinal pigment epithelial cells / Cell therapy / Ophthalmology
    Geographic atrophy secondary to age-related macular degenerationPhase 1
  • ASP1002ASP1002 / Claudin 4/CD137 / T-cell engager bispecific antibody / Oncology
    Gastric and gastroesophageal junction adenocarcinoma; pancreatic adenocarcinomaPhase 1
  • ASP5834ASP5834 / Pan-KRAS / Small molecule degrader / Oncology
    CancerPhase 1
  • VIR-5500VIR-5500 / PSMA/CD3 / T-cell engager / Oncology
    Prostate cancerPhase 1
  • ASP2998ASP2998 / TROP2 / Antibody-drug conjugate (ADC) / Oncology
    CancerPhase 1
  • ASP2138ASP2138 / Claudin 18.2/CD3 / T-cell engager bispecific antibody / Oncology
    CancerPhase 2
  • ASP546CASP546C / Claudin 18.2 / Antibody-drug conjugate (ADC) / Oncology
    CancerPhase 2Europe
  • abiraterone decanoateASP5541/PRL-02 / CYP17 lyase / Small molecule / Oncology
    Prostate cancerPhase 2
  • mirabegronYM178 / Beta-3 receptor / Small molecule / Urology
    Neurogenic detrusor overactivity in pediatric patients aged 6 months to less than 3 yearsPhase 3Europe
  • roxadustatASP1517/FG-4592 / HIF-PH / Small molecule / Nephrology
    Anemia associated with chronic kidney disease in pediatric patientsPhase 3Europe
  • pudexacianinium chlorideASP5354 / Drug-device combination / Other
    Intraoperative ureter visualization for minimally invasive and open abdominopelvic surgeriesPhase 3

Amneal Pharmaceuticals, Inc.

amneal.com
18assets
  • Mesalamine DRAsacol HD / generic small molecule / Gastroenterology
  • EverolimusAfinitor / mTOR / generic small molecule / Oncology
  • Prednisolone acetatePred-Forte / generic small molecule / Ophthalmology
  • EltrombopagPromacta / TPO receptor agonist / generic small molecule / Hematology
  • EpinephrineAdrenalin / adrenergic receptors / generic small molecule / Emergency/Critical Care
  • LenalidomideRevlimid / generic small molecule / Oncology
  • Risperidone ERRisperdal Consta / dopamine/serotonin receptors / generic long-acting injectable / Psychiatry
  • Romidepsin injectionRomidepsin / HDAC / generic small molecule / Oncology
  • CyclosporineRestasis / calcineurin / generic small molecule / Ophthalmology
  • Beclomethasone dipropionateQVAR / glucocorticoid receptor / generic inhaled corticosteroid / Respiratory
  • Sodium BicarbonateNeut / generic injectable / Critical Care
  • Lanreotide injectionSomatuline Depot / somatostatin receptors / generic peptide injectable / Endocrinology/Oncology
  • RifaximinXifaxan / generic small molecule / Gastroenterology
  • Omalizumab biosimilarXOLAIR / IgE / biosimilar monoclonal antibody / Immunology/Allergy
  • Sodium oxybateXyrem / generic small molecule / Neurology
  • BimatoprostLumigan / prostaglandin receptor / generic small molecule / Ophthalmology
  • Denosumab biosimilarsPROLIA & XGEVA / RANKL / biosimilar monoclonal antibody / Osteoporosis/Bone Cancer
  • Albuterol sulfateProAir HFA / beta-2 adrenergic receptor / generic inhaled small molecule / Respiratory

Arrowhead Pharmaceuticals, Inc.

arrowheadpharma.com
18assets
  • PlozasiranARO-APOC3 / REDEMPLO / APOC3 / RNAi therapeutic / Cardiometabolic
    Familial chylomicronemia syndromeIn MarketSevere hypertriglyceridemiaPhase 3ActiveHypertriglyceridemiaPhase 3Active
  • ZodasiranARO-ANG3 / ANGPTL3 / RNAi therapeutic / Cardiometabolic
    Homozygous familial hypercholesterolemiaPhase 3Recruiting
  • OlpasiranAMG 890; ARO-LPA / LPA / RNAi therapeutic / Cardiovascular disease
    Elevated lipoprotein(a)/cardiovascular riskPhase 3Recruiting/Active
  • GSK4532990ARO-HSD / HSD17B13 / RNAi therapeutic / Liver disease
    MASH/NASHPhase 2Recruiting
  • ARO-PNPLA3JNJ-75220795 / PNPLA3 / RNAi therapeutic / Liver disease
    MASH/NASHPhase 1
  • ARO-INHBEINHBE/Activin E / RNAi therapeutic / Obesity/metabolic disease
    Obesity with or without type 2 diabetesPhase 1
  • ARO-ALK7ACVR1C/ALK7 / RNAi therapeutic / Obesity/metabolic disease
    Obesity with or without type 2 diabetesPhase 1Recruiting
  • ARO-MAPTMAPT/tau / RNAi therapeutic / CNS
    Alzheimer's diseasePhase 1Recruiting
  • ARO-ATXN2ATXN2 / RNAi therapeutic / CNS
    Spinocerebellar ataxia 2Phase 1
  • SRP-1005ARO-HTT / HTT / siRNA therapeutic / CNS
    Huntington's diseasePhase 1
  • ARO-RAGERAGE / RNAi therapeutic / Pulmonary
    Inflammatory pulmonary diseasesPhase 2Active
  • ARO-MMP7MMP7 / RNAi therapeutic / Pulmonary
    Idiopathic pulmonary fibrosisPhase 1
  • FazirsiranTAK-999; ARO-AAT / Z-AAT / RNAi therapeutic / Liver disease
    Alpha-1 antitrypsin deficiency-associated liver diseasePhase 3Recruiting
  • ARO-HBVJNJ-3989; JNJ-73763989 / HBV gene products / RNAi therapeutic / Infectious disease
    Chronic hepatitis BPhase 2
  • ARO-DUX4DUX4 / RNAi therapeutic / Muscular disease
    Facioscapulohumeral muscular dystrophyPhase 2
  • ARO-DM1DMPK mRNA / RNAi therapeutic / Muscular disease
    Myotonic dystrophy type 1Phase 2Recruiting
  • ARO-C3Complement component 3 / RNAi therapeutic / Complement mediated disease
    Complement-mediated renal diseasePhase 1RecruitingC3 glomerulopathyPhase 1RecruitingIgA nephropathyPhase 1Recruiting
  • ARO-CFBComplement factor B / RNAi therapeutic / Complement mediated disease
    Complement mediated diseasePhase 1

XOMA Royalty Corporation

xoma.com
18assets
  • Vabysmofaricimab-svoa / VABYSMO / VEGF/Ang-2 / Bispecific antibody / Ophthalmology
    Neovascular age-related macular degeneration (nAMD) and Diabetic macular edema (DME)Approvedapproved
  • Ojemdatovorafenib / OJEMDA / Oncology
    Oncology (undisclosed approved indication)Approvedapproved
  • Miplyffaarimoclomol / MIPLYFFA / Rare Diseases / Neurology
    Niemann-Pick disease type C (NPC)ApprovedapprovedUS
  • Xaciatoclindamycin phosphate vaginal gel 2% / XACIATO / Small molecule / Gynecology / Infectious Disease
    Bacterial VaginosisApprovedapproved
  • Ixinitycoagulation factor IX (recombinant) / IXINITY / Factor IX / Recombinant protein / Hematology
    Hemophilia BApprovedapproved
  • Dsuviasufentanil sublingual tablet / DSUVIA / Opioid receptor / Small molecule / Pain Management
    PainApprovedapproved
  • Dare to Playsildenafil cream / DARE to PLAY / PDE5 / Small molecule / Gynecology / Sexual Health
    Female Sexual Arousal DisorderApprovedapproved
  • ersodetugRZ358 / INSR / Antibody / Metabolic Disorders
    Hypoglycemia due to congenital hyperinsulinism (cHI)Phase 3ongoingHypoglycemia due to tumor hyperinsulinismPhase 3ongoing
  • RZ402RZ402 / Ophthalmology
    Diabetic macular edema (DME)Phase 2ongoing
  • D-FiFCX-007 / Gene Therapy / Dermatology / Rare Diseases
    Dystrophic epidermolysis bullosa (DEB)Phase 3ongoing
  • seralutinibGB002 / PDGFR, CSF1R, and c-KIT / Inhaled tyrosine kinase inhibitor / Respiratory / Cardiovascular
    Pulmonary arterial hypertension (PAH)Phase 3ongoingPulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Phase 2ongoing
  • cetrelimabJNJ-63723283 / PD-1 / Antibody / Oncology / Infectious Disease
    Muscle-invasive bladder cancer (MIBC)Phase 2ongoingChronic Hepatitis B Virus InfectionPhase 2ongoing
  • volixibatLUM-002 / Ileal bile acid transporter (IBAT) / Small molecule / Gastroenterology
    Primary sclerosing cholangitis (PSC)Phase 2bongoingPrimary biliary cholangitis (PBC)Phase 2ongoing
  • osavampatorNeurology / Psychiatry
    Major depressive disorderPhase 3ongoing
  • OHB-607OHB-607 / Recombinant human IGF-I/IGFBP-3 / Recombinant protein / Respiratory / Neonatology
    Prevention of bronchopulmonary dysplasia in extremely premature infantsPhase 2ongoing
  • REC-4881REC-4881 / Allosteric MEK1/2 / Small molecule / Oncology
    Familial adenomatous polyposisPhase 2ongoing
  • NIS793NIS793 / Antibody / Oncology
    Solid tumorsPhase 3ongoing
  • QTORIN rapamycinQTORIN / mTOR / Small molecule / Dermatology / Rare Diseases
    Cutaneous venous malformationsPhase 3ongoingClinically significant angiokeratomasPhase 2ongoing

Neurocrine Biosciences, Inc.

neurocrine.com
17assets
  • direclidineM4 / Small Molecule / Psychiatry
    SchizophreniaPhase 3Bipolar ManiaPhase 2
  • NBI-570M1/M4 / Small Molecule / Psychiatry
    SchizophreniaPhase 2
  • osavampatorAMPA / Small Molecule / Psychiatry
    Major Depressive DisorderPhase 3
  • NBI-986M4 / Small Molecule / Neurology
    Movement DisordersPhase 1
  • NBI-890VMAT2 / Small Molecule / Psychiatry
    Tardive DyskinesiaPhase 2
  • NBI-569M1/M4 / Small Molecule / Psychiatry
    Alzheimer's PsychosisPhase 1
  • NBI-567M1 / Small Molecule / Neurology
    Alzheimer's CognitionPhase 1
  • NBI-355Nav1.2/1.6 / Small Molecule / Neurology
    EpilepsyPhase 1
  • NBIP-1435CRF1 / Peptide / Endocrinology
    Classic Congenital Adrenal HyperplasiaPhase 1
  • NBIP-2118CRF2 / Peptide / Endocrinology
    ObesityPhase 1
  • NBIP-1968TG + NBIP-2118 Combo / Peptide / Endocrinology
    ObesityPhase 4
  • NBIB-223Frataxin / Gene Therapy / Neurology
    Friedreich's AtaxiaPhase 4
  • NBI-675VMAT2 / Small Molecule / Psychiatry
    CNS IndicationsPhase 1
  • NBI-188CRF1 / Small Molecule / Endocrinology
    Women's HealthPhase 4
  • NBIM-1748Immunology
    UndisclosedPhase 4
  • NBIM-1008Immunology
    UndisclosedPhase 4
  • NBIM-1112Immunology
    UndisclosedPhase 1

Regeneron Pharmaceuticals, Inc.

regeneron.com
17assets
  • FianlimabLAG3 / Monoclonal Antibody / Oncology
    1L metastatic melanoma, adjuvant melanomaPhase 3ActiveGlobal
  • CemiplimabLibtayo / PD-1 / Monoclonal Antibody / Oncology
    CancerPhase 2/3ActiveGlobal
  • DavutamigREGN5093 / METxMET / Bispecific Antibody / Oncology
    CancerPhase 2ActiveGlobal
  • ItepekimabIL-33 / Monoclonal Antibody / Immunology & Inflammation / Respiratory
    COPD, CRSwNPPhase 3ActiveGlobal
  • LinvoseltamabLynozyfic / BCMAxCD3 / Bispecific Antibody / Oncology
    Multiple myelomaPhase 2/3ActiveGlobal
  • MarlotamigREGN7075 / EGFRxCD28 / Bispecific Antibody / Oncology
    Solid TumorsPhase 2ActiveGlobal
  • OdronextamabOrdspono / CD20xCD3 / Bispecific Antibody / Oncology
    LymphomaPhase 2ActiveGlobal
  • UbamatamabREGN4018 / MUC16xCD3 / Bispecific Antibody / Oncology
    Ovarian CancerPhase 2ActiveGlobal
  • NezastomigREGN5678 / PSMAxCD28 / Bispecific Antibody / Oncology
    Prostate CancerPhase 2ActiveGlobal
  • RapirosiranALN-HSD / HSD17B13 / siRNA / Cardiovascular & Metabolic
    NASHPhase 2ActiveGlobal
  • ALN-ANG3ALN-ANG3 / ANGPTL3 / siRNA / Cardiovascular & Metabolic
    DyslipidemiaPhase 2ActiveGlobal
  • CemdisiranC5 / siRNA / Ophthalmology / Immunology
    Geographic atrophyClinicalActiveGlobal
  • PozelimabC5 / Monoclonal Antibody / Ophthalmology / Immunology
    Geographic atrophyClinicalActiveGlobal
  • BetV1REGN5713-5715 / BetV1 / Monoclonal Antibody / Immunology & Inflammation
    Birch AllergyClinicalActiveGlobal
  • DB-OTOOtarmeni / Otoferlin / Gene Therapy / Neurology / Hearing Loss
    Otoferlin-related hearing lossPhase 1/2ActiveGlobal
  • MibavademabUnknown / Biologic / Oncology
    CancerPhase 2ActiveGlobal
  • TrevogrumabREGN1033 / Myostatin / Monoclonal Antibody / Metabolic
    Muscle weakness/wastingPhase 2ActiveGlobal

Bristol Myers Squibb

bms.com
16assets
  • mezigdomidecereblon E3 ligase / CELMoD; oral targeted protein degrader / Hematology
    relapsed/refractory multiple myelomaPhase IIIactive
  • iberdomidecereblon E3 ligase / CELMoD; oral targeted protein degrader / Hematology
    multiple myelomaPhase IIIactive
  • golcadomidecereblon E3 ligase / CELMoD; oral targeted protein degrader / Hematology
    aggressive B-cell lymphomaPhase IIactive
  • pumitamigBNT327/BMS-986545 / PD-L1; VEGF-A / bispecific antibody / Oncology
    solid tumorsPhase IIIactive
  • iza-brenantibody-drug conjugate / Oncology
    solid tumorsPhase I/IIactive
  • nivolumabOPDIVO / PD-1 / monoclonal antibody / Oncology
    multiple oncology indicationsPhase IIIactive LCM
  • nivolumab and relatlimab HDPD-1; LAG-3 / antibody combination / Oncology
    oncology indicationsPhase IIIactive LCM
  • ipilimumabYERVOY / CTLA-4 / monoclonal antibody / Oncology
    multiple oncology indicationsPhase IIIactive LCM
  • KarXTCOBENFY / muscarinic receptors / small molecule / Neuroscience
    neuropsychiatric indicationsPhase IIIactive LCM
  • milvexianFactor XIa / small molecule anticoagulant / Cardiovascular
    thrombotic disordersPhase IIIactive
  • BMS-986278BMS-986278 / LPA1 / small molecule antagonist / Fibrosis
    idiopathic pulmonary fibrosisPhase IIIactive
  • BMS-986495BMS-986495 / MTBR tau / antibody / Neuroscience
    Alzheimer's diseasePhase IIactive
  • imzokitugCCR8 / monoclonal antibody / Oncology
    solid tumorsPhase I/IIactive
  • obexelimabCD19; FcγRIIb / bifunctional antibody / Immunology
    autoimmune diseasesPhase IIIactive
  • luspatercept-aamtREBLOZYL / TGF-beta superfamily ligands / recombinant fusion protein / Hematology
    anemia indicationsPhase IIIactive LCM
  • OncoACP3OncoACP3 / prostate cancer target / radiopharmaceutical therapeutic/diagnostic agent / Oncology
    prostate canceractive

Johnson & Johnson

investor.jnj.com
16assets
  • guselkumabTREMFYA / IL-23 / Monoclonal Antibody / Immunology
    PsoriasisPsoriatic ArthritisCrohn's Disease
  • ibrutinibIMBRUVICA / BTK / Small Molecule / Oncology
    Mantle Cell LymphomaOther B-cell malignancies
  • icotrokinraJNJ-2113 / IL-23R / Targeted Oral Peptide / Immunology
    PsoriasisPsoriatic Arthritis
  • JNJ-4804JNJ-4804 / Co-antibody / Co-antibody Therapy / Immunology
    Ulcerative Colitis
  • nipocalimabIMAAVY / FcRn / Monoclonal Antibody / Immunology / Neuroscience
    Generalized Myasthenia GravisRheumatoid ArthritisWarm Autoimmune Hemolytic Anemia
  • aticaprantKOR antagonist / Small Molecule / Neuroscience
    Adjunctive Treatment for Major Depressive Disorder with Anhedonia
  • RPGR Gene TherapyRPGR / Gene Therapy / Vision / Ophthalmology
    Retinitis Pigmentosa
  • teclistamabTECVAYLI / BCMA x CD3 / Bispecific Antibody / Oncology
    Multiple Myeloma
  • sCD59JNJ-1887 / sCD59 / Gene Therapy / Vision / Ophthalmology
    Geographic Atrophy
  • gemcitabine intravesical delivery systemTAR-200 / INLEXZO / DNA synthesis / Drug Delivery System / Oncology
    High Risk Non-Muscle Invasive Bladder Cancer
  • niraparib / abirateroneAKEEGA / PARP / CYP17 / Small Molecule Combination / Oncology
    Metastatic Castration-Sensitive Prostate CancerMetastatic Castration-Resistant Prostate Cancer
  • daratumumabDARZALEX / CD38 / Monoclonal Antibody / Oncology
    Multiple Myeloma
  • erdafitinibBALVERSA / FGFR / Small Molecule / Oncology
    Urothelial Carcinoma
  • apalutamideERLEADA / Androgen Receptor / Small Molecule / Oncology
    Prostate Cancer
  • ciltacabtagene autoleucelCARVYKTI / BCMA / CAR-T Cell Therapy / Oncology
    Multiple Myeloma
  • Filovirus multivalent vaccineVAC69120 / MVA-BN-Filo / Ebola Virus / Vaccine / Infectious Diseases
    Ebola

Zai Lab Limited

zailaboratory.com
16assets
  • NiraparibPARP / Inhibitor / Oncology
    Ovarian Cancer (1st line maintenance)ApprovedOvarian Cancer (Platinum sensitive relapsed maintenance)Approved
  • Tumor Treating FieldsOncology
    Glioblastoma (GBM)ApprovedPancreatic Cancer (1st line)Phase 3 / Pivotal
  • RipretinibTKI / Oncology
    Gastrointestinal Stromal Tumors (GIST) (4th line)Approved
  • RepotrectinibROS1 / TRK / Oncology
    ROS1+ NSCLCApprovedNTRK+ solid tumorsApproved
  • Tisotumab vedotinTF / ADC / Oncology
    Cervical Cancer (2nd line+ r/m)Phase 3 / PivotalCervical Cancer (1st line r/m, combo)Phase 2 / POC
  • Zocilurtatug pelitecanZL-1310 / Zoci / DLL3 / ADC / Oncology
    ES-SCLCPhase 3 / PivotalOther NECsPhase 2 / POC
  • ZL-6201LRRC15 / ADC / Oncology
    Sarcoma & CAF+ Solid TumorPhase 1
  • ZL-1311MUC17xCD3 / Oncology
    GI TumorsPre-clinical
  • ZL-1222PD-1/IL-12 / Oncology
    Solid TumorsPre-clinical
  • EfgartigimodFcRn / Immunology
    Generalized Myasthenia Gravis (gMG)ApprovedChronic Inflammatory Demyelinating Polyneuropathy (CIDP)ApprovedMyositisPhase 3 / Pivotal
  • PovetaciceptBAFF/APRIL / Immunology
    IgA NephropathyPhase 3 / PivotalPrimary Membranous NephropathyPhase 2 / POC
  • ElegrobartIGF-1R / Immunology
    TEDPhase 3 / Pivotal
  • ZL-1503IL13/IL31R / Immunology
    Mod-to-Sev ADPhase 1
  • Xanomeline-TrospiumKarXT / Neuroscience
    SchizophreniaApproved
  • OmadacyclineInfectious Disease
    Acute Bacterial Skin and Skin Structure Infection (ABSSSI)ApprovedCommunity-Acquired Bacterial Pneumonia (CABP)Approved
  • Sulbactam-DurlobactamInfectious Disease
    HABP/VABP caused by Susceptible Isolates of Acinetobacter Baumannii-calcoaceticus ComplexApproved

Takeda Pharmaceutical Company Limited

takeda.com
15assets

Agenus Inc.

agenusbio.com
14assets
  • BotensilimabAGEN1181 / Anti-CTLA-4 / Fc-enhanced anti-CTLA-4 antibody / Oncology
    Non-MSI-H 4L+ metastatic colorectal cancerPhase 3Sites activeNon-MSI-H metastatic colorectal cancer NLMPhase 2Enrollment completePD-1 R/R melanomaPhase 2
  • BalstilimabAGEN2034 / Anti-PD-1 / PD-1 inhibitor antibody / Oncology
    MSS metastatic colorectal cancer in combination with botensilimabPhase 3Sites activePD-1 R/R melanoma in combination with botensilimabPhase 2
  • AGEN2373AGEN2373 / CD137 / CD137 agonist antibody / Oncology
    Solid tumorsPhase 1PD-1 R/R melanoma with botensilimabPhase 2
  • AGEN1571AGEN1571 / Anti-ILT-2 / Antibody / Oncology
    Solid tumorsPhase 1
  • AGEN1777AGEN1777 / Anti-TIGIT x CD96 / Bispecific antibody / Oncology
    Solid tumors with balstilimabPhase 1
  • AGEN1423AGEN1423 / Anti-CD73 x TGFB / Bispecific antibody / Oncology
    Solid tumorsPhase 1
  • INCAGN1876INCAGN1876 / Anti-GITR / Antibody / Oncology
    Solid tumorsPhase 1
  • AGEN1949AGEN1949 / OX40 / OX40 agonist antibody / Oncology
    Solid tumorsPhase 1
  • MK-4830MK-4830 / ILT4 / Anti-ILT4 antagonist antibody / Oncology
    Neoadjuvant ovarian cancerPhase 2Ongoing
  • INCAGN2390INCAGN2390 / TIM-3 / Anti-TIM-3 antagonist antibody / Oncology
    Melanoma and SCCHN in combinationIn development
  • INCAGN2385INCAGN2385 / LAG-3 / Anti-LAG-3 antagonist antibody / Oncology
    Melanoma and SCCHN in combinationIn development
  • CR6086 + BalstilimabCR6086; AGEN2034 / EP4 + PD-1 / EP4 antagonist plus PD-1 antagonist / Oncology
    pMMR-MSS colorectal cancerPhase 1/2Ongoing
  • NLM001 + ZalifrelimabNLM-001 / Hedgehog + CTLA-4 / Hedgehog inhibitor plus CTLA-4 antagonist / Oncology
    Advanced pancreatic cancerPhase 1/2Ongoing
  • OBT076 + BalstilimabOBT076; AGEN2034 / CD205 + PD-1 / Antibody-drug conjugate plus PD-1 antibody / Oncology
    Solid tumorsOngoing

Alvotech

alvotech.com
14assets
  • High-concentration, low-volume adalimumabAVT02 / HUMIRA® / Biosimilar / Immunology
    Biosimilar to HUMIRA®ApprovedApprovedU.S.Europe (EEA, UK, Switzerland, Balkans)CanadaAustraliaSaudi ArabiaIsraelEgyptSouth AfricaMoroccoPeruBolivia
  • ustekinumabAVT04 / STELARA® / Biosimilar / Immunology
    Biosimilar to STELARA®ApprovedApprovedU.S.JapanCanadaEU/EEA
  • denosumabAVT03 / PROLIA®/XGEVA® / Biosimilar / Bone Disease
    Biosimilar to PROLIA®/XGEVA®ApprovedApprovedJapanEU/EEA
  • golimumabAVT05 / SIMPONI®/SIMPONI ARIA® / Biosimilar / Immunology
    Biosimilar to SIMPONI®/SIMPONI ARIA®ApprovedApprovedJapanEU/EEAUnited Kingdom
  • afliberceptAVT06 / EYLEA® / Biosimilar / Ophthalmology
    Biosimilar to EYLEA®ApprovedApprovedEU/EEAJapanUnited Kingdom
  • omalizumabAVT23 / XOLAIR® / Biosimilar / Respiratory
  • vedolizumabAVT16 / ENTYVIO® / Biosimilar / Immunology
  • pembrolizumabAVT33 / KEYTRUDA® / Biosimilar / Oncology
  • certolizumab pegolAVT10 / CIMZIA® / Biosimilar / Immunology
  • ixekizumabAVT28 / TALTZ® / Biosimilar / Immunology
  • canakinumabAVT48 / ILARIS® / Biosimilar / Immunology
  • guselkumabAVT41 / TREMFYA® / Biosimilar / Immunology
  • ofatumumabAVT65 / KESIMPTA® / Biosimilar / Immunology
  • dupilumabAVT19 / DUPIXENT® / Biosimilar / Immunology

Telix Pharmaceuticals Limited

telixpharma.com
14assets
  • 177Lu rosopatamab tetraxetanTLX591-Tx / PSMA / Antibody / Urologic Oncology
    Prostate Cancer
  • 177Lu-DOTA-PSMATLX597-Tx / PSMA / Small molecule / Urologic Oncology
    Prostate Cancer
  • 177Lu-girentuximabTLX250-Tx / CAIX / Antibody / Urologic Oncology
    Kidney Cancer / ccRCC
  • 131I-IPATLX101-Tx / LAT / Small molecule / Neuro-oncology
    Brain Cancer / Glioma
  • 90Y-besilesomabTLX66-Tx / CD66 / Antibody / Hematology
    Bone-marrow conditioning
  • 225Ac-RADmAbTLX592-Tx / PSMA / Antibody / Urologic Oncology
    Prostate Cancer
  • 225Ac-girentuximabTLX252-Tx / CAIX / Antibody / Urologic Oncology
    Kidney Cancer
  • UndisclosedTLX400-Tx / FAP / Small molecule / Urologic Oncology
    Bladder Cancer
  • 211At-APATLX102-Tx / LAT / Small molecule / Neuro-oncology
    Brain Cancer
  • -olaratumab conjugateTLX300-Tx / PDGFRα / Antibody / Musculoskeletal Oncology
    Soft Tissue Sarcoma
  • 153Sm-DOTMPTLX090-Tx / Small molecule / Musculoskeletal Oncology
    Bone metastasesPain palliation
  • 68Ga-PSMA-11TLX591-CDx / Illuccix / Gozellix / PSMA / Diagnostic Radiopharmaceutical / Oncology
    Prostate Cancer Imaging
  • 18F-floretyrosineTLX101-CDx / Pixclara / Pixlumi / LAT / Diagnostic Radiopharmaceutical / Neuro-oncology
    Glioma Imaging
  • 89Zr-DFO-girentuximabTLX250-CDx / Zircaix / CAIX / Diagnostic Radiopharmaceutical / Oncology
    Clear Cell Renal Cell Carcinoma (ccRCC) Imaging

Lantheus Holdings, Inc.

lantheus.com
13assets

Argenx SE

argenx.com
12assets
  • EfgartigimodVYVGART; VYVGART Hytrulo / FcRn / antibody fragment / Autoimmune
    Generalized Myasthenia Gravis (gMG)CommercialChronic Inflammatory Demyelinating Polyneuropathy (CIDP)CommercialPrimary Immune Thrombocytopenia (ITP)CommercialJapan
  • EmpasiprubartC2 / monoclonal antibody / Autoimmune
    Multifocal Motor Neuropathy (MMN)RegistrationalDelayed Graft Function (DGF)Proof of ConceptChronic Inflammatory Demyelinating Polyneuropathy (CIDP)Registrational
  • AdimanebartMuSK / agonist antibody / Neurology
    Congenital Myasthenic Syndromes (CMS)Proof of ConceptSpinal Muscular Atrophy (SMA)Proof of Concept
  • ARGX-109ARGX-109 / IL-6 / antibody / Undisclosed
    UndisclosedPhase 1
  • ARGX-121ARGX-121 / IgA / antibody / Undisclosed
    UndisclosedPhase 1
  • ARGX-213ARGX-213 / FcRn / antibody / Undisclosed
    UndisclosedPhase 1
  • ARGX-118ARGX-118 / Galectin-10 / Airway Inflammation
    Airway InflammationPreclinical
  • ARGX-125ARGX-125 / bispecific antibody / Undisclosed
    UndisclosedPreclinical
  • TSP-101TSP-101 / Fn14 / Undisclosed
    UndisclosedPreclinical
  • LP0145ARGX-112 / IL-22R / SIMPLE Antibody / Dermatology
    Atopic Dermatitispartnered
  • AGMB-101ARGX-114 / MET / HGF-mimetic agonist antibody
  • ABBV-151ARGX-115 / GARP-TGF-beta1 / SIMPLE Antibody / Oncology
    Tumorspartnered

Arcus Biosciences, Inc.

arcusbio.com
12assets

Biohaven Ltd.

biohaven.com
11assets
  • Taldefgrobep AlfaBHV-2000 / myostatin/activin receptor signaling / recombinant protein; myostatin-activin pathway inhibitor / neuromuscular; metabolic
    Spinal muscular atrophyPhase 3ObesityPhase 1
  • OpakalimBHV-7000 / Kv7.2/Kv7.3 potassium channels / small molecule Kv7 activator / neurology; psychiatry
    Focal epilepsyPhase 3Generalized epilepsyPhase 3Major depressive disorderPhase 2
  • TRPM3 AntagonistBHV-2100 / TRPM3 / oral small molecule antagonist / pain
    Pain disordersPhase 2
  • TYK2/JAK1 InhibitorBHV-8000 / TYK2/JAK1 / brain-penetrant small molecule inhibitor / neuroinflammation
    Parkinson's diseasePhase 3Prevention of amyloid therapy induced ARIAPhase 1Alzheimer's diseasePhase 1
  • IgG DegraderBHV-1300 / IgG / MoDE extracellular protein degrader / immunology
    Graves' disease / rheumatoid arthritisPhase 1
  • IgG DegraderBHV-1310 / IgG / MoDE extracellular protein degrader / immunology
    Myasthenia gravisPreclinical
  • Gd-IgA1 TRAP DegraderBHV-1400 / galactose-deficient IgA1 / TRAP extracellular protein degrader / immunology; renal
    IgA nephropathyPhase 1
  • β1AR Autoantibody DegraderBHV-1600 / β1AR autoantibodies / bifunctional MoDE degrader / cardiovascular
    Peripartum cardiomyopathyPhase 1
  • Trop2 ADC +/- PD1BHV-1510 / TROP2 / antibody-drug conjugate / oncology
    Advanced or metastatic epithelial tumorsPhase 1
  • FGFR3 ADCBHV-1530 / FGFR3 / antibody-drug conjugate / oncology
    Urothelial cancer and other tumorsPhase 1
  • CD30 ADCBHV-1500 / CD30 / antibody-drug conjugate / oncology
    Hodgkin lymphomaPreclinical

Biogen Inc.

biogen.com
11assets
  • LecanemabLEQEMBI / Aβ / mAb / Neurology
    Preclinical Alzheimer's diseasePhase 3Early Alzheimer's disease, SC-AI initiationRegulatory review; FDA PDUFA May 24, 2026U.S.
  • DiranersenBIIB080 / tau / ASO / Neurology
    Early Alzheimer's diseasePhase 2PoC readout reported May 14, 2026
  • BIIB091BIIB091 / BTK / peripheral BTK inhibitor / Neurology
    Multiple sclerosisPhase 2
  • Dapirolizumab pegolCD40L / pegylated antibody fragment / Immunology
    Systemic lupus erythematosusPhase 3
  • LitifilimabBDCA2 / mAb / Immunology
    Systemic lupus erythematosusPhase 3Cutaneous lupus erythematosusPhase 3FDA Breakthrough Therapy DesignationU.S.
  • BIIB142BIIB142 / IRAK4 / degrader / Immunology
    Autoimmune diseasePhase 1
  • FelzartamabCD38 / mAb / Rare disease
    Antibody-mediated rejectionPhase 3IgA nephropathyPhase 3Primary membranous nephropathyPhase 3
  • OmaveloxoloneSKYCLARYS / Nrf2 / activator / Rare disease
    Pediatric Friedreich ataxiaPhase 3
  • SalanersenBIIB115 / SMN / ASO / Rare disease
    Spinal muscular atrophyPhase 3
  • ZorevunersenSCN1A / ASO / Rare disease
    Dravet syndromePhase 3
  • Nusinersen high doseSPINRAZA / SMN2 / splice modulator / Rare disease
    Spinal muscular atrophyApproved in U.S.; under review in E.U.U.S.E.U.

Denali Therapeutics Inc.

denalitherapeutics.com
11assets
  • tividenofusp alfa-eknmDNL310; ETV:IDS / AVLAYAH / IDS enzyme replacement; TfR TransportVehicle-enabled delivery / Enzyme TransportVehicle biologic / Lysosomal storage disorders
    Hunter syndrome (MPS II)Approved; Phase 2/3 confirmatory study ongoingU.S. accelerated approval; global Phase 2/3 COMPASS ongoingUSGlobal
  • DNL126ETV:SGSH / SGSH enzyme replacement / Enzyme TransportVehicle biologic / Lysosomal storage disorders
    Sanfilippo syndrome Type A (MPS IIIA)Phase 1/2; Phase 3 plannedOngoing Phase 1/2; global Phase 3 confirmatory study plannedGlobal
  • DNL593TAK-594/DNL593; PTV:PGRN / Progranulin replacement / Protein TransportVehicle biologic / Neurodegenerative disease
    GRN-related frontotemporal dementia (FTD-GRN)Phase 1/2Ongoing; Denali received notice that Takeda will terminate collaboration, with Denali planning to continue developmentGlobal
  • DNL628OTV:MAPT / MAPT / tau / Oligonucleotide TransportVehicle therapeutic / Neurodegenerative disease
    Alzheimer's diseasePhase 1bCTA approved; study start-up underway
  • DNL952ETV:GAA / GAA enzyme replacement / Enzyme TransportVehicle biologic / Lysosomal storage disorders
    Pompe diseasePhase 1IND clinical hold lifted; proceeding to Phase 1US
  • BIIB122/DNL151DNL151; BIIB122 / LRRK2 / Small molecule inhibitor / Neurodegenerative disease
    Parkinson's diseasePhase 2bLUMA enrollment completed; readout expected 2026GlobalLRRK2-associated Parkinson's diseasePhase 2aBEACON ongoing
  • eclitasertibSAR443122/DNL758 / RIPK1 / Small molecule inhibitor / Inflammatory disease
    Ulcerative colitisPhase 2Developed by Sanofi; Phase 2 results expected in 1H 2026
  • DNL921ATV:Abeta / Amyloid beta / Antibody TransportVehicle therapeutic / Neurodegenerative disease
    Alzheimer's diseaseIND-enablingPhase 1/1b initiation planned
  • DNL111ETV:GCase / GCase / Enzyme TransportVehicle biologic / Neurodegenerative disease; lysosomal storage disorders
    Parkinson's diseaseIND-enablingIND-enablingGaucher diseaseIND-enablingIND-enabling
  • DNL622ETV:IDUA / IDUA enzyme replacement / Enzyme TransportVehicle biologic / Lysosomal storage disorders
    MPS IIND-enablingIND-enabling
  • DNL422OTV:SNCA / SNCA / alpha-synuclein / Oligonucleotide TransportVehicle therapeutic / Neurodegenerative disease
    Parkinson's diseaseIND-enablingIND-enabling

Incyte Corporation

incyte.com
11assets
  • INCA033989INCA033989 / mutCALR / Hematology
    CALR-mutated essential thrombocythemia (2L)Phase 3Initiation mid-2026USCALR-mutated myelofibrosis (1L)Phase 1Data expected 2H 2026CALR-mutated myelofibrosis (2L)Phase 3Initiation 2H 2026
  • INCB161734INCB161734 / KRAS G12D / Oncology
    1L G12D-mutated pancreatic ductal adenocarcinoma (PDAC)Phase 3Ongoing (in combo with SOC chemo)KRAS G12D-mutated solid tumorsPhase 1Data expected 2H 2026
  • INCA33890INCA33890 / TGFβR2 × PD-1 / bispecific / Oncology
    1L microsatellite-stable colorectal cancer (MSS CRC)Phase 3Ongoing1L MSS PDAC (combo with SOC)Phase 1Data expected 2H 2026
  • INCB123667INCB123667 / CDK2 / Oncology
    Platinum-resistant ovarian cancer (PROC)PivotalOngoing1L maintenance ovarian cancer (CCNE1+)Phase 3Initiation planned 2H 2026
  • povorcitinibJAK1 / small molecule / Inflammation and Autoimmunity
    Moderate-to-severe hidradenitis suppurativa (HS)Phase 3NDA accepted; approval anticipated 1Q 2027 (US), late 2026 (EU)USEUNonsegmental vitiligoPhase 3Positive data; sNDA submission 1H 2027Moderate-to-severe prurigo nodularis (PN)Phase 3Ongoing; topline data 4Q 2026
  • ruxolitinib creamOpzelura / JAK1/JAK2 / topical / Inflammation and Autoimmunity
    Moderate atopic dermatitisApprovedApproval and launch (ex-US)EUMild-to-moderate hidradenitis suppurativa (HS)Phase 3Ongoing; topline data 4Q 2026
  • axatilimabNiktimvo / CSF-1R / Hematology
    1L chronic GVHD (+ ruxolitinib)PivotalData 2H 20261L chronic GVHD (+ steroids)Data early 20283L+ chronic GVHDApprovedApprovedUS
  • INCB160058INCB160058 / JAK2V617F / Hematology
    JAK2 V617F-mutated myeloproliferative neoplasms (MPNs)Phase 1Data 2H 2026 (ASD formulation)
  • tafasitamabMonjuvi / CD19 / Hematology
    1L diffuse large B-cell lymphoma (DLBCL)Phase 3sBLA submission 1H 2026USRelapsed/refractory DLBCLApprovedApprovedUSEUJapan
  • ruxolitinib XRJakafi XR / JAK1/JAK2 / Hematology
    Myelofibrosis, polycythemia vera, chronic GVHDRegistrationFDA resubmissionUS
  • retifanlimabZynyz / PD-1 / Oncology
    Squamous cell carcinoma of the anal canal (SCAC)ApprovedApproved (EC approval noted)USEUMerkel cell carcinomaApprovedApprovedUSEUJapan

Krystal Biotech, Inc.

krystalbio.com
11assets
  • B-VECB-VEC / VYJUVEK / Type VII collagen (COL7A1) / Gene Therapy (HSV-1 vector) / Dermatology
    Dystrophic Epidermolysis Bullosa (DEB)CommercialApprovedGlobal
  • KB105KB105 / Transglutaminase 1 (TGM1) / Gene Therapy / Dermatology
    TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)Phase 1/2ActiveGlobal
  • KB104KB104 / Serine Peptidase Inhibitor Kazal Type 5 (SPINK5) / Gene Therapy / Dermatology
    Netherton SyndromePreclinicalActiveGlobal
  • KB407KB407 / Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) / Gene Therapy / Respiratory
    Cystic FibrosisPhase 1ActiveGlobal
  • KB408KB408 / Alpha-1 antitrypsin / Gene Therapy / Respiratory
    Alpha-1 Antitrypsin Deficiency (AATD)PreclinicalActiveGlobal
  • KB707KB707 / IL-12 and IL-2 / Gene Therapy (HSV-1 vector) / Oncology
    Locally advanced or metastatic solid tumor malignanciesPhase 1ActiveGlobal
  • KB301KB301 / Type III collagen / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPhase 1/2ActiveGlobal
  • KB302KB302 / Type I collagen / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal
  • KB303KB303 / Elastin / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal
  • KB304KB304 / Type III collagen and Elastin / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal
  • KB305KB305 / Type IV collagen / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal

Sanofi

sanofi.com
11assets
  • amlitelimabOX40L / Monoclonal antibody / Immunology
    Atopic dermatitisPhase 3ActiveGlobal
  • tolebrutinibBTK / Small molecule / Neurology
    Multiple sclerosisRegistrationActiveGlobalUS
  • lunsekimigBiologic / Immunology and Inflammation
    Asthma / Respiratory diseasesPhase 2ActiveGlobal
  • rilzabrutinibBTK / Small molecule / Rare Blood Disorders / Immunology
    Sickle cell diseasePhase 2/3ActiveGlobalIgG4-related diseasePhase 3ActiveGlobalAsthmaPhase 2ActiveGlobal
  • venglustatSmall molecule / Rare Diseases
    Gaucher disease type 3 (GD3)Phase 3ActiveGlobal
  • frexalimabCD40L / Monoclonal antibody / Immunology
    Multiple sclerosisPhase 3ActiveGlobal
  • SAR441566SAR441566 / TNFR1si / Small molecule / Immunology
    Immunological diseasesPhase 2ActiveGlobal
  • duvakitugTL1A / Monoclonal antibody / Immunology
    Ulcerative colitisPhase 2ActiveGlobalCrohn's diseasePhase 2ActiveGlobal
  • itepekimabIL-33 / Monoclonal antibody / Immunology and Inflammation
    COPDPhase 3ActiveGlobal
  • isatuximabSarclisa / CD38 / Monoclonal antibody / Oncology
    Multiple myeloma (subcutaneous)RegistrationActiveEU
  • acoziboroleSmall molecule / Infectious Diseases
    Sleeping sicknessRegistrationActiveAfricaEU

BioAtla, Inc.

bioatla.com
10assets
  • Ozuriftamab vedotinBA3021 / ROR2 / CAB-ROR2-ADC / Oncology
    OPSCCPhase 3
  • Mecbotamab vedotinBA3011 / AXL / CAB-AXL-ADC / Oncology
    Sarcoma (soft tissue and bone)Phase 2mKRAS NSCLCPhase 2
  • EvalstotugBA3071 / CTLA-4 / CAB-CTLA-4 antibody / Oncology
    Unresectable and/or metastatic cutaneous melanomaPhase 2
  • BA3182BA3182 / EpCAM x CD3 / Dual CAB T cell engager / Oncology
    AdenocarcinomaPhase 1ongoing
  • BA3361BA3361 / Nectin-4 / CAB-Nectin4-ADC / Oncology
    Multiple tumor typesPreclinicalIND-approved
  • BA3151BA3151 / B7-H4 / CAB-B7H4-ADC / Oncology
    Breast cancerPreclinical
  • BA3142BA3142 / B7-H3 x CD3 / Dual CAB TCE / Oncology
    Multiple tumor typesPreclinicalIND-ready
  • BA3311BA3311 / EGFR x CD3 / TCE / Oncology
    Multiple tumor typesPreclinical
  • BA3241BA3241 / Trop2 x CD3 / Dual CAB TCE / Oncology
    Epidermoid cancerPreclinical
  • BA3362BA3362 / Nectin4 x CD3 / Dual CAB TCE / Oncology

Corcept Therapeutics Incorporated

corcept.com
10assets
  • Relacorilantglucocorticoid receptor / selective cortisol modulator / Endocrinology
    Hypercortisolism (GRACE)Phase IIIFiledHypercortisolism associated with adrenal adenoma or hyperplasia (GRADIENT)Phase IIIFiledLong-term safety extensionPhase IIFiled
  • KorlymKorlym / glucocorticoid receptor / cortisol modulator / Endocrinology
    Prevalence and treatment of hypercortisolism in difficult-to-control type 2 diabetes (CATALYST)Phase IV
  • LifyorliLifyorli / glucocorticoid receptor / selective cortisol modulator / Oncology
    Platinum-resistant ovarian cancer (ROSELLA)Phase IIIApproved
  • Relacorilant + Nab-paclitaxel + Bevacizumabglucocorticoid receptor / selective cortisol modulator combination / Oncology
    Platinum-resistant ovarian cancer (BELLA Arm A)Phase IIPlatinum-sensitive ovarian cancer (BELLA Arm B)Phase III
  • Relacorilant + Nab-paclitaxelglucocorticoid receptor / selective cortisol modulator combination / Oncology
    Endometrial cancer (BELLA Arm C)Phase IICervical cancer (STELLA)Phase II
  • Relacorilant + Nab-paclitaxel + Gemcitabineglucocorticoid receptor / selective cortisol modulator combination / Oncology
    Pancreatic cancer (TRIDENT)Phase II
  • Nenocorilant + Nivolumabglucocorticoid receptor / selective cortisol modulator combination / Oncology
    Solid tumors (SYNERGY)Phase II
  • Relacorilant + Enzalutamideglucocorticoid receptor / selective cortisol modulator combination / Oncology
    Prostate cancerPhase II
  • Dazucorilantglucocorticoid receptor / selective cortisol modulator / Neurology
    ALS (DAZALS)Phase II
  • Miricorilantglucocorticoid receptor / selective cortisol modulator / Metabolism
    MASH (MONARCH)Phase II

HUTCHMED (China) Limited

hutch-med.com
10assets
  • FruquintinibHMPL-013 / ELUNATE / FRUZAQLA / VEGFR 1/2/3 / Small molecule / Oncology
    Colorectal cancerApproved/MarketedApprovedChinaUSEuropeJapanGastric cancerPhase IIIActiveGlobalOther solid tumors (combination studies)ClinicalActiveGlobal
  • SavolitinibHMPL-504 / AZD6094 / ORPATHYS / c-MET / Small molecule / Oncology
    Non-small cell lung cancer (MET exon 14)Approved/MarketedApprovedChinaNSCLC combinations (with immunotherapy/targeted therapy)Phase IIIActiveGlobal
  • SurufatinibHMPL-012 / SULANDA / VEGFR/FGFR/CSF-1R / Small molecule / Oncology
    Neuroendocrine tumorsApproved/MarketedApprovedChina
  • SovleplenibHMPL-523 / Syk / Small molecule / Hematology/Immunology
    Immune thrombocytopenia (ITP)NDA/Regulatory reviewUnder regulatory reviewChina
  • FanregratinibHMPL-453 / FGFR / Small molecule / Oncology
    Cholangiocarcinoma (FGFR2 fusion)NDA/Regulatory reviewUnder regulatory reviewChina
  • HMPL-760HMPL-760 / BTK (non-covalent) / Small molecule / Oncology/Hematology
    Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)Phase IIIInitiatedChina
  • HMPL-A251HMPL-A251 / HER2 (PI3K/PIKK payload) / Antibody-Targeted Therapy Conjugate (ATTC) / Oncology
    HER2-positive/HER2-low solid tumorsPhase IActiveChinaUS
  • HMPL-A580HMPL-A580 / EGFR (PI3K/PIKK payload) / Antibody-Targeted Therapy Conjugate (ATTC) / Oncology
    Solid tumorsPhase IInitiatedGlobal
  • HMPL-A830HMPL-A830 / ATTC (undisclosed) / Antibody-Targeted Therapy Conjugate (ATTC) / Oncology
    Solid tumorsPreclinical/Phase I plannedPlannedGlobal
  • TazemetostatTAZVERIK / EZH2 / Small molecule / Oncology
    Epithelioid sarcoma / follicular lymphomaLicensed/CommercialLicensed product updateChina

Eli Lilly and Company

lilly.com
10assets

Pfizer, Inc.

pfizer.com
10assets
  • BerobenatidePF-06954522 / GLP-1/GIP / Small Molecule / Internal Medicine
    Chronic Weight ManagementPhase 2bOngoingGlobal
  • elranatamabPF-06863135 / ELREXFIO / BCMA x CD3 / Bispecific Antibody / Oncology
    Double-class Exposed Relapsed / Refractory Multiple MyelomaPhase 3OngoingGlobal
  • ritlecitinibPF-06651600 / LITFULO / JAK3/TEC / Small Molecule / Inflammation and Immunology
    VitiligoPhase 3OngoingGlobalModerate Alopecia AreataPhase 3OngoingGlobal
  • marstacimabPF-06741086 / HYMPAVZI / TFPI / Monoclonal Antibody / Rare Disease
    Hemophilia A/B with InhibitorsRegistrationOngoingGlobal
  • MevrometostatPF-06821497 / EZH2 / Small Molecule / Oncology
    1-2L Metastatic Castration-resistant Prostate Cancer Post-abirateronePhase 3OngoingGlobal
  • Sigvotatug vedotinPF-08046047 / Integrin beta-6 / Antibody-Drug Conjugate (ADC) / Oncology
    Non-Small Cell Lung Cancer (NSCLC)Phase 3OngoingGlobal
  • VepdegestrantARV-471 / Estrogen Receptor (ER) / PROTAC Protein Degrader / Oncology
    ER+/HER2- Metastatic Breast CancerPhase 3OngoingGlobal
  • PCV25PF-07872412 / Pneumococcus / Vaccine / Vaccines
    Pneumococcal InfectionPhase 3OngoingGlobal
  • enfortumab vedotinPADCEV / Nectin-4 / Antibody-Drug Conjugate (ADC) / Oncology
    Muscle-invasive Bladder Cancer (Bladder Sparing)Phase 3OngoingGlobal
  • Lyme Disease Vaccine CandidatePF-07307405 / Borrelia burgdorferi OspA / Vaccine / Vaccines
    Lyme Disease InfectionPhase 3OngoingGlobal

Adagene Inc.

adagene.com
9assets
  • ADG126ADG126 / muzastotug / CTLA-4 / fully human anti-CTLA-4 SAFEbody / Oncology
    advanced/metastatic solid tumorsPhase 1b/2dose expansion ongoing in combination with anti-PD-1 therapies
  • ADG116ADG116 / CTLA-4 / fully human anti-CTLA-4 NEObody / Oncology
    advanced/metastatic solid tumorsPhase 1b/2ongoing
  • ADG206ADG206 / CD137 / masked IgG1 Fc-engineered anti-CD137 POWERbody / Oncology
    advanced/metastatic tumorsPhase 1ongoing
  • ADG106ADG106 / CD137 / fully human ligand-blocking agonistic anti-CD137 IgG4 mAb NEObody / Oncology
    advanced/metastatic solid tumors and/or relapsed/refractory non-Hodgkin's lymphomaPhase 1b/2ongoing
  • ADG153ADG153 / CD47 / masked anti-CD47 IgG1 SAFEbody / Oncology
    hematologic and solid tumorsIND-enablingpreclinical
  • ADG138ADG138 / HER2 x CD3 / HER2xCD3 POWERbody T-cell engager / Oncology
    HER2-expressing solid tumorsIND-enablingpreclinical
  • ADG152ADG152 / CD20 x CD3 / bispecific CD20xCD3 T-cell engager POWERbody / Oncology
    B-cell malignanciesIND-enablingpreclinical
  • ADG104ADG104 / PD-L1 / antibody / Oncology
    cancerPhase 2in development by Sanjin
  • ADG125ADG125 / CSF-1R / antibody / Oncology
    cancerPhase 1in development by Dragon Boat Biopharmaceutical

CRISPR Therapeutics AG -

ir.crisprtx.com
9assets
  • CASGEVYexa-cel / CASGEVY / BCL11A erythroid-specific enhancer / Non-viral ex vivo CRISPR/Cas9 gene-edited autologous cell therapy / Hemoglobinopathies
    Sickle cell disease, ages 5-11Regulatory submissions expected H1 2026Active pediatric expansionGlobalTransfusion-dependent beta thalassemia, ages 5-11Regulatory submissions expected H1 2026Active pediatric expansionGlobal
  • CTX310CTX310 / ANGPTL3 / In vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular/metabolic
    Severe hypertriglyceridemiaPhase 1bActive; update expected H2 2026Refractory hypercholesterolemiaPhase 1bActive; update expected H2 2026Heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemias or severe hypertriglyceridemiaPhase 1Developed/being evaluated
  • CTX320CTX320 / LPA / In vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular
    Elevated lipoprotein(a)Clinical trial / dose escalationActive; Lp(a) program update expected in 2026
  • CTX321CTX321 / LPA / Next-generation in vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular
    Elevated lipoprotein(a)IND/CTA-enablingActive
  • CTX460CTX460 / SERPINA1 / In vivo SyNTase gene correction; LNP delivery / Rare disease
    Alpha-1 antitrypsin deficiencyPreclinical; clinical trial expected mid-2026Active
  • CTX340CTX340 / AGT / In vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular
    Refractory hypertensionIND/CTA-enabling; clinical trial expected H1 2026Active
  • CTX611SRSD107 / Factor XI / FXI mRNA / Long-acting double-stranded siRNA / Thromboembolic/cardiovascular diseases
    Venous thromboembolism prevention after total knee arthroplastyPhase 2Ongoing; top-line data expected H2 2026EuropeAtrial fibrillation, venous thromboembolism, ischemic stroke, cancer-associated thrombosis, chronic kidney disease, peripheral vascular disease, chronic coronary artery diseaseTarget indications disclosed
  • Zugocabtagene geleucelzugo-cel; formerly CTX112 / CD19 / Allogeneic CAR-T cell therapy; CRISPR Cas9 engineered / Autoimmune disease; oncology
    Systemic lupus erythematosusPhase 1Ongoing; update expected H2 2026Systemic sclerosisPhase 1Ongoing; update expected H2 2026Inflammatory myositisPhase 1Ongoing; update expected H2 2026
  • CTX213CTX213 / iPSC-derived allogeneic gene-edited beta islet cell precursor therapy / Regenerative medicine / diabetes
    Type 1 diabetesPreclinical; progressing toward clinicActive

Evotec SE

evotec.com
9assets
  • EVT8683BMS-986419 / eIF2b / Neuroscience
    Neurodegeneration
  • CNTX 6016CB2 / Pain
    Pain
  • EVT801VEGFR3 / Oncology
    Oncology
  • EVT401P2X7 / Immunology
    InflammationAutoimmune
  • EVT894Infectious Diseases
    Chikungunya
  • EXS21546A2a / Oncology
    Oncology
  • DSP-11815-HT1A / Neuroscience
    Obsessive Compulsive Disorder (OCD)
  • CT7001CDK7 / Oncology
    Oncology
  • TPM203Immunology
    Pemphigus Vulgaris

Ideaya Biosciences, Inc.

ideayabio.com
9assets
  • DarovasertibIDE196 / PKC / Small Molecule / Oncology
    1L metastatic uveal melanoma (HLA-A*02:01 negative)Phase 2/3Positive topline; NDA initiationGlobalNeoadjuvant primary uveal melanomaPhase 2/3OngoingUS
  • IDE397IDE397 / MAT2A / Small Molecule / Oncology
    MTAP-deleted solid tumorsPhase 1OngoingUS
  • IDE849IDE849 / DLL3 / ADC / Oncology
    DLL3-expressing solid tumors (SCLC, NEC)Phase 1OngoingUS
  • IDE161IDE161 / PARG / Small Molecule / Oncology
    HRD solid tumorsPhase 1RecruitingUS
  • IDE034IDE034 / PTK7/B7H3 / Bispecific ADC / Oncology
    B7H3/PTK7 solid tumors (NSCLC, CRC, breast, ovarian)Phase 1OngoingUS
  • IDE892IDE892 / PRMT5 / Small Molecule / Oncology
    MTAP-deleted solid tumorsPhase 1OngoingUS
  • IDE574IDE574 / KAT6/7 / Small Molecule / Oncology
    Solid tumors (breast, prostate, CRC, lung)Phase 1OngoingUS
  • IDE275IDE275 / Werner Helicase (WRN) / Small Molecule / Oncology
    MSI-high solid tumorsPhase 1OngoingUS
  • IDE705IDE705 / Pol Theta (POLQ) / Small Molecule / Oncology
    HRD solid tumorsPhase 1OngoingUS

Insmed Incorporated

insmed.com
9assets
  • BrensocatibBRINSUPRI / DPP1 / Small Molecule / Respiratory / Immunology
    Non-Cystic Fibrosis Bronchiectasis (NCFB)MarketedActiveUSEUHidradenitis SuppurativaPhase 2ActiveGlobal
  • Amikacin Liposome Inhalation SuspensionARIKAYCE / Bacterial 30S ribosomal subunit / Liposomal Inhalation Suspension / Respiratory / Infectious Disease
    Refractory Mycobacterium avium complex (MAC) Lung DiseaseMarketedActiveUSEUJPMAC Lung Disease (Label Expansion)Phase 3ActiveGlobal
  • Treprostinil Palmitil Inhalation PowderTPIP / Prostacyclin receptor / Inhalation Powder / Respiratory / Pulmonary
    Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)Phase 3ActiveGlobalPulmonary Arterial Hypertension (PAH)Phase 3ActiveGlobalProgressive Pulmonary Fibrosis (PPF)Phase 3 PlannedActiveGlobal
  • INS1148INS1148 / Stem Cell Factor SCF248 / Monoclonal Antibody / Respiratory / Immunology
    Interstitial Lung Disease (ILD)Phase 2ActiveGlobalModerate-to-severe asthmaPhase 2ActiveGlobal
  • INS1033INS1033 / Unknown / Unknown / Immunology & Inflammation
    Inflammatory diseasesPreclinicalActiveGlobal
  • Intrathecal gene therapy for DMDDystrophin / Gene Therapy / Neurology / Rare Disease
    Duchenne Muscular Dystrophy (DMD)Phase 1ActiveGlobal
  • INS1202INS1202 / Unknown / Unknown / Neurology / Rare Disease
    Amyotrophic Lateral Sclerosis (ALS)Phase 1ActiveGlobal
  • Stargardt Disease Gene TherapyUnknown / Gene Therapy / Ophthalmology / Rare Disease
    Stargardt DiseasePreclinicalActiveGlobal
  • Next-Gen DPP1 InhibitorsDPP1 / Small Molecule / Immunology & Inflammation
    UndisclosedPreclinicalActiveGlobal

Jazz Pharmaceuticals PLC

jazzpharmaceuticals.com
9assets
  • ZanidatamabHER2 / Bispecific Antibody / Oncology
    Biliary Tract Cancers (BTC)Gastroesophageal Adenocarcinoma (GEA)Colorectal Cancer (CRC)
  • LurbinectedinZepzelca / DNA alkylating / Small Molecule / Oncology
    Small Cell Lung Cancer (SCLC)Ewing Sarcoma
  • DordaviproneModeyso / ClpP agonist / DRD2 antagonist / Small Molecule / Oncology
    H3 K27M-mutant diffuse glioma
  • Daunorubicin and cytarabineJZP351 / Vyxeos / Vyxeos Liposomal / Topoisomerase inhibitor / nucleoside metabolic inhibitor / Liposomal Combination / Oncology
    Myelodysplastic Syndromes (MDS)Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
  • JZP898JZP898 / IFNα2b cytokine pro-drug / Biologic / Oncology
    Solid Tumors
  • JZP3507JZP3507 / ClpP agonist / DRD2 antagonist / Small Molecule / Oncology
    Oncology
  • JZP815JZP815 / pan-RAF / Small Molecule / Oncology
    Solid TumorsHematologic Malignancies
  • CannabidiolEpidyolex / Cannabinoid Receptors / Small Molecule / Neuroscience
    Lennox-Gastaut Syndrome (LGS)Dravet Syndrome (DS)Tuberous Sclerosis Complex (TSC)
  • JZP441JZP441 / Orexin-2 receptor agonist / Small Molecule / Neuroscience
    Narcolepsy Type 1Idiopathic Hypersomnia

Merck & Company, Inc.

merck.com
9assets

Moderna, Inc.

modernatx.com
9assets

Sangamo Therapeutics, Inc.

sangamo.com
9assets
  • Isaralgagene civaparvovecST-920 / alpha-galactosidase A (GLA) / Gene Therapy (AAV) / Metabolic Diseases
    Fabry DiseaseBLA/FilingActiveUS
  • Giroctogene fitelparvovecSB-525 / Factor VIII / Gene Therapy (AAV) / Hematology
    Hemophilia APhase 3ActiveUS
  • ST-503ST-503 / Nav1.7 (SCN9A) / Gene Therapy (Zinc Finger Repressor, AAV9) / Neurology
    Small Fiber Neuropathy (Chronic Neuropathic Pain)Phase 1/2ActiveUS
  • ST-506ST-506 / Prion protein (PRNP) / Gene Therapy (Zinc Finger Repressor, STAC-BBB AAV) / Neurology
    Prion DiseasePreclinicalActiveUS
  • TX200TX200 / HLA-A2 / Cell Therapy (Autologous CAR-Treg) / Transplantation
    Prevention of Immune-Mediated Rejection in HLA-A2 Mismatched Kidney TransplantationPhase 1/2ActiveUSEurope
  • IL23R CAR-TregIL23R / Cell Therapy (CAR-Treg) / Autoimmunity
    Inflammatory Bowel Disease (Crohn's Disease)PreclinicalActiveGlobal
  • Genentech Tau ProgramTau / Gene Therapy (Zinc Finger Epigenetic Regulator) / Neurology
    Tauopathies / Alzheimer's DiseasePreclinicalActiveGlobal
  • Takeda Huntington's ProgramHTT / Gene Therapy (Zinc Finger Epigenetic Regulator) / Neurology
    Huntington's DiseasePreclinicalActiveGlobal
  • Alexion C9ORF72 ProgramC9ORF72 / Gene Therapy (Zinc Finger Transcription Factor) / Neurology
    Amyotrophic Lateral Sclerosis (ALS)PreclinicalActiveGlobalFrontotemporal Lobar Degeneration (FTLD)PreclinicalActiveGlobal

Teva Pharmaceutical Industries Limited

ir.tevapharm.com
9assets

Vertex Pharmaceuticals Incorporated

vrtx.com
9assets
  • SuzetrigineVX-548 / Journavx / NaV1.8 / Small Molecule / Pain
    Moderate-to-Severe Acute PainPainful Diabetic Peripheral Neuropathy
  • VX-993VX-993 / NaV1.8 / Small Molecule / Pain
    Painful Diabetic Peripheral NeuropathyModerate-to-Severe Acute Pain
  • Vanzacaftor/tezacaftor/deutivacaftorCFTR / Small Molecule / Cystic Fibrosis
    Cystic Fibrosis
  • VX-522VX-522 / CFTR / mRNA / Cystic Fibrosis
    Cystic Fibrosis (non-responsive to modulators)
  • InaxaplinVX-147 / APOL1 / Small Molecule / Kidney Disease
    APOL1-mediated Kidney Disease (AMKD)
  • VX-407VX-407 / PC1 / Small Molecule / Kidney Disease
    Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  • VX-880VX-880 / Islet Cell / Cell Therapy / Type 1 Diabetes
    Type 1 Diabetes
  • VX-264VX-264 / Islet Cell / Cell Therapy / Type 1 Diabetes
    Type 1 Diabetes
  • PovetaciceptALPN-303 / BAFF/APRIL / Biologic / Autoimmune / Kidney Disease
    IgA Nephropathy

Xencor, Inc.

xencor.com
9assets
  • XmAb819XmAb819 / ENPP3 x CD3 / Bispecific Antibody / Oncology
    Clear Cell Renal Cell Carcinoma (ccRCC)Phase 1ActiveGlobalColorectal Cancer (CRC)Phase 1ActiveGlobalNon-Small Cell Lung Cancer (NSCLC)Phase 1ActiveGlobal
  • XmAb541XmAb541 / CLDN6 x CD3 / Bispecific Antibody / Oncology
    Ovarian CancerPhase 1ActiveGlobalGerm Cell Tumors (GCT)Phase 1ActiveGlobalSolid TumorsPhase 1ActiveGlobal
  • XmAb808XmAb808 / B7-H3 x CD28 / Bispecific Antibody / Oncology
    Prostate Cancer / Solid TumorsPhase 1ActiveGlobal
  • XmAb942XmAb942 / TL1A / Monoclonal Antibody / Immunology
    Ulcerative Colitis (UC)Phase 2ActiveGlobalInflammatory Bowel Disease (IBD)Phase 2ActiveGlobal
  • XmAb412XmAb412 / TL1A x IL23p19 / Bispecific Antibody / Immunology
    Inflammatory Bowel Disease (IBD)Phase 1ActiveGlobal
  • PlamotamabCD20 x CD3 / Bispecific Antibody / Immunology
    Rheumatoid ArthritisPhase 1ActiveGlobal
  • XmAb657XmAb657 / CD19 x CD3 / Bispecific Antibody / Immunology
    Idiopathic Inflammatory MyositisPhase 1ActiveGlobal
  • ObexelimabCD19 x FcγRIIb / Monoclonal Antibody / Immunology
    Autoimmune DiseasesPhase 3ActiveGlobal
  • TobevibartHepatitis B Virus / Monoclonal Antibody / Infectious Disease
    Chronic Hepatitis B / Hepatitis DPhase 3ActiveGlobal

Amphastar Pharmaceuticals, Inc.

amphastar.com
8assets
  • Insulin AspartAMP-004 / interchangeable biosimilar insulin / Diabetes
  • Recombinant Human InsulinAMP-005 / interchangeable biosimilar insulin / Diabetes
  • AMP-028AMP-028 / biosimilar
  • Intranasal epinephrineAMP-019 / adrenergic receptors / intranasal small molecule / Allergy/Immunology
    Anaphylaxis/allergic reactionsdevelopment
  • AMP-105AMP-105 / peptide / Oncology
    Poorly treated cancersdevelopmentUnited StatesCanada
  • AMP-107AMP-107 / VEGFR / topical eye-drop peptide / Ophthalmology
    Wet age-related macular degenerationdevelopmentUnited StatesCanada
  • AMP-109AMP-109 / peptide-docetaxel conjugate / Oncology
    CancerdevelopmentUnited StatesCanada
  • AMP-110AMP-110 / ACTH receptor pathway / synthetic human corticotropin analog peptide
    Multiple indicationsdevelopmentUnited StatesCanada

Crinetics Pharmaceuticals, Inc.

crinetics.com
8assets
  • PaltusotineCRN00808 / PALSONIFY / SST2 / oral nonpeptide SST2 agonist / Endocrinology; oncology
    Acromegaly (US)ApprovedapprovedUSAcromegaly (EU)Registrationalunder reviewEUCarcinoid syndrome associated with NETsPhase 3clinicalGlobal
  • AtumelnantCRN04894 / MC2R/ACTH receptor / oral nonpeptide ACTH receptor antagonist / Endocrinology
    Congenital adrenal hyperplasia (adult)Phase 3clinicalCongenital adrenal hyperplasia (pediatric)Phase 2/3clinicalACTH-dependent Cushing's syndromePhase 2/3planned
  • CRN09682CRN09682 / SST2 / nonpeptide drug conjugate; MMAE payload / Oncology
    SST2-expressing NETs and other SST2-expressing solid tumorsPhase 1/2clinical
  • PTH AntagonistPTH receptor / oral nonpeptide antagonist / Endocrinology
    Hyperparathyroidism and other diseases of hypercalcemiaPreclinicalIND-enabling
  • TSH AntagonistTSH receptor / oral nonpeptide antagonist / Endocrinology
    Graves' disease; thyroid eye diseasePreclinicalIND-enabling
  • SST3 AgonistSST3 / oral nonpeptide agonist / Nephrology
    Polycystic kidney diseasePreclinicalIND-enabling
  • Oral GLP-1 NonpeptideGLP-1 receptor / oral nonpeptide agonist / Metabolic disease
    Diabetes; obesityPreclinicaldisclosed
  • Oral GIP NonpeptideGIP receptor / oral nonpeptide agonist / Metabolic disease
    Diabetes; obesityPreclinicaldisclosed

CureVac N.V.

curevac.com
8assets
  • CVGBMCVGBM / tumor-associated antigens / unmodified mRNA cancer precision immunotherapy / Oncology
    newly diagnosed surgically resected MGMT-unmethylated glioblastoma or astrocytoma with molecular signature of glioblastomaPhase 1ongoing
  • sqNSCLC shared-antigen cancer precision immunotherapy candidateshared tumor antigens / unmodified mRNA cancer precision immunotherapy / Oncology
    squamous non-small cell lung cancerIND/CTA filedIND and CTA submissions filed Q1 2025
  • CV0601CV0601 / SARS-CoV-2 Omicron BA.4-5 spike antigen / mRNA vaccine / Infectious disease
    COVID-19Phase 2study completed August 2024; GSK assumed full control
  • CV0701CV0701 / SARS-CoV-2 Omicron BA.4-5 and original SARS-CoV-2 antigens / bivalent mRNA vaccine / Infectious disease
    COVID-19Phase 2study completed August 2024; GSK assumed full control
  • seasonal influenza mRNA vaccine candidateinfluenza antigens / multivalent mRNA vaccine / Infectious disease
    seasonal influenzaPhase 2GSK assumed full control
  • avian influenza H5N1 mRNA vaccine candidateH5N1 influenza antigens / mRNA vaccine / Infectious disease
    avian influenza H5N1Phase 2GSK assumed full control
  • COVID-19/influenza combination mRNA vaccine candidateSARS-CoV-2 and influenza antigens / combination mRNA vaccine / Infectious disease
    COVID-19 and influenzaPhase 1/2GSK initiated study November 2024; GSK assumed full control
  • UPEC FimH ferritin nanoparticle mRNA vaccine candidateFimH / mRNA vaccine / Infectious disease
    urinary tract infections caused by uropathogenic E. coliPreclinicallead candidate identified

Dyne Therapeutics, Inc.

dyne-tx.com
8assets

Evaxion A/S

evaxion.ai
8assets
  • EVX-01EVX-01 / Personalized neoantigens / Liposomal/peptide personalized cancer vaccine / Cancer
    Advanced melanomaPhase 2
  • EVX-03EVX-03 / Personalized neoantigens and endogenous retrovirus antigens / Targeted DNA personalized cancer vaccine / Cancer
    Solid tumorsPreclinicalCTA/IND ready
  • EVX-04EVX-04 / Tumor-specific antigens derived from endogenous retrovirus elements / DNA off-the-shelf therapeutic cancer vaccine / Cancer
    Acute myeloid leukemiaPreclinicalPlanned first-in-human study
  • EVX-B1EVX-B1 / S. aureus toxins and virulence factors / Protein multi-component prophylactic vaccine / Infectious diseases
    S. aureus skin and soft tissue infectionsPreclinical
  • EVX-B2EVX-B2 / N. gonorrhoeae antigens / Protein multi-component prophylactic vaccine / Infectious diseases
    GonorrheaPreclinical
  • EVX-B2 mRNAEVX-B2 / N. gonorrhoeae antigens / mRNA multi-component prophylactic vaccine / Infectious diseases
    GonorrheaPreclinical
  • EVX-B4EVX-B4 / Group A Streptococcus antigens / Prophylactic vaccine / Infectious diseases
    Group A Streptococcus infectionTarget discovery
  • EVX-V1EVX-V1 / CMV B- and T-cell antigens; pre-fusion glycoprotein B construct / Multi-component prophylactic vaccine / Infectious diseases
    Cytomegalovirus infectionPreclinical

Exelixis, Inc.

exelixis.com
8assets
  • ZanzalintinibXL092 / MET/VEGFR/AXL/MER / Next-generation TKI / Oncology
    Colorectal cancerPivotal / Phase 3STELLAR-303: zanzalintinib + atezolizumab vs. regorafenibNon-clear cell renal cell carcinomaPivotal / Phase 3STELLAR-304: zanzalintinib + nivolumab vs. sunitinibNeuroendocrine tumorsPivotal / Phase 2/3STELLAR-311: zanzalintinib vs. everolimus
  • XL309XL309 / USP1 / USP1 inhibitor / Oncology
    Multiple solid tumorsPhase 1XL309 or XL309 + olaparib
  • XB010XB010 / 5T4 / Next-generation 5T4-MMAE ADC / Oncology
    Multiple solid tumorsPhase 1XB010 or XB010 + pembrolizumab
  • XB628XB628 / PD-L1 + NKG2A / Bispecific antibody / Oncology
    Multiple solid tumorsPhase 1Ongoing clinical study
  • XB371XB371 / Tissue factor / Next-generation TF-TOPOi ADC / Oncology
    Multiple solid tumorsPhase 1Ongoing clinical study
  • ADU-1805ADU-1805 / SIRPα / SIRPα-targeting mAb / Oncology
    Multiple solid tumorsPhase 1ADU-1805 or ADU-1805 + pembrolizumab
  • XB773XB773 / DLL3 / DLL3-TOPOi ADC / Oncology
    Not disclosedDiscovery/PreclinicalDiscovery/Preclinical
  • SSTR2 AgonistSomatostatin receptor subtype 2 / SSTR2 agonist program development candidate / Oncology
    Not disclosedDiscovery/PreclinicalDiscovery/Preclinical

Immunocore Holdings PLC

immunocore.com
8assets
  • TebentafuspKIMMTRAK / gp100 (HLA-A*02) / ImmTAC (TCR bispecific) / Oncology
    metastatic uveal melanomaApprovedmarketedUSEUadjuvant uveal melanomaPhase 3ongoing (ATOM, EORTC-sponsored)2L+ advanced cutaneous melanomaPhase 3ongoing (TEBE-AM)
  • BrenetafuspIMC-F106C / PRAME (HLA-A*02) / ImmTAC (TCR bispecific) / Oncology
    1L advanced cutaneous melanomaPhase 3ongoing (PRISM-MEL-301)ovarian cancerPhase 1/2ongoing (combinations)NSCLCPhase 1/2ongoing (monotherapy and combinations)
  • IMC-P115CIMC-P115C / PRAME (HLA-A*02 HLE) / ImmTAC (TCR bispecific) / Oncology
    multiple solid tumorsPhase 1ongoing
  • IMC-R117CIMC-R117C / PIWIL1 (HLA-A*02) / ImmTAC (TCR bispecific) / Oncology
    colorectal and GI cancersPhase 1/2ongoing
  • IMC-M113VIMC-M113V / Gag (HLA-A*02) / ImmTAV (TCR bispecific) / Infectious Disease
    HIVPhase 1ongoing
  • IMC-I109VIMC-I109V / Envelope (HLA-A*02) / ImmTAV (TCR bispecific) / Infectious Disease
    HBVclinical development
  • IMC-S118AIIMC-S118AI / PPI x PD1 (HLA-A*02) / ImmTAAI (TCR bispecific) / Autoimmune Disease
    type 1 diabetesPhase 1ongoing
  • IMC-U120AIIMC-U120AI / CD1a x PD1 (non-HLA restricted) / ImmTAAI (TCR bispecific) / Autoimmune Disease
    atopic dermatitisIND-enabling

Innate Pharma S.A.

innate-pharma.com
8assets
  • LacutamabKIR3DL2 / Monoclonal antibody / Oncology
    Sézary syndromeMycosis fungoidesCutaneous T cell lymphomas
  • IPH4502IPH4502 / Nectin-4 / Antibody-drug conjugate (ADC) / Oncology
    Solid tumors
  • MonalizumabNKG2A / Monoclonal antibody / Oncology
    Non-small cell lung cancer (NSCLC)
  • IPH6501IPH6501 / CD20 / NK cell engager (ANKET) / Oncology
    B-cell Non-Hodgkin's Lymphoma
  • IPH6101IPH6101 / CD123 / NK cell engager (ANKET) / Oncology / Autoimmune
    Hematologic malignanciesAutoimmune indications
  • IPH6401IPH6401 / BCMA / NK cell engager (ANKET) / Oncology
    Multiple myeloma
  • IPH5201IPH5201 / CD39 / Monoclonal antibody / Oncology
    Solid tumors
  • IPH5301IPH5301 / CD73 / Monoclonal antibody / Oncology
    Solid tumors

Opus Genetics, Inc.

opusgtx.com
8assets
  • OPGx-LCA5OPGx-LCA5 / LCA5 / AAV Gene Therapy / Ophthalmology
    Leber Congenital Amaurosis Type 5 (LCA5)
  • OPGx-BEST1OPGx-BEST1 / BEST1 / AAV Gene Therapy / Ophthalmology
    Best Vitelliform Macular Dystrophy (BVMD)Autosomal Recessive Bestrophinopathy (ARB)
  • OPGx-RDH12OPGx-RDH12 / RDH12 / AAV Gene Therapy / Ophthalmology
    RDH12-associated Leber Congenital Amaurosis (RDH12-LCA)
  • OPGx-MERTKOPGx-MERTK / MERTK / AAV Gene Therapy / Ophthalmology
    MERTK-associated Retinitis Pigmentosa
  • OPGx-RHOOPGx-RHO / RHO / AAV Gene Therapy / Ophthalmology
    Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
  • OPGx-CNGB1OPGx-CNGB1 / CNGB1 / AAV Gene Therapy / Ophthalmology
    CNGB1-associated Inherited Retinal Diseases
  • OPGx-NMNAT1OPGx-NMNAT1 / NMNAT1 / AAV Gene Therapy / Ophthalmology
    NMNAT1-associated Inherited Retinal Diseases
  • Phentolamine Ophthalmic Solution 0.75%Small Molecule / Ophthalmology
    Pharmacologically induced mydriasisPresbyopiaLow-light visual disturbances following keratorefractive surgery

Kymera Therapeutics, Inc.

kymeratx.com
8assets
  • KT-621KT-621 / STAT6 / Targeted Protein Degrader / Immunology / Respiratory
    Atopic DermatitisPhase 2bOngoingGlobalAsthmaPhase 2bOngoingGlobal
  • KT-579KT-579 / IRF5 / Targeted Protein Degrader / Immunology
    Autoimmune Diseases (Lupus, Rheumatoid Arthritis, IBD)Phase 1PlannedGlobal
  • KT-295KT-295 / TYK2 / Targeted Protein Degrader / Immunology
    Inflammatory Bowel Disease (IBD), PsoriasisPhase 1OngoingGlobal
  • KT-485SAR447971 / IRAK4 / Targeted Protein Degrader / Immunology
    Immuno-inflammatory diseasesPreclinicalOngoingGlobal
  • KT-200KT-200 / CDK2 / Molecular Glue Degrader / Oncology
    Breast Cancer and other Solid TumorsPreclinicalOngoingGlobal
  • KT-333KT-333 / STAT3 / Targeted Protein Degrader / Oncology
    Hematological Malignancies and Solid TumorsPhase 1OngoingGlobal
  • KT-253KT-253 / MDM2 / Targeted Protein Degrader / Oncology
    High-Grade Myeloid Malignancies and Solid TumorsPhase 1OngoingGlobal
  • KT-474SAR444656 / IRAK4 / Targeted Protein Degrader / Immunology
    Hidradenitis Suppurativa (HS), Atopic DermatitisPhase 2bDiscontinuedGlobal

PTC Therapeutics, Inc.

ptcbio.com
8assets

Roche Holding AG

roche.com
8assets
  • fenebrutinibBTK / Small molecule / Neuroscience
    Multiple Sclerosis
  • petrelintideAmylin / Peptide / Cardiovascular, Renal & Metabolism
    Obesity
  • CT-996CT-996 / GLP-1 / Small molecule / Cardiovascular, Renal & Metabolism
    Obesity
  • giredestrantEstrogen receptor (SERD) / Small molecule / Oncology
    Early and metastatic breast cancer
  • trontinemabAmyloid beta / TfR / Bispecific antibody / Neuroscience
    Alzheimer's Disease
  • NXT007NXT007 / Factor IX/X / Bispecific antibody / Hematology
    Hemophilia A
  • afimkibartBiologic / Immunology
    Immunological disorders
  • RVT-3101RVT-3101 / TL1A / Monoclonal antibody / Immunology
    Inflammatory Bowel Disease

Royalty Pharma PLC

royaltypharma.com
8assets

Sionna Therapeutics, Inc.

sionnatx.com
8assets
  • SION-719SION-719 / NBD1 (Nucleotide Binding Domain 1 of CFTR) / Small Molecule / Respiratory / Genetic Diseases
    Cystic FibrosisPhase 2aActive
  • SION-451SION-451 / NBD1 (Nucleotide Binding Domain 1 of CFTR) / Small Molecule / Respiratory / Genetic Diseases
    Cystic FibrosisPhase 1Active
  • SION-638SION-638 / NBD1 (Nucleotide Binding Domain 1 of CFTR) / Small Molecule / Respiratory / Genetic Diseases
    Cystic FibrosisPhase 1Active
  • SION-109SION-109 / ICL4 (Intracellular Loop 4 of CFTR) / Small Molecule / Respiratory / Genetic Diseases
    Cystic FibrosisPhase 1Active
  • GalicaftorABBV-2222 / TMD1-directed CFTR corrector / Small Molecule / Respiratory / Genetic Diseases
    Cystic FibrosisPhase 2Active
  • NavocaftorABBV-3067 / CFTR potentiator / Small Molecule / Respiratory / Genetic Diseases
    Cystic FibrosisPhase 2Active
  • ABBV-2851ABBV-2851 / TMD1-directed CFTR corrector / Small Molecule / Respiratory / Genetic Diseases
    Cystic FibrosisPhase 1Active
  • SION-676SION-676 / TMD1-directed CFTR corrector / Small Molecule / Respiratory / Genetic Diseases
    Cystic FibrosisPreclinicalActive

Sarepta Therapeutics, Inc.

sarepta.com
8assets
  • SRP-1001SRP-1001 / FSHD1 / siRNA / Neuromuscular
    Facioscapulohumeral muscular dystrophy, Type 1 (FSHD1)
  • SRP-1003SRP-1003 / DM1 / siRNA / Neuromuscular
    Myotonic dystrophy, Type 1 (DM1)
  • SRP-1002SRP-1002 / siRNA / Pulmonary
    Idiopathic pulmonary fibrosis (IPF)
  • SRP-1004SRP-1004 / siRNA / Neurology
    Spinocerebellar ataxia type 2 (SCA2)
  • SRP-1005SRP-1005 / siRNA / Neurology
    Huntington's disease (HD)
  • SRP-1007SRP-1007 / siRNA / Neurology
    Spinocerebellar ataxia type 1 (SCA1)
  • SRP-1006SRP-1006 / siRNA / Neurology
    Spinocerebellar ataxia type 3 (SCA3)
  • bidridistrogene xeboparvovecSRP-9003 / LGMD2E/R4 β-sarcoglycan / Gene Therapy / Neuromuscular
    Limb-girdle Muscular Dystrophy

Zenas BioPharma, Inc.

zenasbio.com
8assets

Zymeworks Inc.

zymeworks.com
8assets
  • ZanidatamabZW25 / Ziihera / HER2 / Bispecific Antibody / Oncology
    Biliary Tract Cancer (BTC)ApprovedActiveUSEuropeGastroesophageal Adenocarcinoma (GEA)Phase 3ActiveGlobalBreast Cancer (Neoadjuvant and Adjuvant)Phase 2ActiveGlobal
  • ZW191ZW191 / FRα / Antibody-Drug Conjugate (ADC) / Oncology
    Advanced Solid Tumors (Ovarian/Gynecological and Lung/Thoracic)Phase 1ActiveGlobal
  • ZW251ZW251 / GPC3 / Antibody-Drug Conjugate (ADC) / Oncology
    Hepatocellular Carcinoma (HCC) / Solid TumorsPhase 1ActiveGlobal
  • ZW220ZW220 / NaPi2b / Antibody-Drug Conjugate (ADC) / Oncology
    Gynecological and Thoracic CancersPreclinicalActiveGlobal
  • ZW209ZW209 / DLL3 x CD3 x CD28 / Trispecific T-Cell Engager / Oncology
    Thoracic CancersPreclinicalActiveGlobal
  • ZW1528ZW1528 / IL-4Rα x IL-33 / Bispecific Antibody / Autoimmune / Inflammatory Diseases
    Respiratory InflammationPreclinicalActiveGlobal
  • PasritamigJNJ-78278343 / CD3 / Prostate Target / Bispecific Antibody / Oncology
    Solid TumorsClinicalActiveGlobal
  • DS-2243DS-2243 / T-Cell Engager / Bispecific T-Cell Engager / Oncology
    Advanced Solid TumorsPhase 1ActiveGlobal

Ascentage Pharma

ir.ascentage.com
7assets
  • OlverembatinibHQP1351 / BCR-ABL / small molecule TKI / Oncology
    CML-CP/AP with T315I; CML-CP resistant/intolerant to 1st/2nd gen TKIsMarketedApproved in ChinaChinaCMLPhase 3 registrationalOngoing; POLARIS-2GlobalFirst-line Ph+ ALLPhase 3 registrationalOngoing; POLARIS-1Global
  • LisaftoclaxAPG-2575 / Bcl-2 / small molecule inhibitor / Oncology
    CLL/SLL after systemic therapy including BTK inhibitorsMarketedApproved in China 2025ChinaCLL/SLL after BTK inhibitorsPhase 3 registrationalOngoing; GLORA; +BTK inhibitorGlobalFirst-line CLL/SLLPhase 3 registrationalOngoing; GLORA-2; +acalabrutinibGlobal
  • APG-2449APG-2449 / FAK/ALK/ROS1 / small molecule inhibitor / Oncology
    ALK-positive advanced or locally advanced NSCLC, treatment-naivePhase 3 registrationalOngoing; CDE-clearedChinaNSCLC resistant/intolerant to 2nd generation ALK TKIsPhase 3 registrationalOngoing; CDE-clearedChinaPlatinum-resistant ovarian cancerPhase 1b/2Ongoing; +liposomal doxorubicin
  • AlrizomadlinAPG-115 / MDM2-p53 / small molecule inhibitor / Oncology
    Unresectable/metastatic melanoma and other advanced solid tumorsPhase 1b/2Ongoing; monotherapy or +pembrolizumabUnited StatesAustraliaR/R T-PLL or NHLPhase 2aOngoing; monotherapy or +lisaftoclaxUnited StatesAustraliaSalivary gland cancerPhase 2Collaborative research study
  • PelcitoclaxAPG-1252 / Bcl-2/Bcl-xL / small molecule inhibitor / Oncology
    EGFR-mutant NSCLCPhase 1bOngoing; +osimertinibChinaR/R NHLPhase 1b/2OngoingChinaRecurrent ovarian and endometrial cancersPhase 1Ongoing; +cobimetinib
  • APG-5918APG-5918 / EED/PRC2 / small molecule inhibitor / Oncology; Hematology
    Advanced solid tumors and hematologic malignanciesPhase 1OngoingChinaUnited StatesAnemia-related indicationsPhase 1OngoingChina
  • APG-3288APG-3288 / BTK / PROTAC degrader / Oncology
    R/R B-cell malignanciesPhase 1IND cleared; planned/initiating in 2026United StatesChina

Alto Neuroscience, Inc.

altoneuroscience.com
7assets
  • ALTO-207CTC-501 / D3/D2 & 5-HT3 / fixed-dose combination of pramipexole and ondansetron / Neuropsychiatry
    Treatment-resistant depressionPhase 2bactive
  • ALTO-300MT1/2 & 5HT2C / oral small molecule / Neuropsychiatry
    Major depressive disorderPhase 2bactiveUnited States
  • ALTO-100BDNF/neural plasticity / oral small molecule / Neuropsychiatry
    Bipolar depressionPhase 2bactive
  • ALTO-101PDE4 / transdermal PDE4 inhibitor / Neuropsychiatry
    Cognitive impairment associated with schizophreniaPhase 2active
  • ALTO-203Histamine H3 receptor / oral small molecule inverse agonist / Neuropsychiatry
    Major depressive disorder with anhedoniaPhase 2aactive
  • ALTO-202NMDA NR2B/GluN2B / oral small molecule negative allosteric modulator / Neuropsychiatry
    Major depressive disorderactive
  • ALTO-208CTC 413 / D3/D2 & NK-1 / fixed-dose combination of pramipexole and aprepitant / Neurology
    Parkinson's diseaseactive

Arvinas, Inc.

arvinas.com
7assets
  • ARV-102ARV-102 / LRRK2 / oral brain-penetrant PROTAC degrader / Neurology
    Parkinson’s diseasePhase 1/1bunder investigationProgressive supranuclear palsyunder investigation
  • ARV-027ARV-027 / polyQ-AR / oral peripherally restricted PROTAC degrader / Neurology
    Spinal-bulbar muscular atrophyPhase 1/1bunder investigation
  • ARV-806ARV-806 / KRAS G12D / PROTAC degrader / Oncology
    Pancreatic cancerPhase 1/1bunder investigationColorectal cancerPhase 1/1bunder investigationNon-small cell lung cancerPhase 1/1bunder investigation
  • ARV-393ARV-393 / BCL6 / oral PROTAC degrader / Oncology
    Non-Hodgkin lymphoma / B-cell malignanciesPhase 1/1bunder investigation
  • ARV-6723ARV-6723 / HPK1 / oral PROTAC degrader / Oncology
    Advanced solid tumorsPreclinicalunder investigation
  • VepdegestrantARV-471 / ER / oral PROTAC estrogen receptor degrader / Oncology
    ER+/HER2- locally advanced or metastatic breast cancerPhase 3under investigation
  • LuxdegalutamideARV-766; JSB462 / AR / oral PROTAC androgen receptor degrader / Oncology
    Prostate cancerPhase 2under investigation

Genmab A/S

genmab.com
7assets
  • epcoritamabGEN3013 / EPKINLY/TEPKINLY / CD20xCD3 / Bispecific antibody / Oncology
    Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)ApprovedMarketedUSEUJapanRelapsed or refractory follicular lymphoma (FL)ApprovedMarketedUSEURelapsed or refractory FL in combination with rituximab and lenalidomide (R2)ApprovedMarketedUS
  • rinatabart sesutecanRina-S / Rina-S / FRα (folate receptor alpha) / Antibody-drug conjugate (ADC) / Oncology
    Platinum-resistant ovarian cancerPhase 3ActiveGlobalAdvanced endometrial cancerPhase 1/2ActiveGlobal
  • petosemtamabMCLA-158 / EGFRxLGR5 / Bispecific antibody / Oncology
    First-line head and neck squamous cell carcinoma (HNSCC)Phase 3ActiveGlobalSecond/third-line head and neck squamous cell carcinoma (HNSCC)Phase 3ActiveGlobal
  • daratumumabDARZALEX/DARZALEX FASPRO / CD38 / Monoclonal antibody / Oncology
    Multiple myeloma (multiple lines)ApprovedMarketedGlobal
  • ofatumumabKesimpta/Arzerra / CD20 / Monoclonal antibody / Neurology/Oncology
    Relapsing multiple sclerosis (Kesimpta)ApprovedMarketedGlobalChronic lymphocytic leukemia (Arzerra)ApprovedMarketedUSEU
  • tisotumab vedotinTivdak / Tissue factor / Antibody-drug conjugate (ADC) / Oncology
    Recurrent or metastatic cervical cancerApprovedMarketedUSEUJapan
  • HexaBody-CD38GEN3014 / CD38 / HexaBody monoclonal antibody / Oncology
    Multiple myelomaPhase 1/2ActiveGlobal

Structure Therapeutics Inc.

ir.structuretx.com
7assets
  • AleniglipronGSBR-1290 / GLP-1R / Oral small molecule agonist / Metabolic / Obesity
    Obesity / overweight with weight-related comorbidityPhase 2 (ACCESS / ACCESS II); Phase 3 planned 2H 2026Active; End-of-Phase 2 FDA meeting Q2 2026GlobalType 2 diabetes mellitus with obesity/overweightPhase 2Enrolling (38-week study)Global
  • ACCG-2671ACCG-2671 / Amylin/calcitonin receptor (DACRA) / Oral small molecule agonist / Metabolic / Obesity
    ObesityPhase 1Active (SAD study initiated Dec 2025)Global
  • ACCG-3535ACCG-3535 / Amylin/calcitonin receptor (DACRA) / Oral small molecule agonist / Metabolic / Obesity
    ObesityPreclinical / IND-enablingPhase 1 initiation expected 2H 2026Global
  • ANPA-0073ANPA-0073 / Apelin (APJ) receptor / Oral small molecule biased agonist / Metabolic / Obesity
    Obesity (selective/muscle-sparing weight loss)Phase 2 readyPhase 1 SAD/MAD completedGlobal
  • LTSE-2578LTSE-2578 / LPA1R (lysophosphatidic acid 1 receptor) / Oral small molecule antagonist / Pulmonary / Fibrosis
    Idiopathic pulmonary fibrosis (IPF)Phase 1Phase 1 SAD/MAD completedGlobal
  • GIPR ProgramGIPR (and GLP-1R/GIPR) / Oral small molecule (agonist/antagonist) / Metabolic / Obesity
    Obesity and related diseasesDiscovery / PreclinicalActiveGlobal
  • GCGR ProgramGCGR (and GLP-1R/GCGR) / Oral small molecule agonist / Metabolic / Obesity
    Obesity and related diseasesDiscovery / PreclinicalActiveGlobal

Harmony Biosciences Holdings, Inc.

harmonybiosciences.com
7assets
  • PitolisantWAKIX / histamine-3 receptor (H3R) antagonist/inverse agonist / small molecule / Rare neurological disorders
    Prader-Willi syndromePhase 3USNarcolepsy (GR formulation)Phase 3USNarcolepsy (HD formulation)Phase 3US
  • BP1.15205orexin-2 receptor (OX2R) agonist / small molecule / Sleep/wake disorders
    Narcolepsy and other sleep/wake disordersPhase 1USLatin America
  • EPX-1005-HT (serotonin) receptor agonist / small molecule / Rare epilepsies
    Dravet syndromePhase 3USLennox-Gastaut syndromePhase 3US
  • EPX-200selective 5HT2C agonist / small molecule / Rare epilepsies
    Developmental and epileptic encephalopathiesPreclinicalIND-enablingUS
  • CBS-105cell therapy / Rare neurological disorders
    Treatment-resistant narcolepsyPreclinicalUS
  • HBS-102MCHR1 antagonist / small molecule / Rare neurological disorders
    Prader-Willi syndromePreclinicalUS
  • CBS-104cell therapy / Rare epilepsies
    Refractory epilepsyPreclinicalUS

Innoviva, Inc.

inva.com
7assets

Iovance Biotherapeutics, Inc.

iovance.com
7assets
  • LifileucelLN-144 / Amtagvi / Polyclonal Neoantigens / Tumor Infiltrating Lymphocyte (TIL) Therapy / Oncology
    MelanomaNon-Small Cell Lung Cancer (NSCLC)
  • TIL CombinationsPolyclonal Neoantigens / Cell Therapy Combination / Oncology
    Solid Tumors
  • PD-1 Selected TILPolyclonal Neoantigens / PD-1+ / Tumor Infiltrating Lymphocyte (TIL) Therapy / Oncology
    Solid Tumors
  • Third Generation (Gen 3) TILPolyclonal Neoantigens / Tumor Infiltrating Lymphocyte (TIL) Therapy / Oncology
    Solid Tumors
  • PBL TherapyPolyclonal Neoantigens / Peripheral Blood Lymphocyte Therapy / Oncology
    Solid Tumors
  • PD-1 Inactivated TILIOV-4001 / PD-1 / Genetically Modified Cell Therapy / Oncology
    Solid Tumors
  • Modified IL-2 Fusion ProteinIOV-3001 / IL-2 Receptor / Antibody Cytokine Engrafted Protein / Oncology
    MelanomaSolid Tumors

Janux Therapeutics, Inc.

januxrx.com
7assets

Legend Biotech Corporation

legendbiotech.com
7assets

Lexeo Therapeutics, Inc.

lexeotx.com
7assets
  • LX2006LX2006 / FXN / AAV gene therapy / Cardiovascular
    Friedreich's ataxia (FA) cardiomyopathy
  • LX2020LX2020 / PKP2 / AAV gene therapy / Cardiovascular
    PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM)
  • LX2021LX2021 / Cx43 / AAV gene therapy / Cardiovascular
    DSP (Desmoplakin) cardiomyopathyDilated cardiomyopathy
  • LX2022LX2022 / TNNI3 / AAV gene therapy / Cardiovascular
    Hypertrophic cardiomyopathy (HCM)
  • LX1001LX1001 / APOE2 / AAV gene therapy / Neurology
    APOE4-associated Alzheimer's disease
  • LX1021LX1021 / Christchurch-modified APOE2 / AAV gene therapy / Neurology
    APOE4-associated Alzheimer's disease
  • LX1020LX1020 / APOE2 / APOE4 (miRNA) / AAV gene therapy / Neurology
    APOE4-associated Alzheimer's disease

MannKind Corporation

mannkindcorp.com
7assets
  • insulin humanAfrezza / Insulin receptor / Recombinant Protein / Endocrine
    Type 1 and Type 2 Diabetes MellitusMarketedApprovedUSBrazilPediatric Diabetes MellitusPhase 3OngoingUS
  • treprostinilTyvaso DPI / Prostacyclin receptor / Small Molecule / Orphan Lung Diseases
    Pulmonary Arterial Hypertension (PAH)MarketedApprovedUSPulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)MarketedApprovedUS
  • clofazimine inhalation suspensionMNKD-101 / Bacterial DNA / Mycobacterial growth / Small Molecule / Orphan Lung Diseases
    Nontuberculous Mycobacterial (NTM) Lung DiseasePhase 3DiscontinuedUS
  • clofazimine DPIMNKD-102 / Bacterial DNA / Mycobacterial growth / Small Molecule / Orphan Lung Diseases
    Nontuberculous Mycobacterial (NTM) Lung DiseasePreclinicalActiveUS
  • nintedanib DPIMNKD-201 / Tyrosine kinase / Small Molecule / Orphan Lung Diseases
    Idiopathic Pulmonary Fibrosis (IPF)Phase 1CompletedUS
  • dornase alfa DPIMNKD-301 / DNase I / Recombinant Protein / Orphan Lung Diseases
    Cystic FibrosisPreclinicalActiveUS
  • FBM5712 DPIMNKD-501 / ALK-5 kinase / TGF-beta / Small Molecule / Orphan Lung Diseases
    Pulmonary FibrosisPreclinicalActiveUS

OPKO Health, Inc.

opko.com
7assets
  • SomatrogonhGH-CTP / NGENLA / Growth hormone receptor / Biologic / Endocrinology
    Growth Hormone Deficiency (Pediatric)ApprovedactiveUSEUJapanGlobalGrowth Hormone Deficiency (Adults)Phase 3activeGlobal
  • Calcifediol extended-releaseRayaldee / Rayaldee / Vitamin D receptor / Small Molecule / Nephrology
    Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (Hemodialysis)Phase 2activeUS
  • MDX2004MDX2004 / CD3 x CD28 x 4-1BB / Multispecific Antibody / Oncology
    Advanced CancersPhase 1/2aactiveUS
  • MDX2003MDX2003 / T-cell engager / Multispecific Antibody / Oncology
    LymphomaPhase 1activeUS
  • ModeX COVID-19 Multispecific AntibodySARS-CoV-2 / Multispecific Antibody / Infectious Disease
    COVID-19PreclinicalactiveUS
  • ModeX Influenza Multispecific AntibodyInfluenza virus / Multispecific Antibody / Infectious Disease
    InfluenzaPreclinicalactiveUS
  • Oral GLP-2 AgonistGLP-2 / Peptide / Gastroenterology
    Short Bowel SyndromePreclinicalactiveGlobal

Radiopharm Theranostics Limited

radiopharmtheranostics.com
7assets
  • 18F-PivalateRAD 101 / FASN (Fatty acid synthase) / Small Molecule Radiopharmaceutical / Diagnostics
    Brain metastases from solid tumors (Imaging)Phase 2bEnrollingUS
  • 177Lu-RAD202RAD 202 / HER2 / Nanobody Radiotherapeutic / Oncology
    HER2-positive advanced solid tumorsPhase 1ActiveUSGlobal
  • 177Lu-RAD204RAD 204 / PD-L1 / Nanobody Radiotherapeutic / Oncology
    PD-L1 positive advanced solid tumorsPhase 1ActiveUSGlobal
  • 68Ga-TrivehexinRAD 301 / αvβ6-integrin / Peptide Radiopharmaceutical / Diagnostics
    Loco-regional pancreatic cancer (Imaging)Phase 2ActiveGlobal
  • 177Lu-D0301RAD 302 / αvβ6-integrin / Peptide Radiotherapeutic / Oncology
    Solid tumors (PDAC, NSCLC, HNSCC)PreclinicalActiveGlobal
  • BetaBartRV-01 / B7-H3 / Radiotherapeutic / Oncology
    B7H3-expressing solid tumorsPhase 1/2aActiveUS
  • 161Tb-RAD 402RAD 402 / KLK3 (PSA) / Monoclonal Antibody Radiotherapeutic / Oncology
    Advanced prostate cancerPhase 1ActiveAustralia

Solid Biosciences Inc.

solidbio.com
7assets
  • SGT-003SGT-003 / Gene Therapy / Neuromuscular
    Duchenne muscular dystrophy (INSPIRE)Phase 1/2ActiveGlobalDuchenne muscular dystrophy (IMPACT)Phase 3Activeex-U.S.
  • SGT-212SGT-212 / Gene Therapy / Neuromuscular
    Friedreich's ataxia (FA)Phase 1/2ActiveGlobal
  • SGT-501SGT-501 / Gene Therapy / Cardiac
    RYR2-Mediated CPVTPhase 1/2ActiveGlobalCASQ2-Mediated CPVTPreclinicalActiveGlobal
  • SGT-601SGT-601 / TNNT2 / Gene Therapy / Cardiac
    TNNT2-Mediated Dilated Cardiomyopathy (DCM)PreclinicalActiveGlobal
  • SGT-401SGT-401 / BAG3 / Gene Therapy / Cardiac
    BAG3-Mediated Dilated Cardiomyopathy (DCM)PreclinicalActiveGlobal
  • SGT-701SGT-701 / RBM20 / Gene Therapy / Cardiac
    RBM20-Mediated Dilated Cardiomyopathy (DCM)PreclinicalActiveGlobal
  • Undisclosed Cardiac TargetsGene Therapy / Cardiac
    Genetic cardiomyopathies and channelopathiesDiscoveryActiveGlobal

Spyre Therapeutics, Inc.

spyre.com
7assets
  • SPY001SPY001 / α4β7 / Monoclonal antibody / Gastroenterology
    Inflammatory Bowel Disease (IBD)Ulcerative Colitis
  • SPY002SPY002 / TL1A / Monoclonal antibody / Gastroenterology / Rheumatology
    Inflammatory Bowel Disease (IBD)Rheumatoid Arthritis (RA)
  • SPY003SPY003 / IL-23 / Monoclonal antibody / Gastroenterology
    Inflammatory Bowel Disease (IBD)
  • SPY120SPY120 / α4β7 + TL1A / Combination / Gastroenterology
    Inflammatory Bowel Disease (IBD)
  • SPY130SPY130 / α4β7 + IL-23 / Combination / Gastroenterology
    Inflammatory Bowel Disease (IBD)
  • SPY230SPY230 / TL1A + IL-23 / Combination / Gastroenterology
    Inflammatory Bowel Disease (IBD)Ulcerative Colitis
  • SPY072SPY072 / TL1A / Monoclonal antibody / Rheumatology
    Rheumatoid Arthritis (RA)Psoriatic Arthritis (PsA)Axial Spondyloarthritis (axSpA)

Tonix Pharmaceuticals Holding Corp.

tonixpharma.com
7assets

UroGen Pharma Ltd.

urogen.com
7assets

Voyager Therapeutics, Inc.

voyagertherapeutics.com
7assets
  • VY7523VY-TAU01 / Tau / Monoclonal Antibody / Neurology
    Alzheimer's DiseasePhase 1OngoingUnited States
  • VY1706Tau / AAV Gene Therapy / Neurology
    Alzheimer's DiseaseIND-EnablingOngoingUnited States
  • APOE Gene TherapyAPOE / AAV Gene Therapy / Neurology
    Alzheimer's DiseasePreclinicalOngoing
  • NBIB-'223NBIB-223 / Frataxin (FXN) / AAV Gene Therapy / Neurology
    Friedreich's Ataxia (FA)IND-EnablingOngoing
  • GBA1 Gene TherapyGBA1 / AAV Gene Therapy / Neurology
    Parkinson's Disease and GBA1-mediated diseasesIND-EnablingOngoing
  • Novartis Partnered ProgramsUndisclosed / AAV Gene Therapy / Neurology
    Huntington's Disease, Spinal Muscular Atrophy (SMA), UndisclosedPreclinicalOngoing
  • Alexion Partnered ProgramUndisclosed / AAV Gene Therapy / Neurology
    Undisclosed Neurological DiseasePreclinicalOngoing

Acadia Pharmaceuticals

acadia.com
6assets
  • RemlifanserinACP-204 / 5-HT2A receptor / inverse agonist / Neurological Disorders
    Alzheimer’s Disease PsychosisPhase 2RecruitingLewy Body Dementia with PsychosisPhase 2
  • ACP-211ACP-211 / selectively deuterated R-norketamine / Neurological Disorders
    Major Depressive DisorderPhase 2
  • ACP-711ACP-711 / GABAA α3 / modulator / Neurological Disorders
    Essential TremorPhase 1
  • ACP-271ACP-271 / GPR88 / agonist / Neurological Disorders; Rare Diseases
    Tardive DyskinesiaIND EnablingHuntington's DiseaseIND Enabling
  • ACP-2591ACP-2591 / cGP analog / Rare Diseases
    Rett Syndrome; Fragile X SyndromePhase 1
  • STOKE ASOantisense oligonucleotide / Rare Diseases
    SYNGAP1Discovery

AC Immune

acimmune.com
6assets
  • ACI-35.030JNJ-2056; JNJ-64042056 / phosphorylated Tau (pTau) / active immunotherapy / neurodegenerative diseases
    preclinical Alzheimer's diseasePhase 2bongoing
  • ACI-24.060amyloid beta (Abeta) / active immunotherapy / neurodegenerative diseases
    Alzheimer's diseasePhase 2ongoingAlzheimer's disease in Down syndromePhase 2ongoing
  • ACI-7104.056alpha-synuclein (a-syn) / active immunotherapy / neurodegenerative diseases
    Parkinson's diseasePhase 2ongoing
  • ACI-19764NLRP3 inflammasome / small molecule inhibitor / neuroinflammation
    neuro-inflammationPhase 1ongoing
  • Morphomer TauTau / small molecule / neurodegenerative diseases
    Alzheimer's diseasePreclinicalIND-enabling studies planned
  • Morphomer a-synalpha-synuclein (a-syn) / small molecule / neurodegenerative diseases
    Parkinson's diseasePreclinicalreadiness to initiate IND-enabling studies

Alector, Inc.

alector.com
6assets
  • AL101PGRN / antibody / Neurodegenerative diseases
    Alzheimer’s diseasePhase 2
  • AL137-ABCAmyloid beta / ABC-enabled antibody / Neurodegenerative diseases
    Alzheimer’s diseasePreclinical
  • AL050-ABCGCase / ABC-enabled enzyme replacement therapy / Neurodegenerative diseases
    Parkinson’s diseasePreclinicalGaucher diseasePreclinicalLewy body dementiaPreclinical
  • AL064-ABCTau / ABC-enabled siRNA / Neurodegenerative diseases
    Alzheimer’s diseaseResearchFrontotemporal dementiaResearch
  • ADP062-ABCAlpha-synuclein / ABC-enabled siRNA / Neurodegenerative diseases
    Parkinson’s diseaseResearch
  • ADP065-ABCNLRP3 / ABC-enabled siRNA / Neurodegenerative diseases
    Alzheimer’s diseaseResearchParkinson’s diseaseResearch

Allogene Therapeutics, Inc.

allogene.com
6assets
  • cemacabtagene ansegedleucelcema-cel; ALLO-501A / CD19 / Allogeneic CAR T cell therapy / Hematologic malignancies
    Large B-cell lymphoma, MRD-positive first-line consolidationPivotal Phase 2EnrollingUSCanadaSouth KoreaAustralia
  • ALLO-316ALLO-316 / CD70 / Allogeneic CAR T cell therapy / Solid tumors; hematologic malignancies
    Advanced/metastatic clear cell renal cell carcinomaPhase 1bExpansion cohort enrollment completed; strategic opportunities being exploredCD70+ hematologic malignanciesIND-enablingCD70+ solid tumorsIND-enabling
  • ALLO-329ALLO-329 / CD19/CD70 / Allogeneic dual CAR T cell therapy; CRISPR gene-edited; Dagger technology / Autoimmune disease
    Systemic lupus erythematosus including lupus nephritisPhase 1OngoingIdiopathic inflammatory myopathiesPhase 1OngoingSystemic sclerosisPhase 1Ongoing
  • ALLO-213ALLO-213 / DLL3 / Allogeneic CAR T cell therapy / Solid tumors
    Small cell lung cancerIND-enabling
  • ALLO-182ALLO-182 / Claudin 18.2 / Allogeneic CAR T cell therapy / Solid tumors
    Gastric and pancreatic solid tumorsIND-enabling
  • BCMA/CD70 dual CAR T constructBCMA/CD70 / Allogeneic dual CAR T cell therapy; Dagger technology / Hematologic malignancies
    Multiple myelomaPreclinical

Apellis Pharmaceuticals, Inc.

apellis.com
6assets

Autolus Therapeutics PLC

autolus.com
6assets
  • obe-celAUCATZYL / CD19 / autologous CAR T-cell therapy / Hematology/oncology; autoimmune
    r/r adult ALLApprovedFDA/MHRA/EMA approvedUSUKEUPediatric B-ALLPhase 2CATULUSSystemic Lupus ErythematosusPhase 1CARLYSLE
  • AUTO1/22CD19 & CD22 / dual-targeting autologous CAR T-cell therapy / Hematology/oncology
    Pediatric B-ALLPhase 1CARPALL
  • AUTO8BCMA & CD19 / autologous CAR T-cell therapy / Hematology/oncology
    Multiple MyelomaPhase 1MCARTYLight Chain AmyloidosisPhase 1ALARIC
  • AUTO4/5TRBC1/2 / programmed T-cell therapy / Hematology/oncology
    TRBC1/2+ Peripheral TCLPreclinicalLibrA T1
  • AUTO6NGGD2 / autologous CAR T-cell therapy / Solid tumors
    NeuroblastomaPhase 1MAGNETO
  • AUTO9programmed T-cell therapy / Hematology/oncology
    Acute Myeloid LeukemiaPreclinicalTBD

Axsome Therapeutics, Inc.

axsome.com
6assets
  • AXS-05AXS-05 / AUVELITY / NMDA receptor; sigma-1 receptor; CYP2D6 / oral small molecule; dextromethorphan-bupropion / CNS
    Smoking cessationPhase 2/3 plannedOn track to initiate in Q2 2026US
  • SolriamfetolSUNOSI / DNRI; TAAR1; 5-HT1A / oral small molecule / CNS
    ADHD, childrenPhase 3 plannedOn track to initiate in Q2 2026USADHD, adolescentsPhase 3 plannedOn track to initiate in Q2 2026USMDD with EDS symptomsPhase 3CLARITY initiatedUS
  • AXS-12AXS-12 / Norepinephrine reuptake inhibitor; cortical dopamine modulator / oral small molecule; reboxetine / CNS
    Cataplexy in narcolepsyNDA submittedFDA filing acceptance decision pendingUS
  • AXS-14AXS-14 / Norepinephrine reuptake inhibitor / oral small molecule; esreboxetine / CNS
    FibromyalgiaPhase 3FORWARD ongoingUS
  • AXS-17AXS-17 / GABA-A receptor α2,3 subtype-selective PAM / oral small molecule / CNS
    EpilepsyPhase 2 trial-enablingUnderwayUS
  • AXS-20AXS-20 / PDE10A / oral small molecule; balipodect / CNS
    SchizophreniaPre-Phase 3Phase 3 trial-enabling activities anticipated in 2026USTourette syndromePlanned evaluationUS

Beam Therapeutics Inc.

beamtx.com
6assets
  • Ristoglogene autogetemcelBEAM-101 / Risto-cel / HBG1/2 promoter; fetal hemoglobin activation / Ex vivo autologous CD34+ HSPC base-edited cell therapy / Hematology
    Sickle cell diseasePhase I/IIOngoing BEACON Phase 1/2 trial; FDA orphan drug and RMAT designationsU.S.
  • ESCAPEBEAM-103 / CD117; HbF edit + CD117 edit-antibody pair / Anti-CD117 monoclonal antibody plus edited cell therapy; in vivo and/or ex vivo / Hematology
    Sickle cell diseasePhase I-EnablingBeta-thalassemiaPhase I-Enabling
  • In vivo HSC editingHbF activation / In vivo LNP base editing / Hematology
    Sickle cell diseaseResearchBeta-thalassemiaResearch
  • BEAM-302BEAM-302 / SERPINA1 E342K/PiZ mutation correction / In vivo LNP base editing / Liver-targeted genetic diseases
    Alpha-1 antitrypsin deficiencyPhase I/IIOngoing Phase 1/2 trial; FDA orphan drug and RMAT designationsU.S.
  • BEAM-301BEAM-301 / G6PC R83C mutation correction / In vivo LNP base editing / Liver-targeted genetic diseases
    Glycogen storage disease IaPhase I/IIOngoing Phase 1/2 trial
  • BEAM-304BEAM-304 / PAH mutation correction / In vivo LNP base editing / Liver-targeted genetic diseases
    PhenylketonuriaPhase I-EnablingPlanned Phase 1/2 trialU.S.

BioXcel Therapeutics, Inc.

bioxceltherapeutics.com
6assets
  • BXCL501BXCL501 / IGALMI / alpha-2 receptor agonist / orally dissolving/sublingual film formulation of dexmedetomidine / Neuroscience
    Acute agitation associated with bipolar disorders or schizophrenia, at homePhase 3Company-sponsored SERENITY programAcute agitation associated with Alzheimer's dementiaPhase 3Company-sponsored TRANQUILITY program; paused subject to fundingOpioid use disorderPhase 2Investigator-sponsored
  • BXCL701BXCL701 / DPP8/9 and FAP / oral innate immune activator / Immuno-oncology
    Small cell neuroendocrine prostate cancerPhase 2Company-sponsored; FDA meeting expectedUSUKSmall cell lung cancerPreclinicalCompany-sponsored; initiate Phase 1b/2 expectedMetastatic pancreatic ductal adenocarcinomaPhase 2Investigator-sponsored; Phase 2 readout expected
  • BXCL502BXCL502 / latrepirdine / Neuroscience
    Chronic agitation in dementiaPreclinicalDevelopment paused due to strategic reprioritization
  • BXCL503BXCL503 / Neuroscience
    Apathy in dementiaPreclinicalDevelopment paused due to strategic reprioritization
  • BXCL504BXCL504 / Neuroscience
    Aggression in dementiaPreclinicalDevelopment paused due to strategic reprioritization
  • BXCL702BXCL702 / DPP inhibitor / novel DPP inhibitor / Immuno-oncology
    Solid tumorsPreclinicalBXCL701 follow-on; candidate nomination expected

Cocrystal Pharma, Inc.

cocrystalpharma.com
6assets

Eton Pharmaceuticals, Inc.

etonpharma.com
6assets
  • AmglidiaAmglidia / glyburide oral suspension / Pediatric endocrinology / rare disease
    Neonatal diabetes mellitusLate-stage development; NDA submission anticipated in 2026In developmentUnited States
  • ET-700ET-700 / extended-release zinc acetate formulation / Rare metabolic disease
    Wilson diseasePilot clinical study / proof-of-conceptFirst patient dosed; topline results expected H2 2026; potential pivotal study in early 2027United States
  • ET-800ET-800 / Rare disease
    UndisclosedLate-stage developmentIn development
  • ZENEO hydrocortisone autoinjectorZENEO / hydrocortisone autoinjector / Endocrinology
    Adrenal insufficiency / adrenal crisis managementLate-stage developmentIn developmentUnited States
  • KHINDIVI revised formulationKHINDIVI / hydrocortisone oral solution / Pediatric endocrinology
    Adrenocortical insufficiency label expansion to younger pediatric patientsBioequivalence study; supplemental NDA plannedStudy initiated; supplement expected in Q3 2026; potential mid-2027 approvalUnited States
  • INCRELEX label expansionINCRELEX / IGF-1 receptor pathway / mecasermin injection / Pediatric endocrinology
    Severe primary IGF-1 deficiency definition harmonization / label expansionPlanned clinical studyFDA feedback requested; study could initiate in H1 2026 if favorableUnited States

Fate Therapeutics, Inc.

fatetherapeutics.com
6assets
  • FT819FT819 / CD19 / iPSC-derived off-the-shelf CAR T-cell therapy / Autoimmunity
    Systemic Lupus ErythematosusPhase 1RMATUSSystemic Sclerosis (SSc)Phase 1USANCA associated Vasculitis (AAV)Phase 1US
  • FT839FT839 / CD19/CD38/CD20; CD19/CD38/BCMA/GPRC5D / Next-generation CAR T-cell therapy / Autoimmunity; Oncology
    Pan-indication without lympho-conditioning chemotherapyPhase 1USPan-indication (hematologic) without lympho-conditioning chemotherapyPhase 1US
  • FT522FT522 / CD19/CD20 / Cellular immunotherapy / Autoimmunity
    Pan-indication without lympho-conditioning chemotherapyPhase 1US
  • FT825FT825 / HER2/EGFR / iPSC-derived off-the-shelf CAR T-cell therapy / Oncology
    Solid tumorsPhase 1EnrollingUS
  • UndisclosedUndisclosed / Cellular immunotherapy / Oncology
    Solid tumorsPhase 1US
  • FT836FT836 / MICA/B/EGFR/HER2 / Next-generation CAR T-cell therapy / Oncology
    Pan-indication (solid/hematologic) without lympho-conditioning chemotherapyPhase 1US

Harrow, Inc.

harrow.com
6assets

Humacyte, Inc.

humacyte.com
6assets
  • Symvess (ATEV)Symvess / Acellular Tissue Engineered Vessel / Vascular Disease
    Vascular trauma repairApprovedFDA Approved (Dec 2024)United StatesArteriovenous access for hemodialysisPhase 3V007 met primary endpoints; V012 ongoing; sBLA planned H2 2026United StatesPeripheral artery disease (PAD)Phase 2Completed Phase 2 trials and expanded access; positive limb salvage dataUnited StatesEurope
  • CTEVCoronary Tissue Engineered Vessel / Cardiovascular Disease
    Coronary artery bypass grafting (CABG)PreclinicalPositive NHP data; IND submitted; first-in-human planned H2 2026United States
  • Biovascular Pancreas (BVP)Biovascular Pancreas™ / Bioengineered Organ / Diabetes
    Type 1 diabetesPreclinicalPositive preclinical data; NHP studies planned; first-in-human planned 2027
  • Urinary ConduitAdvanced Tissue Construct / Urology
    Urinary diversion after cystectomyPreclinical
  • Tracheal ReplacementAdvanced Tissue Construct / Otolaryngology
    Tracheal replacementPreclinical
  • Esophageal ReplacementAdvanced Tissue Construct / Gastroenterology
    Esophageal replacementPreclinical

Immunome, Inc.

immunome.com
6assets

Inovio Pharmaceuticals, Inc.

inovio.com
6assets
  • INO-3107INO-3107 / HPV-6 and HPV-11 / DNA immunotherapy / HPV-related rare disease
    Recurrent Respiratory Papillomatosis (RRP) in adultsBLA accepted under accelerated approval, PDUFA Oct 30 2026United States
  • VGX-3100VGX-3100 / HPV-16/18 / DNA immunotherapy / HPV-related diseases
    Cervical dysplasia (HSIL)3Ongoing (partnered)ChinaAnal dysplasia
  • INO-3112INO-3112 / HPV-16/18 / DNA immunotherapy / Oncology
    HPV16/18-positive oropharyngeal squamous cell carcinoma (OPSCC)3Phase 3 planningUnited StatesEurope
  • INO-5401INO-5401 / Tumor-associated antigens / DNA immunotherapy / Oncology
    Glioblastoma (GBM)1Ongoing Phase 1; Phase 2 planning (as INO-5412 w/ Akeso)United StatesPrevention in BRCA1/2 mutation carriers1Ongoing Phase 1United States
  • INO-4201INO-4201 / Ebola virus / DNA medicine / Infectious diseases
    Ebola vaccine booster (to ERVEBO)2Phase 2 planning; Phase 1b completed
  • DMAb SARS-CoV-2SARS-CoV-2 / DNA-encoded monoclonal antibody / Infectious diseases
    SARS-CoV-21Ongoing Phase 1; data expected/reportedUnited States

Invivyd, Inc.

invivyd.com
6assets
  • PemivibartPEMGARDA / SARS-CoV-2 / Monoclonal Antibody / Infectious Diseases
    Pre-exposure prophylaxis (PrEP) of COVID-19
  • VYD2311VYD2311 / SARS-CoV-2 / Monoclonal Antibody / Infectious Diseases
    COVID-19 prevention
  • AdintrevimabSARS-CoV-2 / Monoclonal Antibody / Infectious Diseases
    COVID-19 prevention and treatment
  • Measles mAbMeasles (rubeola) virus / Monoclonal Antibody / Infectious Diseases
    Measles treatment and post-exposure prophylaxis
  • RSV mAbRespiratory Syncytial Virus (RSV) / Monoclonal Antibody / Infectious Diseases
    RSV infection
  • Influenza mAbInfluenza virus / Monoclonal Antibody / Infectious Diseases
    Influenza infection

Molecular Partners AG

molecularpartners.com
6assets
  • MP0712MP0712 / DLL3 / Radio-DARPin Therapy / Oncology
    Small Cell Lung Cancer (SCLC)Neuroendocrine Tumors
  • MP0726MP0726 / MSLN / Radio-DARPin Therapy / Oncology
    Ovarian Cancer
  • MP0533MP0533 / CD33 x CD123 x CD70 x CD3 / Multispecific T Cell Engager / Oncology
    Relapsed/Refractory AMLAML/MDS
  • MP0317MP0317 / FAP x CD40 / Tumor-localized CD40 Agonist / Oncology
    Advanced Solid TumorsCholangiocarcinoma
  • MP0632MP0632 / CD2 x CD3 x MSLN x EpCAM / Switch-DARPin T Cell Engager / Oncology
    MSLN/EpCAM Expressing Solid TumorsOvarian Cancer
  • MP0621MP0621 / cKIT x CD16a x CD47 / Switch-DARPin / Hematology
    Conditioning for Hematopoietic Stem Cell Transplantation

MapLight Therapeutics, Inc.

maplightrx.com
6assets

MetaVia Inc.

metaviatx.com
6assets
  • DA-1726DA-1726 / GLP1R / GCGR (Glucagon-like peptide-1 receptor and glucagon receptor) / Oxyntomodulin (OXM) analogue / Cardiometabolic Diseases
    ObesityPhase 1ActiveGlobalMetabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 1ActiveGlobal
  • VanoglipelDA-1241 / GPR119 (G-protein-coupled receptor 119) / Small Molecule / Cardiometabolic Diseases
    Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2aActiveGlobalType 2 Diabetes (T2D)Phase 1CompletedGlobal
  • ANA001ANA001 / Unknown / Oral Niclosamide Formulation / Infectious Diseases
    Moderate COVID-19Phase 2LegacyUS
  • NB-01NB-01 / Unknown / Unknown / Neurology
    Painful Diabetic NeuropathyUnknownLegacyGlobal
  • NB-02NB-02 / Unknown / Unknown / Neurology
    Cognitive Impairment / Neurodegenerative DiseasesUnknownLegacyGlobal
  • GemcabeneUnknown / Small Molecule / Cardiovascular / Infectious Diseases
    DyslipidemiaUnknownLegacyGlobalAcute COVID-19UnknownLegacyGlobal

Nurix Therapeutics, Inc.

nurixtx.com
6assets

Intellia Therapeutics, Inc.

intelliatx.com
6assets

Ocugen, Inc.

ocugen.com
6assets

Organon & Co.

organon.com
6assets

Os Therapies Incorporated

ostherapies.com
6assets
  • OST-HER2OST31-164 / HER2 / Bioengineered Listeria monocytogenes (Immunotherapy) / Oncology
    Osteosarcoma (Pulmonary Metastatic)Phase 2bActiveGlobalBreast CancerPhase 1ActiveGlobalCanine OsteosarcomaApprovedMarketedUS
  • OST-AXALAXAL / ADXS-HPV / HPV / Listeria-based Immunotherapy / Oncology
    HPV-associated cancersPhase 3ActiveGlobal
  • OST-503ADXS-503 / KRAS G12 position-related antigens / Listeria-based Immunotherapy / Oncology
    Non-Small Cell Lung Cancer (NSCLC)Phase 2ActiveGlobalGlioblastoma (GBM)Phase 2ActiveGlobalPancreatic CancerPreclinicalActiveGlobal
  • OST-504OST-PSA / ADXS-504 / ADXS31142 / PSA / Listeria-based Immunotherapy / Oncology
    Prostate Cancer (Castration-Resistant)Phase 1bActiveGlobal
  • OST-tADCVarious / Tunable Antibody-Drug Conjugate (ADC) / Oncology
    Ovarian CancerPreclinicalActiveGlobalBreast CancerPreclinicalActiveGlobal
  • OST-HOT constructsShared hotspot mutations and cancer-testes antigens / Listeria-based Immunotherapy / Oncology
    Solid TumorsPreclinicalActiveGlobal

ProQR Therapeutics N.V.

proqr.com
6assets
  • AX-0810AX-0810 / NTCP (SLC10A1) / RNA Editing Oligonucleotide (Axiomer EON) / Liver
    Biliary AtresiaPrimary Sclerosing Cholangitis
  • AX-0811AX-0811 / NTCP / RNA Editing Oligonucleotide (Axiomer EON) / Liver
    Cholestatic Diseases
  • AX-0422AX-0422 / IDUA / RNA Editing Oligonucleotide (Axiomer EON) / Metabolic / Rare Disease
    Hurler Syndrome
  • AX-2402AX-2402 / MECP2 (R270X) / RNA Editing Oligonucleotide (Axiomer EON) / CNS / Rare Disease
    Rett Syndrome
  • AX-2911AX-2911 / PNPLA3 / RNA Editing Oligonucleotide (Axiomer EON) / Liver / Metabolic
    MASH
  • AX-1412AX-1412 / B4GALT1 / RNA Editing Oligonucleotide (Axiomer EON) / Cardiovascular
    Cardiovascular Disease

Ultragenyx Pharmaceutical Inc.

ultragenyx.com
6assets
  • rivunatpagene miziparvovecUX701 / ATP7B / AAV9 gene therapy / Inborn Errors of Metabolism
    Wilson disease
  • rebisufligene etisparvovecUX111 / AAV gene therapy / Neurogenetic
    Sanfilippo syndrome type A (MPS IIIA)
  • avalotcagene ontaparvovecDTX301 / OTC / AAV8 gene therapy / Inborn Errors of Metabolism
    Ornithine transcarbamylase (OTC) deficiency
  • DTX401DTX401 / AAV gene therapy / Inborn Errors of Metabolism
    Glycogen storage disease type Ia (GSDIa)
  • GTX-102GTX-102 / UBE3A / Antisense oligonucleotide (ASO) / Neurogenetic
    Angelman Syndrome
  • setrusumabUX143 / Biologic / Bone-Endocrine
    Osteogenesis imperfecta

Revolution Medicines, Inc.

revmed.com
6assets
  • DaraxonrasibRMC-6236 / RAS(ON) multi-selective / Small Molecule / Oncology
    Pancreatic Ductal Adenocarcinoma (PDAC)Non-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)
  • ZoldonrasibRMC-9805 / RAS(ON) G12D / Small Molecule / Oncology
    Non-Small Cell Lung Cancer (NSCLC)Solid Tumors
  • ElironrasibRMC-6291 / RAS(ON) G12C / Small Molecule / Oncology
    KRAS-G12C mutant cancersNon-Small Cell Lung Cancer (NSCLC)Solid Tumors
  • RMC-5127RMC-5127 / RAS(ON) G12V / Small Molecule / Oncology
    RAS-G12V mutant cancers
  • RMC-0708RMC-0708 / RAS(ON) Q61H / Small Molecule / Oncology
    RAS-Q61H mutant cancers
  • RMC-8839RMC-8839 / RAS(ON) G13C / Small Molecule / Oncology
    RAS-G13C mutant cancers

Recursion Pharmaceuticals, Inc.

recursion.com
6assets

Schrodinger, Inc.

schrodinger.com
6assets
  • SGR-1505SGR-1505 / MALT1 / Small Molecule / Oncology
    Relapsed/Refractory B-cell MalignanciesPhase 1Active
  • SGR-3515SGR-3515 / PKMYT1 / Wee1 / Small Molecule / Oncology
    Advanced Solid TumorsPhase 1Active
  • SGR-4174SGR-4174 / SOS1 / Small Molecule / Oncology
    KRAS-driven CancersPreclinicalActive
  • SGR-2921SGR-2921 / CDC7 / Small Molecule / Oncology
    Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS)Phase 1Discontinued
  • ACCG-2671ACCG-2671 / Calcitonin Receptor (DACRA) / Small Molecule / Metabolic
    ObesityPhase 1Active
  • AJ1-11095AJ1-11095 / JAK2 / Small Molecule / Hematology
    MyelofibrosisPreclinicalActiveUS

Silence Therapeutics PLC

silence-therapeutics.com
6assets
  • DivesiranSLN124 / TMPRSS6 / siRNA / Hematologic Conditions
    Polycythemia VeraOther Blood Disorders
  • ZerlasiranSLN360 / LPA / siRNA / Cardiovascular Disease
    Elevated Lp(a)Atherosclerotic Cardiovascular Disease
  • SLN312SLN312 / ANGPTL3 / siRNA / Cardiometabolic
    Dyslipidemia
  • SLN548SLN548 / CFB / siRNA / Complement
  • SLN365SLN365 / GPR146 / siRNA / Cardiometabolic
    Homozygous familial hypercholesterolemia (HoFH)
  • SLN098SLN098 / INHBE / siRNA / Metabolic
    Obesity

Tactile Systems Technology, Inc.

tactilemedical.com
6assets

Tempest Therapeutics, Inc.

tempesttx.com
6assets
  • AmezalpatTPST-1120 / PPARα antagonist / Small Molecule / Oncology
    Hepatocellular Carcinoma (HCC)CholangiocarcinomaRenal Cell Carcinoma (RCC)
  • TPST-1495TPST-1495 / Dual EP2/EP4 Antagonist / Small Molecule / Oncology / Gastrointestinal
    Familial Adenomatous Polyposis (FAP)Solid Tumors
  • TREX-1 InhibitorTREX-1 / Small Molecule / Oncology
    Solid Tumors
  • TPST-2003TPST-2003 / CD19/BCMA / Autologous CAR-T Cell Therapy / Oncology
    Relapsed/Refractory Multiple Myeloma (rrMM)
  • TPST-3003TPST-3003 / CD19/BCMA / Allogeneic Cell Therapy / Oncology
    Relapsed/Refractory Multiple Myeloma (rrMM)
  • TPST-4003TPST-4003 / CD19/BCMA / In Vivo Cell Therapy / Immunology / Autoimmune
    Systemic Lupus Erythematosus (SLE)Immunology Disorders

Entrada Therapeutics, Inc.

entradatx.com
6assets

United Therapeutics Corporation

unither.com
6assets
  • TreprostinilTyvaso / Prostacyclin receptor / Small Molecule / Respiratory
    Idiopathic Pulmonary Fibrosis (IPF)
  • RalinepagProstacyclin receptor / Small Molecule / Cardiopulmonary
    Pulmonary Arterial Hypertension (PAH)
  • UKidneyUKidney / Xenotransplantation / Organ Transplantation
    End Stage Renal Disease
  • UThymoKidneyUThymoKidney / Xenotransplantation / Organ Transplantation
    End Stage Renal Disease
  • miroliverELAPmiroliverELAP / Regenerative Medicine / Organ Transplantation
    Acute Liver Failure
  • Centralized Lung Evaluation System (CLES)Ex-vivo Perfusion System / Organ Transplantation
    Lung Transplant

Valneva SE

valneva.com
6assets

Vir Biotechnology, Inc.

vir.bio
6assets
  • ElebsiranVIR-2218 / HBV / siRNA / Infectious Diseases
    Chronic Hepatitis Delta (CHD)Phase 3ActiveGlobalChronic Hepatitis B (CHB)Phase 2ActiveGlobal
  • TobevibartVIR-3434 / HBV / Monoclonal Antibody / Infectious Diseases
    Chronic Hepatitis Delta (CHD)Phase 3ActiveGlobalChronic Hepatitis B (CHB)Phase 2ActiveGlobal
  • VIR-1388VIR-1388 / HIV / T Cell Vaccine / Infectious Diseases
    HIV PreventionPhase 1ActiveUnited StatesSouth Africa
  • VIR-5500VIR-5500 / PSMA / Masked T-Cell Engager / Oncology
    Solid TumorsPhase 1ActiveGlobal
  • VIR-5525VIR-5525 / EGFR / Masked T-Cell Engager / Oncology
    Solid TumorsPhase 1ActiveGlobal
  • VIR-5818VIR-5818 / HER2 / Masked T-Cell Engager / Oncology
    Solid TumorsPhase 1ActiveGlobal

Viking Therapeutics, Inc.

vikingtherapeutics.com
6assets
  • VK2735 (Subcutaneous)VK2735 / Dual GLP-1/GIP receptor agonist / Peptide / Metabolic Disorders
    Obesity
  • VK2735 (Oral)VK2735 / Dual GLP-1/GIP receptor agonist / Peptide / Metabolic Disorders
    Obesity
  • VK2809VK2809 / Thyroid hormone receptor beta (TRβ) agonist / Small molecule / Metabolic Disorders
    NASHFibrosisNAFLD
  • VK0214VK0214 / Thyroid hormone receptor beta (TRβ) agonist / Small molecule / Rare Diseases
    X-linked adrenoleukodystrophy (X-ALD)
  • Amylin Agonist (DACRAs)Dual amylin and calcitonin receptor agonist (DACRA) / Agonist / Metabolic Disorders
    ObesityMetabolic disorders
  • VK5211VK5211 / Selective androgen receptor modulator (SARM) / Small molecule / Musculoskeletal Disorders
    Hip fracture recoveryMuscle and bone disorders

Vistagen Therapeutics, Inc.

vistagen.com
6assets
  • fasedienolPH94B / peripheral nasal chemosensory receptors / Intranasal pherine / Psychiatry
    Social Anxiety Disorder (SAD)
  • itruvonePH10 / peripheral nasal chemosensory receptors / Intranasal pherine / Psychiatry
    Major Depressive Disorder (MDD)
  • refisolonePH80 / peripheral nasal chemosensory receptors / Intranasal pherine / Women's Health
    Menopausal Vasomotor SymptomsPremenstrual Dysphoric Disorder (PMDD)
  • PH15PH15 / peripheral nasal chemosensory receptors / Intranasal pherine / Neurology/Psychiatry
    Psychomotor and cognitive impairment due to mental fatigue
  • PH284PH284 / peripheral nasal chemosensory receptors / Intranasal pherine / Oncology Supportive Care
    Cancer Cachexia
  • AV-101AV-101 / NMDA receptor glycine site / Small molecule / Neurology/Psychiatry
    Neurological disorders

Xilio Therapeutics, Inc.

xiliotx.com
6assets
  • VilastobartXTX101 / CTLA-4 / Monoclonal Antibody / Oncology
    Advanced solid tumors / MSS mCRCPhase 2ActiveGlobal
  • Efarindodekin alfaXTX301 / IL-12 / Cytokine / Oncology
    Advanced solid tumorsPhase 2ActiveGlobal
  • XTX501XTX501 / PD-1 / IL-2 / Bispecific Antibody / Cytokine / Oncology
    Non-small cell lung cancer (NSCLC) and other solid tumorsPreclinicalActiveGlobal
  • PSMA+STEAP1 Masked T Cell EngagerPSMA / STEAP1 / T Cell Engager / Oncology
    Prostate cancerPreclinicalActiveGlobal
  • CLDN18.2 Masked T Cell EngagerCLDN18.2 / T Cell Engager / Oncology
    Gastric, pancreatic, esophageal, and lung cancersPreclinicalActiveGlobal
  • Undisclosed Masked T Cell EngagerUndisclosed / T Cell Engager / Oncology
    CancerPreclinicalActiveGlobal

Aclaris Therapeutics, Inc.

aclaristx.com
5assets
  • BosakitugATI-045 / TSLP / humanized anti-TSLP monoclonal antibody / immuno-inflammatory; respiratory; dermatology
    atopic dermatitisPhase 2ongoing
  • ATI-052ATI-052 / TSLP; IL-4Rα / humanized bispecific antibody / immuno-inflammatory; respiratory; dermatology
    atopic dermatitisPhase 1bongoingasthmaPhase 1bongoingasthmaPhase 2bplanned
  • ATI-2138ATI-2138 / ITK; JAK3 / oral covalent small-molecule inhibitor / T cell-mediated autoimmune diseases; dermatology
    lichen planusPhase 2bplannedatopic dermatitisPhase 2acompleted
  • ATI-9494ATI-9494 / ITK; TXK/RLK / oral covalent small-molecule inhibitor / Th1, Th2 and Th17-driven diseases
    undisclosed inflammatory diseasespreclinicalIND planned
  • LepzacitinibATI-1777 / JAK1; JAK3 / topical soft small-molecule inhibitor / dermatology
    atopic dermatitisPhase 2bseeking partner

Annexon, Inc.

annexonbio.com
5assets
  • TanruprubartANX005 / C1q / classical complement pathway / IV mAb / Autoimmune / neurology
    Guillain-Barré SyndromeMAA filed; FDA discussions ongoingactiveUSEU
  • VonaprumentANX007 / C1q / classical complement pathway / IVT Fab / Ophthalmology
    Geographic AtrophyPhase 3ARCHER II enrollment completed; data expected 2H26
  • ANX1502ANX1502 / Classical complement pathway / Oral small molecule / Autoimmune
    Cold Agglutinin DiseaseProof-of-conceptactive; update upon CAD study completion in 2026
  • ANX005ANX005 / C1q / classical complement pathway / IV mAb / Neurodegeneration
    Huntington’s DiseasePoised for late-stage Phase 2b/3activeAmyotrophic Lateral SclerosisPoised for late-stage Phase 2b/3active
  • ANX009ANX009 / C1q / classical complement pathway / Subcutaneous Fab / Autoimmune
    Lupus NephritisEvaluating options for future development

Ascendis Pharma A/S

ascendispharma.com
5assets
  • TransCon hGHSKYTROFA / growth hormone / TransCon prodrug therapy / Endocrinology Rare Diseases
    Turner syndrome (children aged 1–10)Phase 2United StatesMulti-Indication: Turner syndrome, ISS, SHOX Deficiency, SGA (children aged 2–17)Phase 3MultinationalPediatric GHDPhase 3Japan
  • TransCon CNPC-type natriuretic peptide / TransCon prodrug therapy / Endocrinology Rare Diseases
    Achondroplasia (infants aged 0–<2)Pivotal Phase 2MultinationalAchondroplasia (children aged 2–11)Pivotal Phase 2MultinationalAchondroplasia (adolescents aged 12–18)Pivotal Phase 2bMultinational
  • TransCon CNP + TransCon hGHCNP; growth hormone / TransCon prodrug therapy combination / Endocrinology Rare Diseases
    Achondroplasia (children aged 2–11)Phase 2Multinational
  • TransCon PTHYORVIPATH / parathyroid hormone / TransCon prodrug therapy / Endocrinology Rare Diseases
    Adult Hypoparathyroidism (dosing expansion)Phase 3United StatesAdult HypoparathyroidismPhase 3China
  • TransCon IL-2 β/γ (Systemic)IL-2 β/γ / TransCon prodrug therapy / Oncology
    Various tumor typesPhase 2Multinational

ArriVent BioPharma, Inc.

arrivent.com
5assets
  • FirmonertinibEGFR TKI / oral small molecule / Oncology
    1L NSCLC EGFR exon 20 insertion mutationsPhase 3Monotherapyglobal1L+ NSCLC EGFR PACC mutationsPhase 3MonotherapyglobalAdjuvant EGFR uncommon mutationsPhase 3Monotherapy
  • ARR-217ARR-217 / CDH17 ADC / antibody-drug conjugate / Oncology
    GI tumorsPreclinical
  • ARR-002ARR-002 / antibody-drug conjugate / Oncology
    Solid tumorsDiscovery
  • ARR-421ARR-421 / antibody-drug conjugate / Oncology
    Solid tumorsDiscovery
  • ARR-173ARR-173 / antibody-drug conjugate / Oncology
    Solid tumorsDiscovery

BridgeBio Pharma, Inc.

bridgebio.com
5assets
  • AcoramidisAttruby / TTR (Transthyretin) / Small Molecule / Genetic disease
    Early-Stage Variant Transthyretin Amyloidosis (ATTRv)Phase 3Under investigation
  • BBP-418BBP-418 / FKRP / Small Molecule / Genetic disease; neuromuscular
    Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)Phase 3Investigational; FORTIFY interim analysis met endpoints
  • EncaleretCASR / Small Molecule / Endocrine; genetic disease
    Autosomal Dominant Hypocalcemia Type 1 (ADH1)Phase 3NDA planned/submission stated for H1 2026; pediatric registrational trial initiatedUSEUChronic HypoparathyroidismPhase 2NIH investigator-initiated study; Phase 3 planned in 2026
  • InfigratinibFGFR3 / Small Molecule / Skeletal dysplasia; genetic disease
    AchondroplasiaPhase 3PROPEL 3 registrational study; infant/toddler study enrollingUSEUHypochondroplasiaPhase 2ACCEL 2/3 Phase 2 portion dosed; data expected H2 2026
  • BBP-812BBP-812 / ASPA / Gene Therapy / Genetic disease; neurology
    Canavan DiseaseInvestigational AAV gene therapy

BioCryst Pharmaceuticals, Inc.

biocryst.com
5assets
  • ORLADEYO (berotralstat)ORLADEYO / plasma kallikrein / oral small-molecule inhibitor / Rare diseases
    Hereditary angioedema (HAE) prophylaxisApproved/Commercialmarketed
  • ORLADEYO (berotralstat) in PediatricsORLADEYO / plasma kallikrein / oral small-molecule inhibitor / Rare diseases
    Hereditary angioedema (HAE) prophylaxis, ages 2 to <12Approved/Commercialmarketed
  • NavenibartSTAR-0215 / plasma kallikrein / monoclonal antibody inhibitor / Rare diseases
    Hereditary angioedema (HAE) prophylaxisPhase 3/Pivotalinvestigational
  • BCX17725BCX17725 / KLK5 / protein therapeutic / Rare diseases
    Netherton syndromePhase 1investigational
  • STAR-0310STAR-0310 / OX40 / monoclonal antibody antagonist / Immunology/Dermatology
    Atopic dermatitisPreclinicalinvestigational; strategic alternatives planned

Bicycle Therapeutics PLC

bicycletherapeutics.com
5assets
  • nuzefatide pevedotinBT5528 / EphA2 / Bicycle Drug Conjugate / Oncology
    High EphA2-expressing tumorsPhase I/IIOngoingMetastatic pancreatic ductal adenocarcinomaPhase IIOngoing
  • zelenectide pevedotinBT8009 / Nectin-4 / Bicycle Drug Conjugate / Oncology
    Nectin-4-expressing tumorsPhase I/IIOngoing Duravelo-1Metastatic urothelial cancerPhase IIOngoing Duravelo-2
  • BT7480BT7480 / Nectin-4/CD137 / Bicycle TICA / Oncology
    Advanced solid tumors associated with Nectin-4 expressionPhase I/IIOngoing; seeking partner for future development
  • BT1702BT1702 / MT1-MMP / Bicycle Radioligand / Oncology
    MT1-MMP-expressing tumorsIND-enabling / human imagingCompany-sponsored BRC clinical trial planned in 2027
  • ION286/AZD4063ION286/AZD4063 / TfR1 / TfR1-targeted Bicycle conjugate / Cardiomyopathy
    CardiomyopathyPhase 1Ongoing

BioMarin Pharmaceutical Inc.

biomarin.com
5assets
  • BMN 333BMN 333 / C-type natriuretic peptide pathway / Long-acting CNP peptide / Skeletal Conditions
    AchondroplasiaPhase 2/3Registration-enabling study enrolling
  • BMN 351BMN 351 / Dystrophin / Oligonucleotide / Innovation
    Duchenne muscular dystrophyPhase 1/2Clinical data update expected year-end 2026
  • BMN 401BMN 401 / ENPP1 / Subcutaneous enzyme replacement therapy / Enzyme Therapies
    ENPP1 deficiencyPhase 3ENERGY 3 met 1 of 2 co-primary endpoints; next steps under evaluation
  • vosoritideVOXZOGO / CNP receptor/NPR-B pathway / Peptide / Skeletal Conditions
    HypochondroplasiaPhase 3Positive pivotal data; sNDA planned Q3 2026USEUAchondroplasiasNDAFull approval sNDA submitted April 2026USHypochondroplasia under 3 years oldPhase 2Enrollment progressing
  • pegvaliase-pqpzPALYNZIQ / Phenylalanine ammonia lyase / Enzyme therapy / Enzyme Therapies
    Phenylketonuria adolescents 12+RegulatoryFDA approved February 2026; EU approval expected 2026USEU

Bolt Biotherapeutics, Inc.

boltbio.com
5assets
  • BDC-4182BDC-4182 / Claudin 18.2 / Boltbody ISAC / Oncology
    Gastric cancerPhase 1Ongoing dose-escalationGastroesophageal cancerPhase 1Ongoing dose-escalation
  • BDC-3042BDC-3042 / Dectin-2 / Agonist monoclonal antibody / Oncology
    Non-small cell lung cancer, melanoma and other solid tumorsPhase 1Dose-escalation complete; seeking partner
  • CEA ISACCEA/CEACAM5 / Boltbody ISAC / Oncology
    Colorectal, non-small cell lung, pancreatic and gastric cancersPreclinicalPre-IND; seeking partner
  • PD-L1 ISACPD-L1 / Boltbody ISAC / Oncology
    Solid tumors resistant to checkpoint inhibitorsPreclinicalPre-IND; seeking partner
  • Caprin-1 ISACCaprin-1 / Boltbody ISAC / Oncology

Cellectis S.A.

cellectis.com
5assets
  • Lasme-celCD22 / allogeneic CAR-T / Oncology
    relapsed/refractory B-cell acute lymphoblastic leukemiaPhase 2BALLI-01; pivotal Phase 2 first interim analysis expected Q4 2026
  • Eti-celCD20, CD22 / dual allogeneic CAR-T / Oncology
    relapsed/refractory Non-Hodgkin lymphomaPhase 1NatHaLi-01; full Phase 1 dataset expected Q4 2026
  • Cemacabtagene ansegedleucelCema-cel / CD19 / allogeneic CAR-T / Oncology
    large B-cell lymphomaPivotal Phase 2ALPHA3
  • ALLO-316ALLO-316 / CD70 / allogeneic CAR-T / Oncology
    advanced or metastatic clear cell renal cell carcinomaPhase 1TRAVERSE
  • IOV-4001IOV-4001 / PD-1 / TALEN-modified tumor-infiltrating lymphocyte therapy / Oncology
    unresectable or metastatic melanomaIOV-GM1-201stage III or IV NSCLCIOV-GM1-201

Clearside Biomedical, Inc.

clearsidebio.com
5assets
  • CLS-AX (axitinib)CLS-AX / VEGF receptors-1, -2 and -3 / Small molecule tyrosine kinase inhibitor / Ophthalmology
    Wet AMDPhase 3 readyFDA end-of-Phase 2 alignment
  • XIPERE (triamcinolone acetonide injectable suspension)XIPERE; ARCATUS / Corticosteroid injectable suspension / Ophthalmology
    Uveitic macular edemaApproved/commercialUnited StatesAustraliaSingaporeUveitic macular edemaClinical development/commercialization partnerChinaDiabetic macular edemaClinical development/commercialization partnerAsia Pacific ex-Japan
  • Bel-SarViral-like drug conjugate / Ophthalmology/oncology
    Choroidal melanomaPartner clinical development program
  • ABBV-RGX-314ABBV-RGX-314 / anti-VEGF / AAV gene therapy / Ophthalmology
    Diabetic retinopathyPartner clinical development programWet AMDPartner clinical development program
  • AvoralstatPlasma kallikrein / Small molecule plasma kallikrein inhibitor / Ophthalmology
    Diabetic macular edemaPartner clinical development program

Cogent Biosciences, Inc.

cogentbio.com
5assets
  • bezuclastinibCGT9486 / KIT exon 17/KIT D816V / small molecule tyrosine kinase inhibitor / Oncology; hematology
    NonAdvanced Systemic MastocytosisNDA acceptedFDA review; PDUFA December 30, 2026USGastrointestinal Stromal Tumors after prior imatinibNDA submittedFDA reviewUSAdvanced Systemic Mastocytosisregistration-directed trial completedNDA planned 1H 2026US
  • CGT4255CGT4255 / mutant ErbB2/HER2 / CNS-penetrant small molecule inhibitor / Oncology
    Advanced solid tumors with HER2 mutations or HER2 overexpressionPhase 1dose escalation ongoing
  • CGT6297CGT6297 / PI3Kα / small molecule inhibitor / Oncology
    PI3Kα-mutant cancersPhase 1initiated
  • CGT1815CGT1815 / pan-KRAS(ON) / small molecule inhibitor / Oncology
  • CGT1145CGT1145 / JAK2 V617F / small molecule inhibitor / Hematology

Coya Therapeutics, Inc.

coyatherapeutics.com
5assets
  • COYA 302COYA 302 / Treg enhancement; T effector and macrophage depletion / Treg-enhancing/T effector and macrophage-depleting biologic combination; low-dose IL-2 + CTLA4-Ig / Neurodegenerative diseases
    Amyotrophic lateral sclerosisPhase 2Fast Track; ALSTARS Phase 2 enrollingUSCanadaFrontotemporal dementiaIND acceptedactiveUSAlzheimer's diseasePreclinical/POCactive
  • COYA 301COYA 301 / IL-2; Treg function and expansion / Proprietary low-dose IL-2 biologic / Neurodegenerative diseases
    Alzheimer's diseaseIND-enablingactive
  • COYA 303COYA 303 / IL-2; GLP-1 receptor / COYA 301 + GLP-1 receptor agonist combination / Inflammatory diseases
    UndisclosedDiscoveryactive
  • COYA 201COYA 201 / Allogeneic Treg-derived exosomes / Undisclosed
    UndisclosedPreclinicalactive
  • COYA 206COYA 206 / Antigen-directed allogeneic Treg-derived exosomes / Undisclosed
    UndisclosedPreclinicalactive

Entera Bio Ltd.

enterabio.com
5assets
  • EB613EB613 / PTH 1-34, teriparatide / oral peptide tablet / Osteoporosis
    Postmenopausal women with low BMD and high-risk osteoporosisPhase 3Phase 3 protocol submitted to FDA; registrational program plannedU.S.
  • EB612EB612 / LA-PTH 1-34 / oral long-acting PTH analog peptide tablet / Hypoparathyroidism
    HypoparathyroidismPreclinicalDevelopment ongoing; pre-IND initiatives underway
  • OXMOPK-88006 / GLP-1 & glucagon agonist / oral oxyntomodulin peptide tablet / Obesity / metabolic diseases
    Obesity and metabolic diseasesPreclinicalIND filing expected late H1 2026U.S.
  • GLP-2Long-acting GLP-2 / oral GLP-2 peptide tablet / Short bowel syndrome
    Short bowel syndromePreclinicalProof-of-concept single-dose pharmacokinetic study completed in rodents
  • EB613EB613 / PTH 1-34, teriparatide / oral peptide tablet / Stress fractures
    Stress fracturesInvestigator Sponsored Trial

Gyre Therapeutics, Inc.

gyretx.com
5assets
  • HydronidoneF351 / TGFβRI/p38γ (anti-fibrotic) / Small molecule / Fibrosis
    CHB-associated liver fibrosisNDA (priority review)NDA submission for conditional approval expected 1H 2026; Breakthrough Therapy designation (NMPA, Mar 2021)ChinaMASH-associated liver fibrosisIND-enablingU.S. IND application anticipated in 2026United States
  • PirfenidoneETUARY / Anti-fibrotic / Small molecule / Fibrosis/Respiratory
    Idiopathic pulmonary fibrosis (IPF)Approved/MarketedApproved in China (2011); commercializedChinaPneumoconiosis (PD)Phase 352-week Phase 3 trial enrollment completed (272 patients, 18 sites)ChinaRadiation-induced lung injury (RILI) with or without immune-related pneumonitisClinicalIn developmentChina
  • F573F573 / Caspase inhibitor / Small molecule / Hepatology
    Acute/acute-on-chronic liver failure (ALF/ACLF)ClinicalIn developmentChina
  • F528F528 / Small molecule / Respiratory
    Chronic obstructive pulmonary disease (COPD)PreclinicalIn developmentChina
  • F230F230 / Small molecule / Cardiopulmonary
    Pulmonary arterial hypertension (PAH)PreclinicalIn developmentChina

Jaguar Health, Inc.

jaguar.health
5assets
  • CrofelemerMytesi / CFTR and CaCC channels / Botanical Drug / Gastrointestinal
    HIV-Related DiarrheaApprovedMarketedUnited StatesCancer Therapy-related Diarrhea (CTD) / Chemotherapy-induced overactive bowelPhase 3ActiveUnited StatesIrritable Bowel SyndromeIn DevelopmentActiveUnited States
  • Crofelemer Powder for Oral SolutionCFTR and CaCC channels / Botanical Drug / Gastrointestinal / Rare Disease
    Microvillus Inclusion Disease (MVID)Late StageActiveUnited StatesEuropeShort Bowel Syndrome with Intestinal Failure (SBS-IF)Late StageActiveUnited StatesEurope
  • NP-300NP-300 / Unknown / Botanical Drug / Gastrointestinal / Infectious Disease
    Cholera Diarrhea / Infectious DiarrheaIn DevelopmentActiveGlobal
  • GelclairGelclair / Unknown / Bioadherent Oral Gel / Supportive Care / Oncology
    Oral MucositisApprovedMarketedUnited States
  • Crofelemer (Animal Health)Canalevia-CA1 / CFTR and CaCC channels / Botanical Drug / Animal Health
    Chemotherapy-induced diarrhea in dogsApprovedMarketedUnited States

Korro Bio, Inc.

korrobio.com
5assets
  • KRRO-121KRRO-121 / Glutamine Synthetase (GS) / GalNAc-conjugated oligonucleotide (RNA Editing) / Metabolic / Liver
    Urea Cycle Disorders (UCD) / Hepatic Encephalopathy (HE)PreclinicalActiveGlobal
  • AATD GalNAc ProgramSERPINA1 mRNA / GalNAc-conjugated oligonucleotide (RNA Editing) / Rare Diseases / Respiratory / Liver
    Alpha-1 Antitrypsin Deficiency (AATD)PreclinicalActiveGlobal
  • AMPKγ1 ProgramAMPKγ1 / GalNAc-conjugated oligonucleotide (RNA Editing) / Metabolic / Liver
    Liver Function / LongevityPreclinicalActiveGlobal
  • ALS ProgramTDP-43 mRNA / Oligonucleotide (RNA Editing) / Neurology
    Amyotrophic Lateral Sclerosis (ALS)PreclinicalActiveGlobal
  • Cardiometabolic ProgramUndisclosed / Oligonucleotide (RNA Editing) / Metabolic / Cardiovascular
    Cardiometabolic DiseasePreclinicalActiveGlobal

Kyowa Kirin Co., Ltd.

kyowakirin.com
5assets
  • ziftomenibKOMZIFTI / Menin / Small Molecule / Oncology
    Acute Myeloid Leukemia (AML) (Combination)Phase 3ActiveGlobalRelapsed or refractory (R/R) NPM1-mutant AMLPre-RegistrationNDA Submitted / Priority ReviewUS
  • rocatinlimabKHK4083 / AMG 451 / OX40 / Monoclonal Antibody / Immunology/Allergy
    Moderate to Severe Atopic DermatitisPhase 3ActiveGlobalUSEUJPPrurigo NodularisPhase 3ActiveGlobalAsthmaPhase 2ActiveGlobal
  • atidarsagene autotemcelOTL-200 / Lenmeldy / Libmeldy / ARSA / Hematopoietic Stem Cell (HSC) Gene Therapy / Rare Diseases
    Early-onset Metachromatic Leukodystrophy (MLD)Pre-RegistrationPreparation underway for clinical trial / Regulatory ReviewJP
  • tivozanibKHK4951 / VEGF Receptor Tyrosine Kinase / Small Molecule / Ophthalmic
    Ophthalmic DiseasesPhase 2/3ActiveGlobal
  • mogamulizumabKW-0761 / POTELIGEO / CCR4 / Monoclonal Antibody / Oncology
    Mycosis fungoides and Sézary syndromePre-RegistrationFiledCanada

Lexaria Bioscience Corp.

lexariabioscience.com
5assets

Ligand Pharmaceuticals Incorporated

investor.ligand.com
5assets
  • sparsentansparsentan / Filspari / ETA/AT1 receptors / Small molecule / Nephrology
    IgA Nephropathy
  • ensifentrineensifentrine / Ohtuvayre / PDE3/PDE4 / Small molecule / Respiratory
    COPD
  • pneumococcal 15-valent conjugate vaccineV114 / Vaxneuvance / Pneumococcal serotypes / Vaccine / Infectious Disease
    Pneumococcal disease
  • carfilzomibcarfilzomib / Kyprolis / Proteasome / Small molecule / Oncology
    Multiple Myeloma
  • berdazimerberdazimer / Zelsuvmi / Nitric oxide / Small molecule / Dermatology
    Molluscum contagiosum

Lisata Therapeutics, Inc.

lisata.com
5assets
  • CertepetideLSTA1 / alpha-v integrins / Cyclic Peptide / Oncology
    Advanced Solid TumorsPancreatic Ductal Adenocarcinoma (PDAC)Cholangiocarcinoma (CCA)
  • LSTA12LSTA12 / HONEDRA / CD34+ / Cell Therapy / Cardiovascular
    Critical Limb Ischemia (CLI)
  • LSTA14LSTA14 / OLOGO / CD34+ / Cell Therapy / Cardiovascular
    No-Option Refractory Disabling Angina (NORDA)
  • XOWNAXOWNA / CD34+ / Cell Therapy / Cardiovascular
    Coronary Microvascular Dysfunction (CMD)
  • LSTA201LSTA201 / CD34+ / Cell Therapy / Nephrology
    Diabetic Kidney Disease (DKD)

Lantern Pharma Inc.

lanternpharma.com
5assets
  • LP-300LP-300 / PTPN11 / Small molecule / Oncology
    Non-small cell lung cancer (NSCLC) in never-smokers
  • LP-184LP-184 / PTGR1-activated alkylating agent / Small molecule / Oncology
    Solid tumorsCNS cancersGlioblastoma multiforme (GBM)
  • LP-284LP-284 / PKC-beta / Small molecule / Oncology
    Hematologic malignanciesAggressive B-cell lymphomas
  • STAR-001STAR-001 / Unknown / Small molecule / Oncology
    CNS cancersBrain metastases
  • ADC ProgramUnknown / Antibody-drug conjugate (ADC) / Oncology
    Cancer

Veradermics, Incorporated

veradermics.com
5assets
  • VDPHL01VDPHL01 / Small molecule / Dermatology
    Androgenetic Alopecia (Pattern Hair Loss)
  • VDAAVDAA / Topical small molecule / Dermatology
    Alopecia Areata
  • VDADVDAD / Dermatology
    Atopic Dermatitis
  • VDMCVDMC / Dermatology
    Molluscum Contagiosum
  • VDMN-21VDMN-21 / Immune stimulatory / Microarray / Dermatology
    Warts

Mbx Biosciences, Inc.

mbxbio.com
5assets

MacroGenics, Inc.

macrogenics.com
5assets

MeiraGTx Holdings PLC

meiragtx.com
5assets

Mirum Pharmaceuticals, Inc.

mirumpharma.com
5assets
  • MaralixibatLIVMARLI / IBAT / Small molecule / Rare Liver Diseases
    Alagille syndrome (ALGS)Progressive familial intrahepatic cholestasis (PFIC)Biliary atresia
  • VolixibatSHP626 / IBAT / Small molecule / Rare Liver Diseases
    Primary sclerosing cholangitis (PSC)Primary biliary cholangitis (PBC)
  • MRM-3379MRM-3379 / PDE4D / Small molecule / Neurocognitive Disorders
    Fragile X syndrome
  • Cholic acidCHOLBAM / Bile acid replacement / Small molecule / Rare Liver Diseases
    Bile acid synthesis disordersPeroxisomal disorders (Zellweger spectrum disorders)
  • ChenodiolCTEXLI / Bile acid replacement / Small molecule / Rare Genetic Disorders
    Cerebrotendinous xanthomatosis (CTX)

Monopar Therapeutics Inc.

monopartx.com
5assets
  • ALXN1840ALXN1840 / Copper / Small Molecule / Rare Diseases
    Wilson Disease
  • MNPR-101-ZrMNPR-101-Zr / uPAR / Radiopharmaceutical / Oncology
    Advanced Solid Cancers (Imaging)
  • MNPR-101-LuMNPR-101-Lu / uPAR / Radiopharmaceutical / Oncology
    Advanced Solid Cancers
  • MNPR-101-AcMNPR-101-Ac / uPAR / Radiopharmaceutical / Oncology
    Advanced Solid Cancers
  • MNPR-101MNPR-101 / uPAR / Monoclonal Antibody / Oncology
    Solid Tumors

Merus N.V.

merus.nl
5assets
  • PetosemtamabMCLA-158 / EGFR x LGR5 / Bispecific Antibody / Oncology
    1L PD-L1+ r/m head and neck squamous cell carcinoma (with pembrolizumab)Phase 3OngoingGlobal2/3L r/m head and neck squamous cell carcinomaPhase 3OngoingGlobal1L metastatic colorectal cancer (with standard chemotherapy)Phase 2OngoingGlobal
  • ZenocutuzumabMCLA-128 / BIZENGRI / HER2 x HER3 / Bispecific Antibody / Oncology
    Pancreatic adenocarcinoma (NRG1 fusion-positive)ApprovedApprovedUnited StatesNon-small cell lung cancer (NRG1 fusion-positive)ApprovedApprovedUnited StatesOther non-NRG1+ cancerPhase 2OngoingGlobal
  • MCLA-129MCLA-129 / EGFR x c-MET / Bispecific Antibody / Oncology
    Solid tumorsPhase 1/Phase 2OngoingGlobal2L+ EGFRm non-small cell lung cancer (with chemotherapy)Phase 2OngoingGlobal
  • BesufetamigONO-4685 / PD-1 x CD3 / Bispecific Antibody / Oncology, Immunology
    Relapsed/Refractory T Cell LymphomaPhase 1OngoingGlobalPsoriasisPhase 1OngoingGlobal
  • INCA33890INCA33890 / PD-1 x TGFBr2 / Bispecific Antibody / Oncology
    Select advanced solid tumorsPhase 1OngoingGlobal

Nektar Therapeutics

nektar.com
5assets

Neumora Therapeutics, Inc.

neumoratx.com
5assets
  • navacaprantNMRA-140 / Kappa opioid receptor (KOR) antagonist / Small molecule / Neuropsychiatry
    Major Depressive Disorder
  • NMRA-511NMRA-511 / Vasopressin 1a receptor (V1aR) antagonist / Small molecule / Neuropsychiatry / Neurodegenerative
    Alzheimer's disease agitation
  • NMRA-215NMRA-215 / NLRP3 inhibitor / Small molecule / Endocrinology / Metabolic
    Obesity
  • NMRA-861NMRA-861 / M4 muscarinic receptor positive allosteric modulator (M4 PAM) / Small molecule / Neuropsychiatry
    SchizophreniaNeuropsychiatric disorders
  • NMRA-898NMRA-898 / M4 muscarinic receptor positive allosteric modulator (M4 PAM) / Small molecule / Neuropsychiatry
    SchizophreniaNeuropsychiatric disorders

Novavax, Inc.

novavax.com
5assets

Pacira BioSciences, Inc.

pacira.com
5assets
  • triamcinolone acetonideZILRETTA / Small Molecule Formulation / Musculoskeletal Pain
    Shoulder Osteoarthritis (OA)Phase 3Active
  • iovera°iovera° / Device / Neurology/Pain
    SpasticityClinicalActive
  • bupivacaine liposomeEXPAREL / Small Molecule Formulation / Pain Management
    Acute Post-Surgical Pain (Pediatric 0 to < 6)ClinicalActive
  • enekinragene inzadenovecPCRX-201 / IL-1Ra / Gene Therapy / Musculoskeletal Pain
    Osteoarthritis of the Knee (OAK)Phase 2Active
  • PCRX-2002PCRX-2002 / Unknown / Pain Management
    Post-Surgical PainClinicalActive

Processa Pharmaceuticals, Inc.

processapharmaceuticals.com
5assets

Vaxcyte, Inc.

vaxcyte.com
5assets
  • VAX-31VAX-31 / Streptococcus pneumoniae (31 Serotypes) / Pneumococcal Conjugate Vaccine (PCV) / Infectious Diseases
    Invasive Pneumococcal Disease (IPD) and Pneumonia in AdultsPhase 3OngoingUnited StatesInvasive Pneumococcal Disease (IPD) in InfantsPhase 2OngoingUnited States
  • VAX-24VAX-24 / Streptococcus pneumoniae (24 Serotypes) / Pneumococcal Conjugate Vaccine (PCV) / Infectious Diseases
    Invasive Pneumococcal Disease (IPD) in InfantsPhase 2OngoingUnited States
  • VAX-A1VAX-A1 / Group A Streptococcus / Conjugate Vaccine / Infectious Diseases
    Group A Strep InfectionsPreclinicalOngoing
  • VAX-GIVAX-GI / Shigella / Vaccine / Infectious Diseases
    Shigellosis / Shigella InfectionsPreclinicalOngoing
  • VAX-XLVAX-XL / Streptococcus pneumoniae / Pneumococcal Conjugate Vaccine (PCV) / Infectious Diseases
    Invasive Pneumococcal Disease (IPD)PreclinicalOngoing

PepGen Inc.

pepgen.com
5assets

Precigen, Inc.

precigen.com
5assets

ProMIS Neurosciences Inc. -

promisneurosciences.com
5assets
  • PMN310PMN310 / Amyloid-Beta / Monoclonal Antibody / Neurology
    Alzheimer's Disease
  • PMN267PMN267 / TDP-43 / Monoclonal Antibody / Neurology
    Amyotrophic Lateral Sclerosis (ALS)Frontotemporal Dementia (FTD)Limbic-predominant age-related TDP-43 encephalopathy (LATE)
  • PMN442PMN442 / Alpha-Synuclein / Monoclonal Antibody / Neurology
    Parkinson's Disease (PD)Multiple System Atrophy (MSA)Dementia with Lewy Bodies (DLB)
  • PMN311PMN311 / Amyloid-Beta / Vaccine / Neurology
    Alzheimer's Disease
  • PMN440PMN440 / Alpha-Synuclein / Vaccine / Neurology
    Parkinson's Disease

PureTech Health PLC

puretechhealth.com
5assets
  • deupirfenidoneLYT-100 / Small Molecule / Respiratory / Fibrotic Diseases
    Idiopathic Pulmonary Fibrosis (IPF)Phase 3ActiveGlobal
  • LYT-200LYT-200 / Biologic / Oncology
    Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)Phase 1ActiveGlobalSolid TumorsPhase 1ActiveGlobal
  • GlyphAlloSPT-300 / Allopregnanolone / Small Molecule / Neuropsychiatry
    Anxiety and Mood DisordersPhase 2ActiveGlobal
  • GlyphAgoSPT-320 / Small Molecule / Neuropsychiatry
    Neurological / Neuropsychiatric IndicationsPhase 1ActiveGlobal
  • xanomeline and trospium chlorideKarXT / Cobenfy / Muscarinic Receptors / Small Molecule / Neuropsychiatry
    SchizophreniaApprovedActiveUS

Protagonist Therapeutics, Inc.

protagonist-inc.com
5assets

uniQure N.V.

uniqure.com
5assets
  • AMT-130AMT-130 / Huntingtin protein (mHTT) / Gene Therapy (AAV5) / Central Nervous System
    Huntington's DiseasePhase 1/2ActiveGlobal
  • AMT-191AMT-191 / Alpha-galactosidase A (GLA) / Gene Therapy / Rare Diseases
    Fabry DiseasePhase 1/2aActiveGlobal
  • AMT-260AMT-260 / Undisclosed / Gene Therapy / Central Nervous System
    Refractory Mesial Temporal Lobe EpilepsyPhase 1/2aActiveGlobal
  • AMT-162AMT-162 / SOD1 / Gene Therapy / Central Nervous System
    Amyotrophic Lateral Sclerosis (ALS)Preclinical/ClinicalActiveGlobal
  • etranacogene dezaparvovecAMT-061 / HEMGENIX / Factor IX / Gene Therapy (AAV5) / Hematology
    Hemophilia BApprovedMarketedUSGlobal

Roivant Sciences Ltd. -

roivant.com
5assets
  • BrepocitinibJAK1 / TYK2 / Small Molecule / Autoimmune & Inflammatory
    DermatomyositisPhase 3ActiveGlobalNon-infectious UveitisPhase 3ActiveGlobalCutaneous SarcoidosisPhase 2ActiveGlobal
  • IMVT-1402IMVT-1402 / FcRn / Monoclonal Antibody / Autoimmune
    Rheumatoid Arthritis (difficult-to-treat)Phase 2ActiveGlobalGraves' DiseasePhase 2/3ActiveGlobal
  • BatoclimabFcRn / Monoclonal Antibody / Autoimmune
    Thyroid Eye Disease (TED)Phase 3ActiveGlobalMyasthenia Gravis (MG)Phase 3ActiveGlobalChronic Inflammatory Demyelinating Polyneuropathy (CIDP)Phase 2bActiveGlobal
  • MosliciguatRVT-304 / sGC / Small Molecule / Pulmonary
    Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)Phase 2ActiveGlobal
  • NamilumabGM-CSF / Monoclonal Antibody / Autoimmune & Inflammatory
    SarcoidosisPhase 2ActiveGlobal

Shuttle Pharmaceuticals Holdings, Inc.

shuttlepharma.com
5assets
  • RopidoxuridineIPdR / Radiation Sensitizer / Small Molecule / Oncology
    GlioblastomaPhase 2ActiveUnited StatesSarcomasPhase 1/Phase 2ActiveUnited States
  • SP-2-225SP-2-225 / HDAC6 / Small Molecule / Oncology
    Breast Cancer / Solid TumorsPreclinicalActiveUnited States
  • SP-1-303SP-1-303 / Class I HDAC / Small Molecule / Oncology
    ER+ Breast CancerPreclinicalActiveUnited States
  • SP-1-161SP-1-161 / HDAC / Small Molecule / Oncology
    Solid TumorsDiscoveryActiveUnited States
  • PSMA-B ligandPSMA-B / PSMA / Radiopharmaceutical / Oncology
    Metastatic Prostate CancerPreclinicalActiveUnited States

Seaport Therapeutics, Inc.

seaporttx.com
5assets

Scholar Rock Holding Corporation

scholarrock.com
5assets

Viridian Therapeutics, Inc.

viridiantherapeutics.com
5assets

Viatris Inc.

viatris.com
5assets
  • MR-146MR-146 / AAV Gene Therapy / Ophthalmology
    Neurotrophic keratopathy (NK)
  • Low Dose Estrogen Weekly PatchEstrogen / Progestin receptors / Transdermal Patch / Women's Health
    Contraception
  • PitolisantHistamine H3 receptor / Small molecule / Neurology
    Obstructive Sleep Apnea Syndrome
  • SelatogrelP2Y12 receptor / Small molecule / Cardiovascular
    Acute Myocardial Infarction
  • CenerimodS1P1 receptor / Small molecule / Immunology
    Systemic lupus erythematosus (SLE)

Wave Life Sciences Ltd.

wavelifesciences.com
5assets
  • WVE-006WVE-006 / AAT transcript (Pi*ZZ mutation) / RNA editing oligonucleotide (AIMer) / Genetic/Respiratory/Liver Diseases
    Alpha-1 antitrypsin deficiency (AATD)
  • WVE-007WVE-007 / INHBE mRNA / siRNA / Metabolic Diseases
    Obesity
  • WVE-008WVE-008 / PNPLA3 I148M / RNA editing oligonucleotide / Liver Diseases
    PNPLA3-related liver disease
  • WVE-N531WVE-N531 / DMD Exon 53 / Exon skipping oligonucleotide / Neuromuscular Diseases
    Duchenne muscular dystrophy (DMD)
  • WVE-003WVE-003 / Mutant huntingtin (mHTT) mRNA / Allele-selective silencing oligonucleotide / Neurological Diseases
    Huntington's disease (HD)

AbCellera

abcellera.com
4assets
  • ABCL635ABCL635 / NK3R / antibody medicine / Endocrinology / Women's Health
    Vasomotor Symptoms (VMS) associated with menopausePhase 2active
  • ABCL575ABCL575 / OX40L / monoclonal antibody / Immunology & Inflammation
    Atopic Dermatitis (AD)Phase 1active
  • ABCL688ABCL688 / Undisclosed GPCR / Ion Channel / antibody medicine / Autoimmunity
    Undisclosed autoimmunity indicationIND-Enablingactive
  • ABCL386ABCL386 / Undisclosed / antibody medicine / Oncology
    Undisclosed oncology indicationIND-Enablingactive

Abeona Therapeutics Inc.

abeonatherapeutics.com
4assets
  • prademagene zamikeracelpz-cel / ZEVASKYN / COL7A1 / autologous cell-based gene therapy / Dermatology / rare disease
    recessive dystrophic epidermolysis bullosa (RDEB)Approvedapproved
  • PSMA SIR-TABO-701 / PSMA / engineered autologous T-cell therapy / Oncology
    Advanced prostate cancerPreclinicalpreclinical
  • UX111UX111 / SGSH / in vivo AAV9 gene therapy / Rare disease / CNS
    Sanfilippo Syndrome Type A (MPS IIIA)Phase 3clinical
  • TSHA-102TSHA-102 / MECP2 / intrathecal AAV9 gene transfer therapy / Rare disease / CNS
    Rett SyndromePhase 1/2clinical

Agios Pharmaceuticals, Inc.

agios.com
4assets
  • MitapivatPYRUKYND®; AQVESME™ / PK / PK activator / Rare diseases; hematology
    Adult PK deficiencyApprovedAdult thalassemiaApprovedU.S.KSAUAEAdult sickle cell diseaseRegulatory submissionU.S.
  • TebapivatPK / PK activator / Rare diseases; hematology
    Lower-risk myelodysplastic syndromesClinical developmentSickle cell diseaseClinical development
  • AG-181AG-181 / PAH / PAH stabilizer / Rare diseases; metabolic disorders
    PhenylketonuriaClinical development
  • AG-236AG-236 / TMPRSS6 / siRNA / Rare diseases; hematology
    Polycythemia veraClinical development

Akebia Therapeutics, Inc.

ir.akebia.com
4assets
  • PraliciguatsGC / soluble guanylate cyclase stimulator / Kidney disease
    Focal segmental glomerulosclerosisPhase 2first patient enrolled Dec 2025
  • Ebribafusp alfaAKB-097 / C3d/factor H / anti-C3d-factor H fusion protein; complement inhibitor / Rare kidney diseases
    IgA nephropathyPhase 2 plannedbasket trial planned 2H 2026Lupus nephritisPhase 2 plannedbasket trial planned 2H 2026C3 glomerulopathyPhase 2 plannedbasket trial planned 2H 2026
  • AKB-9090AKB-9090 / HIF-PH / HIF-PH inhibitor / Kidney disease; acute care
    Cardiac surgery-associated acute kidney injuryPhase 1first participants dosed Apr 2026Acute respiratory distress syndromePreclinical
  • AKB-10108AKB-10108 / HIF-PH / HIF-PH inhibitor / Other disease areas
    Retinopathy of prematurityPreclinical

Alumis Inc.

alumis.com
4assets
  • EnvudeucitinibESK-001 / TYK2 / oral small molecule TYK2 inhibitor / Immunology
    Plaque psoriasisPhase 3ONWARD3 LTE ongoing; NDA planned 2H 2026GlobalJapanSystemic lupus erythematosusPhase 2LUMUS ongoing; topline data expected 2026Global
  • A-005A-005 / TYK2 / CNS-penetrant allosteric TYK2 inhibitor / Neuroinflammation
    Multiple sclerosisPhase 1 completed; Phase 2 plannedPhase 2 initiation planned H1 2026
  • LonigutamabIGF-1R / subcutaneous humanized IgG1 monoclonal antibody / Endocrinology/Immunology
    Thyroid eye diseaseDevelopment program evaluation ongoing
  • IRF5/Additional TargetsIRF5, additional targets
    Undisclosed

Amylyx Pharmaceuticals, Inc.

amylyx.com
4assets
  • AvexitideGLP-1 receptor / GLP-1 receptor antagonist / Endocrine/metabolic diseases
    Post-bariatric hypoglycemia (PBH)Phase 3LUCIDITY completed enrollment; topline data expected Q3 2026USCongenital hyperinsulinism (HI)Clinical development next steps under discussionUS
  • AMX0035AMX0035 / ER stress and mitochondrial dysfunction / Oral fixed-dose combination of sodium phenylbutyrate and taurursodiol / Neurodegenerative/rare diseases
    Wolfram syndromePhase 2HELIOS positive Week 48 data; pivotal Phase 3 planned pending FDA alignmentUSEU
  • AMX0114AMX0114 / Calpain-2 (CAPN2) / Antisense oligonucleotide (ASO) / Neurodegenerative diseases
    Amyotrophic lateral sclerosis (ALS)Phase 1LUMINA Cohort 2 fully enrolled; biomarker data expected H1 2026US
  • AMX0318AMX0318 / GLP-1 receptor / Long-acting GLP-1 receptor antagonist / Endocrine/metabolic diseases
    PBH and other rare diseasesIND-enablingIND-enabling studies underway; IND targeted for 2027

Apogee Therapeutics, Inc.

apogeetherapeutics.com
4assets
  • ZumilokibartAPG777 / IL-13 / subcutaneous half-life extended monoclonal antibody / immunology and inflammation
    Atopic dermatitisPhase 2in-progress; Part B enrollment completedAsthmaPhase 1complete; positive Phase 1b dataEosinophilic esophagitisPhase 1in-progress
  • APG279APG279 / IL-13 + OX40L / coformulation of zumilokibart (APG777) + APG990 monoclonal antibodies / immunology and inflammation
    Atopic dermatitisPhase 1in-progress; Phase 1b PoC fully enrolled
  • APG273APG273 / IL-13 + TSLP / combination of zumilokibart (APG777) + APG333 monoclonal antibodies / respiratory immunology and inflammation
    Asthma / COPDPreclinicalin-progress
  • APG808APG808 / IL-4Rα / antibody / respiratory immunology and inflammation
    AsthmaPhase 1bpositive interim results announced May 2025

AtaiBeckley Inc.

ataibeckley.com
4assets
  • BPL-003BPL-003 / Intranasal mebufotenin benzoate / Mental health
    Treatment-resistant depressionPhase 2In development
  • VLS-01VLS-01 / 5-HT1/2/6/7 receptor agonist / Oral transmucosal DMT buccal film / Mental health
    Treatment-resistant depressionPhase 2In development
  • EMP-01EMP-01 / Oral R-MDMA / Mental health
    Social anxiety disorderPhase 2Positive topline results announced
  • Novel 5-HT2A Receptor Agonists5-HT2A receptor / Small-molecule neuroplastogens / Mental health
    Opioid use disorderDiscoveryIn developmentTreatment-resistant depressionDiscoveryIn development

Capricor Therapeutics, Inc.

capricor.com
4assets
  • DeramiocelCAP-1002 / allogeneic CDCs / Neuromuscular disease
    Duchenne muscular dystrophy (DMD)Phase 3in progressBecker muscular dystrophy (BMD)Preclinicalin progress
  • StealthX™STX-S / Exosome-based vaccine / Infectious disease
    SARS-CoV-2Phase 1in progress
  • StealthX™Therapeutic Exosomes
    EvaluatingPreclinicalin progress
  • CDC-ExosomesExosome Platform / Neuromuscular disease
    Duchenne muscular dystrophyPreclinicalin progress

Cullinan Therapeutics, Inc.

cullinantherapeutics.com
4assets
  • CLN-978CLN-978 / CD19xCD3 / bispecific T cell engager / Immunology
    OUTRACE: Rheumatoid arthritisPhase 1Initial data in RA in Q2 2026 and repeat dosing data in Q3 2026EuropeOUTRACE: Systemic lupus erythematosusPhase 1bInitial data in SLE in Q2 2026GlobalOUTRACE: Sjögren’s diseasePhase 1Initial data in Sjögren’s disease in Q4 2026Global
  • VelinotamigBCMAxCD3 / bispecific T cell engager / Immunology
    Autoimmune diseasesIND-EnablingGenrix Bio initiated a Phase 1 study in China in Q4 2025; initial data expected in Q4 2026; clinical trial status not yet recruitingChina
  • ZipalertinibEGFR ex20ins / tyrosine kinase inhibitor (TKI) / Oncology
    REZILIENT1: Non-small cell lung cancerPhase 2U.S. FDA accepted NDA for relapsed EGFR ex20ins NSCLC; PDUFA target action date February 27, 2027United StatesREZILIENT2: Non-small cell lung cancerPhase 2Parallel cohort study ongoingREZILIENT3: Non-small cell lung cancerPhase 3Phase 3 1L study fully enrolled; Taiho expects topline results by end of 2026Global
  • CLN-049CLN-049 / FLT3xCD3 / bispecific T cell engager / Oncology
    Acute myeloid leukemia and myelodysplastic syndromePhase 1Dose escalation update in H2 2026; dose expansion cohorts to initiate in Q2 2026 and complete enrollment in Q4 2026Measurable residual disease in acute myeloid leukemiaPhase 1Phase 1 study ongoing

Compugen Ltd.

cgen.com
4assets
  • COM701COM701 / PVRIG / Fc-reduced anti-PVRIG antibody / Oncology
    Relapsed platinum-sensitive ovarian cancer; maintenance therapyAdaptive platform trialongoing
  • COM701 + COM902 + pembrolizumabPVRIG; TIGIT; PD-1 / Antibody combination / Oncology
    Platinum-resistant ovarian cancerProof of concept
  • rilvegostomigPD-1/TIGIT / Fc-reduced anti-PD-1/TIGIT bispecific antibody / Oncology
    NSCLCPhase 3; Phase 1/2ongoingGastrointestinal cancerPhase 3; Phase 1/2ongoingEndometrial cancerPhase 3ongoing
  • GS-0321GS-0321 / IL18BP / Anti-IL18BP antibody / Oncology
    Solid tumorsPhase 1ongoing

Clene Inc.

clene.com
4assets
  • CNM-Au8®CNM-Au8 / mitochondrial function / NAD pathway; neuroprotection and remyelination / oral gold nanocrystal suspension / Neurology
    Amyotrophic Lateral Sclerosis (ALS)Global Phase 3 plannedPlanned; EAPs ongoing; regulatory agency engagement ongoingUSEUGlobalMultiple Sclerosis (MS)Phase 3 plannedPlanned; EAP ongoing; Repair-MS target engagement and safety confirmedUSGlobalParkinson’s Disease (PD)In development; REPAIR-PD trial listed
  • CNM-ZnAgCNM-ZnAg / zinc-silver ionic solution / Infectious disease
    Antiviral and antimicrobial usesDemonstrated antiviral and antimicrobial properties
  • CNM-AgZn17CNM-AgZn17 / topical gel polymer suspension of silver and zinc ions / Infectious disease / wound healing
    Infectious diseasesIn developmentWound healingIn development
  • CNM-PtAu7CNM-PtAu7 / gold-platinum nanotherapeutic / Oncology
    CancerIn vitroInitial research

Compass Therapeutics, Inc.

compasstherapeutics.com
4assets
  • tovecimigCTX-009 / DLL4 x VEGF-A / bispecific antibody / Oncology
    Biliary tract cancer (2L)Phase 2/3Met primary endpoint; PFS/OS expected late Q1 2026Colorectal cancer (monotherapy 3L/4L)Phase 2CompletedDLL4+ tumors basket studyAdditional indications planned H1 2026
  • CTX-471CTX-471 / CD137 / agonistic antibody / Oncology
    NCAM (CD56) basket studyTrial initiation expected Q1 2026Post-checkpoint basket studyCompleted
  • CTX-8371CTX-8371 / PD-1 x PD-L1 / bispecific antibody / Oncology
    Solid tumorsPhase 1Expansion cohorts initiated; Phase 1 data expected H1 2026
  • CTX-10726CTX-10726 / PD-1 x VEGF-A / bispecific antibody / Oncology
    Solid tumorsIND-enabling preclinicalPhase 1 initiation expected Q1 2026

Contineum Therapeutics, Inc.

contineum-tx.com
4assets
  • PIPE-791LPA1R / small molecule LPA1R antagonist / inflammation; immunology; neuroscience
    Idiopathic pulmonary fibrosisPhase 2activeProgressive MSPhase 1deferredChronic painPhase 1bactive
  • CTX-343LPA1R / peripherally restricted small molecule LPA1R antagonist / peripheral indications
    PeripheralPreclinicaldeferred
  • PIPE-307JNJ-5120 / M1R / small molecule M1R antagonist / neuroscience
    Relapsing-remitting MSPhase 2licensedMajor depressive disorderPhase 2licensed
  • CalpainCalpain / calpain inhibitor
    UndisclosedPreclinicalactive

Cytokinetics, Incorporated

cytokinetics.com
4assets
  • AficamtenMYQORZO / cardiac myosin inhibitor / small molecule / Cardiovascular
    oHCMApproved & CommercializedApproved in U.S., China, & EUU.S.ChinaEUoHCM (vs. metoprolol)Phase 3MAPLE-HCMPediatric oHCMPhase 2CEDAR-HCM
  • Ulacamtencardiac myosin inhibitor / small molecule / Cardiovascular
    HFpEFPhase 2AMBER-HFpEF
  • Omecamtiv Mecarbilcardiac myosin activator / small molecule / Cardiovascular
    HFrEFPhase 3COMET-HF
  • CK-089CK-089 / fast skeletal muscle troponin activator / small molecule / Neuromuscular
    Muscular Dystrophy, OtherPhase 1

Bright Minds Biosciences Inc.

brightmindsbio.com
4assets

Design Therapeutics, Inc.

designtx.com
4assets
  • DT-216P2DT-216P2 / FXN GAA repeat expansion / frataxin expression / GeneTAC small molecule / Genetic disease / neurology
    Friedreich ataxiaPhase 1/2RESTORE-FA multiple-dose trial opened/ongoing; evaluates IV and subcutaneous administrationex-U.S.
  • DT-168DT-168 / TCF4 CTG repeat expansion / GeneTAC small molecule eye drop / Ophthalmology / genetic disease
    Fuchs endothelial corneal dystrophyPhase 2Biomarker trial opened/ongoing in FECD patients scheduled for corneal transplant surgery
  • DT-818DT-818 / DMPK CTG repeat expansion / GeneTAC small molecule / Neuromuscular / genetic disease
    Myotonic dystrophy type 1Phase 1 plannedPatient dosing in Phase 1 MAD trial anticipated in H1 2026Australia
  • Huntington's disease GeneTAC programHTT CAG repeat expansion / mutant huntingtin expression / GeneTAC small molecule / Neurology / genetic disease
    Huntington's diseasePreclinicalProgram disclosed; candidate not named

Dogwood Therapeutics, Inc.

dwtx.com
4assets
  • Halneuron® NaV1.7 InjectionHAL / Halneuron® / NaV1.7 / subcutaneous small-molecule/peptide analgesic injection / Pain / neuropathy
    Chemotherapy-induced neuropathic pain (CINP)Phase 2bOngoing; FDA Fast Track designationU.S.General cancer painPhase 2aCompleteAcute surgical painPreclinical
  • SP16 Intravenous AdministrationSP16 IV / LRP1 agonist / IV peptide therapeutic / Neuropathy / cancer-related pain
    Chemotherapy-induced peripheral neuropathy (CIPN)Phase 1bNCI funded / forthcoming
  • IMC-1IMC-1 / Herpesvirus suppression / COX-2 inhibition / Fixed-dose combination of anti-herpesvirus medication and COX-2 inhibitor / Pain / fatigue illness
    FibromyalgiaPhase 2aPreviously demonstrated efficacy; disclosed as a novel therapeutic under antiviral combinations
  • IMC-2IMC-2 / Herpesvirus suppression / COX-2 inhibition / Fixed-dose combination of anti-herpesvirus medication and COX-2 inhibitor / Pain / fatigue illness
    Long COVIDOpen-label investigator-initiated study completed/reported; disclosed as a novel therapeutic under antiviral combinations

Edgewise Therapeutics, Inc.

edgewisetx.com
4assets
  • SevasemtenMyosin ATPase / Oral fast skeletal myosin inhibitor / Muscular dystrophy
    Becker muscular dystrophyPivotal / Phase 3Duchenne muscular dystrophyPhase 2
  • EDG-7500EDG-7500 / Undisclosed cardiac sarcomeric target / Oral selective cardiac sarcomere modulator / Cardiovascular
    Hypertrophic cardiomyopathyPhase 2
  • EDG-15400EDG-15400 / Undisclosed cardiac sarcomeric target / Oral selective cardiac sarcomere modulator / Cardiovascular
    HFpEFPhase 1
  • EDG-003EDG-003 / Undisclosed target / Cardiometabolic
    CardiometabolicPreclinical

4D Molecular Therapeutics, Inc.

4dmoleculartherapeutics.com
4assets
  • 4D-1504D-150 / VEGF family members / Intravitreal AAV genetic medicine / Retina
    Wet AMDPivotal / Phase 34FRONT-1 and 4FRONT-2 Phase 3; PRISM Phase 1/2 ongoingDiabetic macular edemaPivotal readySPECTRA clinical trial Part 1
  • 4D-7104D-710 / CFTR / Aerosol-delivered AAV genetic medicine / Pulmonology
    Cystic fibrosis lung disease; not modulator-amenable / ineligible or discontinued CFTR modulator therapyPhase 2AEROW Phase 1/2 study; pipeline lists Phase 2
  • 4D-1754D-175 / Complement factor H / complement pathway / Intravitreal AAV genetic medicine / Retina
    Geographic atrophySeeking partnerships to advance
  • 4D-7254D-725 / Aerosol-delivered AAV genetic medicine / Pulmonology
    Alpha-1 antitrypsin lung diseasePreclinicalSeeking partnerships to advance

Lakefront Biotherapeutics N.V.

glpg.com
4assets

Monte Rosa Therapeutics, Inc.

monterosatx.com
4assets
  • MRT-6160MRT-6160 / VAV1 / Oral molecular glue degrader / Immunology & Inflammation
    Immune-mediated diseasesClinical
  • MRT-8102MRT-8102 / NEK7 / Oral molecular glue degrader / Immunology & Inflammation
    IL-1β/NLRP3-driven inflammatory diseasesPhase 1
  • MRT-2359MRT-2359 / GSPT1 / Oral molecular glue degrader / Oncology
    Castration-resistant prostate cancerPhase 1/2Ongoing
  • Cyclin E1 degrader programCCNE1 / CDK2 / Molecular glue degrader / Oncology
    CCNE1-amplified tumorsPreclinicalLead optimizationER+ breast cancerPreclinicalLead optimization

Hcw Biologics Inc.

hcwbiologics.com
4assets
  • HCW9302HCW9302 / IL-2Rα / IL-2 fusion protein / Autoimmune
    Alopecia areataPhase 1OngoingUS
  • HCW11-006HCW11-006 / Multiple cytokines (IL-15/IL-15Rα, IL-7, IL-21, IL-2) / Multi-functional fusion immunotherapeutic / Oncology
    CancerPhase 1Planned by licenseeChina
  • HCW11-018bHCW11-018b / Tissue Factor/CD3 / Tetra-valent bispecific T-cell engager (Big BiTE) / Oncology
    Solid tumorsPreclinicalIND-enablingGlobal
  • HCW11-040HCW11-040 / PD-1 (pembrolizumab-based) + TGF-β / Tetra-valent immune checkpoint inhibitor fusion / Oncology
    Solid tumorsPreclinicalIND-enablingGlobal

ImmunityBio, Inc.

immunitybio.com
4assets
  • nogapendekin alfa inbakiceptN-803 / ANKTIVA® / IL-15 receptor / Cytokine fusion protein / Interleukin-15 superagonist / Oncology, Infectious Diseases
    BCG Unresponsive NMIBC Carcinoma In-Situ & Papillary (QUILT-3.032)ApprovedMarketedUSBCG Naïve NMIBC (QUILT-2.005)Phase 2/Phase 3ActiveUSNon-Small Cell Lung Cancer (ResQ201A)Phase 3ActiveGlobal
  • PD-L1 t-haNKPD-L1 / Cell Therapy / Engineered NK cells / Oncology
    Advanced Solid TumorsPhase 2ActiveUS
  • AldoxAlbumin-bound doxorubicin complex / Oncology
    Advanced Solid TumorsPhase 2ActiveUS
  • Recombinant BCGVaccine / Immunotherapy / Oncology
    Bladder CancerExpanded AccessActiveUS

Immatics N.V.

immatics.com
4assets
  • anzu-cel (IMA203)IMA203 / anzutresgene autoleucel / PRAME / Autologous TCR-T cell therapy / Solid Tumors
    2L+ cutaneous melanomaPhase 3ongoingUSEU5Uveal melanomaPhase 1bongoingUSEU5PRAME+ solid tumorsPhase 1ongoingUSEU5
  • IMA203CD8 (GEN2)IMA203CD8 / PRAME / Autologous TCR-T cell therapy (next-gen with CD8) / Solid Tumors
    PRAME+ advanced solid tumorsPhase 1dose escalation ongoingUSEU5Ovarian and endometrial cancersPhase 1ongoingUSEU5
  • IMA402IMA402 / PRAME / Half-life extended TCR bispecific (TCER) / Solid Tumors
    Recurrent/refractory solid tumors (melanoma, gynecologic, sqNSCLC)Phase 1/2Phase 1b expansion ongoingUSEU
  • IMA401IMA401 / MAGEA4/8 / TCR bispecific (TCER) / Solid Tumors
    Recurrent/refractory solid tumors (HNSCC, sqNSCLC, melanoma)Phase 1dose escalation completedUSEU

In8bio, Inc.

in8bio.com
4assets
  • INB-100INB-100 / DeltEx Allo allogeneic γδ T cell therapy / Oncology
    Acute leukemia post-HSCTPhase 1Expansion cohort enrollingUS
  • INB-200INB-200 / DeltEx DRI autologous genetically modified γδ T cell therapy / Oncology
    Newly diagnosed glioblastomaPhase 1Treatment completed; long-term follow-upUS
  • INB-400INB-400 / DeltEx DRI autologous and allogeneic γδ T cell therapy / Oncology
    Newly diagnosed glioblastomaPhase 2Enrollment suspended; treatment completed; data collection ongoingUS
  • INB-619INB-619 / CD19 / γδ T cell engager (TCE) / Oncology and autoimmune diseases
    CD19+ B-cell malignanciesPreclinicalIND-enabling studiesB-cell mediated autoimmune diseasesPreclinicalIND-enabling studies

MiNK Therapeutics, Inc.

investor.minktherapeutics.com
4assets
  • agenT-797agenT-797 / Allogeneic native iNKT cell therapy / Oncology and Immunology
    Critical pulmonary immune failure (severe hypoxemic respiratory failure/pneumonia/ARDS)Phase 2randomized adaptive placebo-controlled ongoingUSSolid tumor cancers (checkpoint-refractory, incl. gastric/esophageal/GEJ adenocarcinoma)Phase 2investigator-sponsored ongoing (NCT06251973)USGraft-versus-host disease (GvHD prevention)expanding development
  • MiNK-215MiNK-215 / FAP / IL-15 armored FAP-CAR-iNKT cell therapy / Oncology
    Solid tumors (NSCLC, CRC liver metastases)PreclinicalIND-enabling studies underway
  • MiNK-413MiNK-413 / BCMA / IL-15 armored BCMA-CAR-iNKT cell therapy / Oncology
    Multiple myelomaPreclinical
  • PRAME TCR-iNKTPRAME / TCR-engineered iNKT cell therapy / Oncology
    Pediatric cancers/solid tumorsPreclinicalIND-enabling

Disc Medicine, Inc.

discmedicine.com
4assets
  • bitopertinGlyT1 / Small Molecule / Hematology
    Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)Phase 3OngoingGlobalDiamond-Blackfan AnemiaPhase 2OngoingUS
  • DISC-0974DISC-0974 / Hemojuvelin (HJV) / Monoclonal Antibody / Hematology
    Anemia of Myelofibrosis (MF)Phase 2OngoingGlobalAnemia of Chronic Kidney Disease (CKD)Phase 1/Phase 2OngoingGlobalAnemia of Inflammatory Bowel Disease (IBD)Phase 2PlannedGlobal
  • DISC-3405DISC-3405 / TMPRSS6 (Matriptase-2) / Monoclonal Antibody / Hematology
    Polycythemia Vera (PV)Phase 2OngoingGlobalSickle Cell Disease (SCD)Phase 1bOngoingGlobal
  • DISC-0998DISC-0998 / Hemojuvelin (HJV) / Monoclonal Antibody / Hematology
    Inflammatory-disease-associated anemiaPreclinicalOngoingGlobal

Kailera Therapeutics, Inc.

kailera.com
4assets

Karyopharm Therapeutics Inc.

karyopharmmedicalaffairs.com
4assets
  • SelinexorKPT-330 / XPOVIO / XPO1 (Exportin 1) / Small Molecule / Oncology
    Multiple MyelomaMarketedActiveUSGlobalEndometrial CancerPhase 3ActiveUSGlobalMyelofibrosisPhase 3ActiveUSGlobal
  • EltanexorKPT-8602 / XPO1 (Exportin 1) / Small Molecule / Oncology
    Myelodysplastic NeoplasmsPhase 2PausedUSColorectal CancerPhase 2PausedUSProstate CancerPhase 2PausedUS
  • KPT-9274KPT-9274 / PAK4 / NAMPT / Small Molecule / Oncology
    Solid Tumors & LymphomaPhase 1PausedUS
  • VerdinexorKPT-335 / XPO1 (Exportin 1) / Small Molecule / Veterinary Oncology / Infectious Diseases
    Canine LymphomaMarketedActiveUS

TuHURA Biosciences, Inc.

tuhurabio.com
4assets
  • IFx-2.0IFx-Hu2.0 / Innate Immune System / Personalized Cancer Vaccine / Innate Immune Agonist / Oncology
    Advanced or Metastatic Merkel Cell Carcinoma (1st line, adjunctive to pembrolizumab)Phase 3OngoingUnited StatesMerkel Cell Carcinoma of Unknown Primary (MCCUP)Phase 1/Phase 2OngoingUnited States
  • TBS-2025KVA12123 / VISTA / Monoclonal Antibody / Oncology
    Advanced Solid Tumor CancerPhase 1OngoingUnited StatesmutNPM1 Acute Myeloid Leukemia (AML)Phase 1/Phase 2PlannedUnited States
  • Bi-functional ADCsMyeloid-derived suppressor cells (MDSCs) / Antibody-Drug Conjugate (ADC) / Oncology
    Solid TumorsPreclinicalOngoingUnited States
  • REM-001Unknown / Photodynamic Therapy / Oncology
    Cutaneous Metastatic Breast Cancer (CMBC)Phase 3OngoingUnited States

Pasithea Therapeutics Corp.

pasithea.com
4assets
  • PAS-004PAS-004 / MEK 1/2 / Macrocyclic Small Molecule / Oncology / Rare Diseases
    Neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN)MAPK pathway-driven advanced solid tumors
  • PAS-003PAS-003 / α5β1 Integrin / Monoclonal Antibody / Neurology
    Amyotrophic Lateral Sclerosis (ALS)
  • PAS-001PAS-001 / C4A / Small Molecule / Psychiatry
    Schizophrenia
  • PAS-002PAS-002 / Neurology
    Multiple Sclerosis (MS)

Kura Oncology, Inc.

kuraoncology.com
4assets
  • ZiftomenibKO-539 / KOMZIFTI / Menin-KMT2A/MLL interaction / Small molecule / Hematologic Malignancies
    R/R NPM1-mutated AMLNewly Diagnosed AMLFLT3-mutated AML
  • DarlifarnibKO-2806 / Farnesyl transferase / Small molecule / Oncology
    Clear cell renal cell carcinoma (ccRCC)Solid tumors
  • TipifarnibFarnesyl transferase / Small molecule / Oncology
    HRAS-mutant Head and Neck Squamous Cell Carcinoma (HNSCC)PIK3CA-dependent HNSCC
  • KO-7246KO-7246 / Menin / Small molecule / Cardiometabolic
    DiabetesCardiometabolic disease

Madrigal Pharmaceuticals, Inc.

madrigalpharma.com
4assets

MediciNova, Inc.

medicinova.com
4assets

Satellos Bioscience Inc.

satellos.com
4assets
  • SAT-3247SAT-3247 / AAK1 / Small molecule / Degenerative muscle diseases
    Duchenne Muscular Dystrophy (DMD)Facioscapulohumeral Muscular Dystrophy (FSHD)
  • SAT-3153SAT-3153 / Notch polarity kinase / Small molecule / Degenerative muscle diseases
    Duchenne Muscular Dystrophy (DMD)
  • BertilimumabiCo-008 / Eotaxin-1 (CCL11) / Monoclonal antibody / Immunology
    Bullous Pemphigoid
  • iCo-019iCo-019 / Fungal cell membrane / Small molecule (Oral Amphotericin B) / Infectious Diseases
    Fungal infections

NovaBridge Biosciences

novabridge.com
4assets
  • GivastomigCLDN18.2 x 4-1BB / Bispecific Antibody / Oncology
    Gastric CancerGastrointestinal Malignancies
  • RagistomigPD-L1 x 4-1BB / Bispecific Antibody / Oncology
    Solid Tumors
  • UliledlimabCD73 / Monoclonal Antibody / Oncology
    Cancer
  • VIS-101VEGF-A x ANG-2 / Bispecific Antibody / Ophthalmology
    Wet Age-Related Macular Degeneration (AMD)Diabetic Macular Edema (DME)

Neonc Technologies Holdings, Inc.

neonc.com
4assets
  • NEO100NEO-100 / Unknown / Small Molecule / Oncology, Neurology
    Malignant GliomasGrade 4 AstrocytomaParkinson's Disease
  • NEO212NEO-212 / DNA / Small Molecule Conjugate / Oncology
    Malignant Gliomas
  • NEO214NEO-214 / DR5, PDE4 / Small Molecule Conjugate / Oncology
    Glioblastoma (GBM)Multiple Myeloma
  • NEO400NEO-400 / Unknown / Small Molecule Conjugate / Dermatology, Oncology
    UV-Induced Skin DamageTopical Oncology

Nuvation Bio Inc.

nuvationbio.com
4assets
  • TaletrectinibIBTROZI / ROS1 / Small Molecule / Oncology
    Advanced ROS1+ NSCLC
  • SafusidenibmIDH1 / Small Molecule / Oncology
    Diffuse IDH1-mutant gliomaAstrocytomaOligodendroglioma
  • NUV-1511NUV-1511 / Undisclosed / Drug-Drug Conjugate (DDC) / Oncology
    Advanced solid tumors
  • NUV-868NUV-868 / BET (BD2-selective) / Small Molecule / Oncology
    Advanced solid tumors

Omeros Corporation

omeros.com
4assets
  • NarsoplimabOMS721 / Yartemlea / MASP-2 / Monoclonal antibody / Hematology / Complement-Mediated Diseases
    Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
  • ZaltenibartOMS906 / MASP-3 / Monoclonal antibody / Hematology / Nephrology
    Paroxysmal nocturnal hemoglobinuria (PNH)C3 glomerulopathy
  • OMS1029OMS1029 / MASP-2 / Biologic / Complement-Mediated Diseases
  • OMS527OMS527 / PDE7 / Small molecule / Addiction
    Cocaine use disorder

Pharming Group N.V.

pharming.com
4assets

Praxis Precision Medicines, Inc.

praxismedicines.com
4assets
  • UlixacaltamidePRAX-944 / T-type calcium channel / Small molecule / Neurology
    Essential Tremor
  • RelutriginePRAX-562 / Persistent sodium current (NaV) / Small molecule / Neurology
    Developmental and Epileptic Encephalopathies (DEEs)SCN2A-DEESCN8A-DEE
  • VormatriginePRAX-628 / Sodium channels (NaV) / Small molecule / Neurology
    Focal Onset EpilepsyEpilepsy
  • ElsunersenSCN2A mRNA / Antisense oligonucleotide (ASO) / Neurology
    SCN2A Developmental and Epileptic Encephalopathy

Palvella Therapeutics, Inc.

palvellatx.com
4assets

REGENXBIO Inc.

regenxbio.com
4assets

Relay Therapeutics, Inc.

relaytx.com
4assets
  • ZovegalisibRLY-2608 / Mutant PI3Kα / Small molecule / Oncology & Genetic Disease
    HR+/HER2- metastatic breast cancer (PI3Kα-mutated)Phase 3ActiveGlobalPIK3CA-driven vascular malformations/anomaliesPhase 1ActiveGlobal
  • LirafugratinibRLY-4008 / FGFR2 / Small molecule / Oncology
    FGFR2-altered solid tumorsClinicalOut-licensedGlobal
  • RLY-8161RLY-8161 / NRAS / Small molecule / Oncology
    NRAS-driven solid tumorsPreclinicalActiveGlobal
  • Fabry disease programUndisclosed / Non-inhibitory chaperone / Genetic Disease
    Fabry diseasePreclinicalActiveGlobal

Rhythm Pharmaceuticals, Inc.

rhythmtx.com
4assets

Scynexis, Inc.

scynexis.com
4assets
  • SCY-770PXL-770 / AMP-activated protein kinase (AMPK) / Small Molecule / Rare Diseases / Nephrology
    Autosomal Dominant Polycystic Kidney Disease (ADPKD)Phase 2ActiveGlobal
  • SCY-247SCY-247 / 1,3-beta-glucan synthase / Small Molecule / Infectious Diseases
    Treatment and Prevention of Invasive Fungal InfectionsPhase 1ActiveUnited States
  • Fungerp analogs1,3-beta-glucan synthase / Small Molecule / Infectious Diseases
    Treatment of resistant fungiPreclinicalActiveGlobal
  • IbrexafungerpSCY-078 / BREXAFEMME / 1,3-beta-glucan synthase / Small Molecule / Infectious Diseases
    Vulvovaginal candidiasis (VVC) and Recurrent VVCApprovedActiveUnited StatesInvasive Candidiasis (IC)Phase 3ActiveGlobal

Septerna, Inc.

septerna.com
4assets
  • SEP-479SEP-479 / PTH1R / Small Molecule / Endocrinology
    HypoparathyroidismPhase 1Active
  • SEP-631SEP-631 / MRGPRX2 / Small Molecule / Immunology and Inflammation
    Chronic spontaneous urticaria (CSU)Phase 1ActiveOther mast cell diseasesPhase 1Active
  • TSHR ProgramTSHR / Small Molecule / Endocrinology
    Graves' diseasePreclinicalActiveThyroid eye diseasePreclinicalActive
  • Novo Nordisk Partnered ProgramsGLP-1R, GIPR, GCGR, Undisclosed / Small Molecule / Metabolic Diseases
    Metabolic diseasesDiscoveryActive

Silo Pharma, Inc.

silopharma.com
4assets
  • SPC-15SPC-15 / 5-HT4 receptor agonist / Small Molecule / Psychiatry
    PTSD and stress-induced anxiety disordersPreclinicalActiveGlobal
  • SP-26SP-26 / NMDA receptor antagonist / Implant / Neurology
    Fibromyalgia and chronic painPreclinicalActiveGlobal
  • SPC-14SPC-14 / Unknown / Small Molecule / Neurology
    Alzheimer's diseasePreclinicalActiveGlobal
  • SPU-16SPU-16 / Unknown / Peptide / Neurology
    Multiple sclerosisPreclinicalActiveGlobal

Sol-Gel Technologies Ltd.

sol-gel.com
4assets
  • patidegibSGT-610 / Hedgehog signaling pathway (SMO) / Small molecule / Dermatology
    Gorlin syndrome (prevention of new BCC lesions)High-frequency basal cell carcinoma (BCC)
  • erlotinibSGT-210 / EGFR / Small molecule / Dermatology
    Undisclosed indications
  • tretinoin and benzoyl peroxide cream, 0.1%/3%TWYNEO / Retinoid receptors / Bacterial proteins / Small molecule / Dermatology
    Acne vulgaris
  • benzoyl peroxide cream, 5%EPSOLAY / Bacterial proteins / Small molecule / Dermatology
    Inflammatory lesions of rosacea

Sutro Biopharma, Inc.

sutrobio.com
4assets

TScan Therapeutics, Inc.

tscan.com
4assets
  • TSC-100TSC-100 / HA-1 / TCR-T Cell Therapy / Hematologic Malignancies
    Acute Myeloid Leukemia (AML) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesAcute Lymphoblastic Leukemia (ALL) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesMyelodysplastic Syndromes (MDS) (Post-HCT Relapse Prevention)Phase 1ActiveUnited States
  • TSC-101TSC-101 / HA-2 / TCR-T Cell Therapy / Hematologic Malignancies
    Acute Myeloid Leukemia (AML) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesAcute Lymphoblastic Leukemia (ALL) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesMyelodysplastic Syndromes (MDS) (Post-HCT Relapse Prevention)Phase 1ActiveUnited States
  • ImmunoBank TCR-T CandidatesT-Plex / Multiple Targets (e.g., PRAME, HPV16, MAGE-A1) / Multiplexed TCR-T Cell Therapy / Oncology
    Solid TumorsPhase 1ActiveUnited States
  • Novel TargetsUnidentified Autoantigens / Targeted Therapeutics / Autoimmune Disorders
    Crohn's DiseaseDiscoveryActiveUnited States

Tango Therapeutics, Inc.

tangotx.com
4assets

Vaxart, Inc.

vaxart.com
4assets

Xenon Pharmaceuticals Inc. -

xenon-pharma.com
4assets
  • AzetukalnerXEN1101 / Kv7.2/Kv7.3 potassium channel opener / Small Molecule / Neurology and Psychiatry
    Focal Onset Seizures (FOS)Phase 3OngoingGlobalPrimary Generalized Tonic-Clonic Seizures (PGTCS)Phase 3OngoingGlobalMajor Depressive Disorder (MDD)Phase 3OngoingGlobal
  • XEN1120XEN1120 / Kv7 potassium channel opener / Small Molecule / Pain
    PainPhase 1OngoingUnited States
  • XEN1701XEN1701 / NaV1.7 sodium channel modulator / Small Molecule / Pain
    PainPhase 1OngoingUnited States
  • NBI-921355NBI-921355 / NaV1.2 / NaV1.6 sodium channel inhibitor / Small Molecule / Neurology
    EpilepsyPhase 1OngoingGlobal

Acumen Pharmaceuticals

acumenpharm.com
3assets
  • SabirnetugACU193 / toxic soluble amyloid beta oligomers (AβOs) / humanized monoclonal antibody; intravenous formulation / Neurology
    Early Alzheimer's diseasePhase 2ongoing ALTITUDE-ADGlobal
  • SabirnetugACU193 / toxic soluble amyloid beta oligomers (AβOs) / humanized monoclonal antibody; subcutaneous formulation / Neurology
    Early Alzheimer's diseasePhase 1clinical development
  • Enhanced Brain Delivery (EBD™)TfR brain transporter + AβO mAb / blood-brain-barrier-penetrating antibody therapy / Neurology
    Early Alzheimer's diseasePreclinicalpreclinicalPre-clinical Alzheimer's diseasePreclinicalpreclinical

Alkermes PLC

alkermes.com
3assets
  • Sodium oxybate extended-release oral suspensiononce-nightly extended-release oral suspension / Sleep disorders
    Idiopathic hypersomniaPhase 3Evaluating in REVITALYZ
  • Olanzapine and samidorphanLYBALVI / oral small molecule combination / Psychiatry
    Schizophrenia and bipolar I disorder (pediatric)Phase 3Evaluating in ENLIGHTEN-Youth
  • AlixorextonALKS 2680 / orexin 2 receptor / oral small molecule agonist / Sleep disorders
    Narcolepsy type 1Phase 3Brilliance Studies programNarcolepsy type 2Phase 3Brilliance Studies programIdiopathic hypersomniaPhase 2Vibrance-3

Aprea Therapeutics, Inc.

aprea.com
3assets
  • APR-1051APR-1051 / WEE1 kinase / Oral small-molecule WEE1 inhibitor / Oncology
    CCNE1, CCNE2, FBXW7, PPP2R1A advanced solid tumorsPhase 1Monotherapy; potential safety/efficacy clinical data 2Q 2026; complete dose escalation 2Q 2027HPV+ oropharyngeal squamous cell carcinoma; cervical, vaginal or vulvar squamous cell carcinomaPhase 1MonotherapyKRAS G12/13 & TP53 colorectal cancerPhase 1Monotherapy
  • ATRN-119ATRN-119 / Mosipasertib / ATR / Oral macrocyclic small-molecule ATR inhibitor / Oncology
    ATRi synthetic lethal gene alterations in advanced solid tumors (ovarian, CRC, lung)Phase 1/2aMonotherapy; RP2D determinedHematological cancers (AML, MDS)Phase 1/2aMonotherapy; RP2D determined
  • APR-1602APR-1602 / DYRK1 / Oral small-molecule DYRK1 inhibitor / Oncology
    Solid tumors and hematological cancersIND-enablingReady to enter IND-enabling studies; milestone 4Q 2026

Aquestive Therapeutics, Inc.

aquestive.com
3assets
  • AnaphylmAQST-109 / Anaphylm / epinephrine prodrug / dibutepinephrine sublingual film / Allergy/immunology
    Type 1 allergic reactions, including anaphylaxisNDA resubmission plannedclinical/regulatoryUS
  • AQST-108AQST-108 / epinephrine prodrug / epinephrine topical gel / Dermatology
    Multiple potential indicationsPhase 1clinical
  • LibervantLibervant / GABA-A receptor positive allosteric modulator / diazepam buccal film / Neurology
    Acute repetitive seizures / cluster seizuresRegulatory/approvedpipeline-listedUS

Arcutis Biotherapeutics, Inc.

arcutis.com
3assets
  • Topical Roflumilast CreamARQ-151 / ZORYVE / PDE4 / small molecule topical cream / Dermatology
    Plaque psoriasis 0.3% (2-5 yr)sNDA submittedPDUFA June 29, 2026USAtopic dermatitis 0.05% (3-24 mo)Phase 2planned sNDA submission Q2 2026US
  • Topical Roflumilast FoamARQ-154 / ZORYVE / PDE4 / small molecule topical foam / Dermatology
    Vitiligo 0.3%Phase 2acurrently enrolling; advancement decision Q4 2026Hidradenitis suppurativa 0.3%Phase 2acurrently enrolling; advancement decision Q1 2027
  • ARQ-234ARQ-234 / CD200R / fusion protein biologic / Dermatology
    Atopic dermatitisPhase 1a/1benrolling

Artiva Biotherapeutics, Inc.

artivabio.com
3assets
  • AlloNKAB-101 / AlloNK® / CD20 combinations / Allogeneic off-the-shelf non-genetically modified cryopreserved NK cell therapy / Autoimmune disease; oncology
    Refractory rheumatoid arthritisPhase 2aongoing; lead indication; Fast TrackUSSjögren’s diseasePhase 2aongoingUSIdiopathic inflammatory myopathiesPhase 2aongoingUS
  • CAR-NKAB-205 / CD5 / Allogeneic anti-CD5 CAR-NK cell therapy expressing soluble IL-15 / Oncology
    Hematologic malignanciesPreclinicalcollaborator-funded
  • CAR-NKAB-201 / HER2 / Allogeneic anti-HER2 CAR-NK cell therapy expressing soluble IL-15 / Oncology
    Solid tumorsPreclinicalcollaborator-funded; US orphan drug designationUS

aTyr Pharma, Inc.

atyrpharma.com
3assets
  • EfzofitimodNRP2 modulator / tRNA synthetase-derived biologic immunomodulator / Interstitial lung disease
    Pulmonary sarcoidosisPhase 3SSc-ILDPhase 2Other ILD (CTD-ILD; CHP)Phase 1
  • ATYR0101ATYR0101 / LTBP1 modulator / Fibrosis
    FibrosisPreclinical
  • ATYR0750ATYR0750 / FGFR4 modulator / Liver disorders
    Liver disordersPreclinical

Azitra Inc.

azitrainc.com
3assets
  • ATR-12ATR-12 / LEKTI replacement / SPINK5 / Topical live biotherapeutic; engineered S. epidermidis expressing rhLEKTI-D6 / Dermatology
    Netherton syndromePhase 1bclinicalUS
  • ATR-04ATR-04 / IL-36g reduction; S. aureus inhibition / Topical live biotherapeutic; auxotrophic engineered S. epidermidis strain SE484 / Dermatology / oncology supportive care
    EGFR inhibitor-associated rashPhase 1/2clinicalUS
  • ATR-01ATR-01 / Filaggrin / FLG / Topical protein candidate; FLG5-6 with cell-penetrating peptide / Dermatology
    Ichthyosis vulgarisPreclinicalpreclinical

BioAge Labs, Inc.

bioagelabs.com
3assets
  • BGE - 102BGE-102 / NLRP3 / CNS-penetrant NLRP3 inhibitor / Metabolic diseases
    CV riskPhase 1Diabetic macular edemaPhase 1
  • APJ OralAPJ / APJ agonist / Metabolic diseases
    ObesityLead optimization
  • APJ ParenteralAPJ / APJ agonist / Metabolic diseases
    ObesityLead optimization

Barinthus Biotherapeutics PLC

barinthusbio.com
3assets
  • VTP-1000VTP-1000 / gluten antigens; mTOR inhibitor co-delivery / antigen-specific immunotherapy; SNAP Tolerance Platform / Autoimmunity
    Celiac diseasePreclinicalPhase 1 SAD data expected Q4 2025; MAD/challenge data in 2026Worldwide rights
  • VTP-300VTP-300 / HBV antigens / HBV immunotherapeutic; ChAdOx/MVA viral vectors / Infectious diseases
    Chronic hepatitis BPhase 2Pursuing partnership opportunities for advancementWorldwide rights
  • VTP-800/850VTP-800/850 / prostate cancer-associated antigens including PSA, PAP, STEAP1 and 5T4 / prostate cancer immunotherapeutic; ChAdOx/MVA viral vectors / Cancer
    Prostate cancerPhase 1Pursuing partnership opportunities for advancementWorldwide rights

Coherus Oncology, Inc.

coherus.com
3assets
  • LOQTORZI (toripalimab-tpzi)LOQTORZI / PD-1 / Anti-PD-1 monoclonal antibody / Oncology
    1L Nasopharyngeal Carcinoma (combo with chemotherapy)ApprovedApprovedUnited States2L+ Nasopharyngeal Carcinoma (monotherapy)ApprovedApprovedUnited States
  • TagmokitugCHS-114 / CCR8 / Anti-CCR8 monoclonal antibody / Oncology
    4L+ Colorectal Cancer (combo with toripalimab)Phase 22L HNSCC (combo with toripalimab)Phase 12L Gastric Cancer/GEJ/EAC (combo with toripalimab)Phase 1
  • CasdozokitugIL-27 / IL-27 antagonist monoclonal antibody / Oncology
    1L Hepatocellular Carcinoma (combo with toripalimab + bevacizumab)Phase 2

Cingulate Inc.

cingulate.com
3assets
  • CTx-1301CTx-1301 / PTR multi-core modified-release dexmethylphenidate tablet / CNS
    ADHDNDA submittedSubmitted July 31, 2025US
  • CTx-1302CTx-1302 / PTR multi-core modified-release dextroamphetamine tablet / CNS
    ADHDPreclinical/formulationInitial formulation study plannedUS
  • CTx-2103CTx-2103 / 5-HT1A partial agonist / PTR multi-core modified-release buspirone tablet / CNS
    AnxietyPre-INDClinical trials planned 4Q 2026US

Cellectar Biosciences, Inc.

cellectar.com
3assets
  • Iopofosine I 131CLR 131 / tumor cells via phospholipid drug conjugate delivery / PDC radiotherapeutic; iodine-131 beta emitter / Oncology
    Relapsed/refractory Waldenström macroglobulinemiaPhase 2 pivotalcompletedRelapsed/refractory multiple myelomaPhase 2bongoingCNS lymphomaPhase 2bongoing
  • CLR 121125CLR 125 / tumor cell nucleus via phospholipid ether platform / PLE radioconjugate; iodine-125 Auger emitter / Oncology
    Relapsed/refractory triple-negative breast cancerPhase 1bongoing
  • CLR 121225CLR 225 / tumor cells via phospholipid ether platform / PLE radioconjugate; actinium-225 alpha emitter / Oncology
    Pancreatic cancerPhase 1planned

Climb Bio, Inc.

climbbio.com
3assets
  • Budoprutug IVCD19 / monoclonal antibody / immune-mediated diseases
    Primary Membranous NephropathyPhase 2Immune ThrombocytopeniaPhase 1Systemic Lupus ErythematosusPhase 1
  • Budoprutug SCCD19 / monoclonal antibody / immune-mediated diseases
    Autoimmune DiseasePhase 1healthy volunteer trial
  • CLYM116CLYM116 / APRIL / monoclonal antibody / immune-mediated diseases
    IgA NephropathyPhase 1healthy volunteer trial

Centessa Pharmaceuticals PLC

centessa.com
3assets
  • cleminorextonORX750 / OX2R / oral orexin receptor 2 agonist / Sleep-wake disorders
    Narcolepsy Type 1 (NT1)Phase 2aactiveNarcolepsy Type 2 (NT2)Phase 2aactiveIdiopathic Hypersomnia (IH)Phase 2aactive
  • ORX142ORX142 / OX2R / oral orexin receptor 2 agonist / Neurology/neurodegenerative disorders
    Neurological & neurodegenerative disordersPhase 1active
  • ORX489ORX489 / OX2R / oral orexin receptor 2 agonist / Neuropsychiatry
    Neuropsychiatric disordersPreclinicalactive

Context Therapeutics Inc.

contexttherapeutics.com
3assets
  • CTIM-76CTIM-76 / CLDN6 x CD3 / TCE bispecific antibody / Oncology
    recurrent ovarian cancer and other advanced solid tumorsPhase 1ongoingplatinum-resistant ovarian cancerPhase 1FDA Fast TrackUS
  • CT-95CT-95 / MSLN x CD3 / TCE bispecific antibody / Oncology
    advanced solid tumorsPhase 1ongoing
  • CT-202CT-202 / Nectin-4 x CD3 / TCE bispecific antibody / Oncology
    Nectin-4-positive solid tumorsPhase 1planned; HREC approved and TGA CTN acknowledgedAustralia

Corvus Pharmaceuticals, Inc.

corvuspharma.com
3assets
  • SoquelitinibCPI-818 / ITK / Oral small molecule ITK inhibitor / Immune diseases; oncology
    Relapsed/refractory peripheral T-cell lymphoma (PTCL)Registration Phase 3EnrollingUnited StatesModerate-to-severe atopic dermatitisPhase 2Initiated/enrollingUnited StatesModerate-to-severe atopic dermatitisPhase 1b/2Enrolling; partner-ledChina
  • CiforadenantCPI-444 / Adenosine A2A receptor / Oral small molecule checkpoint inhibitor / Oncology
    Cancer indicationsClinical-stageGreater China
  • MupadolimabCPI-006 / CD73 / Anti-CD73 monoclonal antibody / Oncology
    Non-small cell lung cancer (NSCLC)Phase 1/1bPartner-led evaluationChina

CytomX Therapeutics, Inc.

cytomx.com
3assets
  • varsetatug masetecanCX-2051 / Varseta-M / EpCAM / Probody ADC; Topo-1 payload / Oncology
    3L+ metastatic colorectal cancerPhase 1active2L/3L mCRC; Varseta-M + bevacizumabtrials anticipated 2H 20262L mCRC; Varseta-M + bevacizumab + chemotherapytrials anticipated 2H 2026
  • CX-801CX-801 / IFN-alpha 2b / Probody cytokine / Oncology
    Advanced/metastatic melanomaPhase 1active
  • CX-908CX-908 / P-Cadherin x CD3 / Probody T-cell engager / Oncology
    Solid tumorsPreclinicalactive

Cybin Inc.

helus.com
3assets
  • HLP0035-HT2A and other serotonin receptors / Deuterated novel serotonergic agonist; oral / Mental health
    Adjunctive treatment of Major Depressive Disorder (MDD)Phase 3Dosing underway; FDA Breakthrough Therapy Designation
  • HLP004Serotonin receptors / Deuterated novel serotonergic agonist; intramuscular / Mental health
    Generalized Anxiety Disorder (GAD)Phase 2Enrollment complete
  • HLP005CYB005 / Phenethylamines and tryptamines / CNS disorders
    CNS DisordersPreclinical

Day One Biopharmaceuticals, Inc.

dayonebio.com
3assets
  • TovorafenibDAY101 / OJEMDA / RAF / MAPK pathway / Oral small-molecule type II RAF inhibitor / Oncology
    BRAF-altered relapsed pLGGApprovedOJEMDA received FDA accelerated approval; FIREFLY-1 pivotal Phase 2 follow-up ongoing/disclosedU.S.Frontline RAF-altered pLGGPhase 3 / RegistrationalFIREFLY-2 pivotal Phase 3
  • Emiltatug ledadotinEmi-Le / B7-H4 / Antibody-drug conjugate (ADC) / Oncology
    Adenoid cystic carcinoma (ACC), adult and pediatric solid tumorsPhase 1B7-H4-targeted ADC; Phase 1 data anticipated mid-2026 per company investor materials
  • DAY301MTX-13 / CB-002 / PTK7 / Antibody-drug conjugate (ADC) / Oncology
    Adult and pediatric solid tumorsPhase 1Phase 1a data anticipated 2H 2026 per company investor materials

Edesa Biotech, Inc. -

edesabiotech.com
3assets
  • EB06 Anti-CXCL10 Monoclonal antibodyEB06 / CXCL10 / Monoclonal antibody / Dermatological diseases
    VitiligoPhase 2Health Canada CTA approved; IND in processCanadaUnited States
  • EB01 (daniluromer)EB01 / sPLA2 / Topical sPLA2 inhibitor / Dermatological diseases
    Allergic contact dermatitisPhase 2b completedTopline results available
  • ParidiprubartEB05 / TLR4 / Monoclonal antibody / Respiratory diseases
    Acute respiratory distress syndromePhase 3Phase 3 results reported; selected for U.S. government-funded Phase 2 platform studyUnited StatesCanada

Erasca, Inc.

erasca.com
3assets
  • ERAS-0015ERAS-0015 / RAS / Small molecule molecular glue / Oncology
    RAS-mutant solid tumorsPhase 1AURORAS-1; in clinicWorldwide
  • ERAS-4001ERAS-4001 / KRAS / Small molecule / Oncology
    KRAS-mutant solid tumorsPhase 1BOREALIS-1; in clinicWorldwide
  • ERAS-12ERAS-12 / EGFR D2/D3 / Large molecule; bispecific antibody / Oncology
    EGFR and RAS/MAPK altered tumorsWorldwide

Generate Biomedicines, Inc.

generatebiomedicines.com
3assets

Damora Therapeutics, Inc.

damoratx.com
3assets
  • DMR-001DMR-001 / mutant calreticulin (mutCALR) / Fc-null, half-life extended anti-mutCALR monoclonal antibody; subcutaneous biologic / Hematology/oncology
    mutCALR-driven essential thrombocythemiaPreclinical / IND-enablingIND or CTA submission planned mid-2026; clinical proof-of-concept datasets expected beginning mid-2027USex-USmutCALR-driven myelofibrosisPreclinical / IND-enablingIND or CTA submission planned mid-2026; clinical proof-of-concept datasets expected beginning mid-2027USex-US
  • DMR-002DMR-002 / mutant calreticulin (mutCALR) / mutCALR-targeted mechanism; undisclosed / Hematology/oncology
    mutCALR-driven myeloproliferative neoplasmsPreclinical / IND-enablingIND or CTA submission planned 2H 2026USex-US
  • DMR-003DMR-003 / mutant calreticulin (mutCALR) x CD3 / bispecific antibody; T-cell engager / Hematology/oncology
    mutCALR-driven myeloproliferative neoplasmsPreclinical / IND-enablingIND or CTA submission planned 2027USex-US

Genprex, Inc.

genprex.com
3assets
  • quaratusugene ozeplasmid (REQORSA)REQORSA / TUSC2 / non-viral gene therapy / Oncology
    EGFR-mutant NSCLC (osimertinib-resistant)Phase 1/2Phase 2a expansion enrollingUnited Statesextensive-stage SCLC (maintenance with atezolizumab)Phase 1/2expansion enrollingUnited States
  • GPX-002GPX-002 / PDX1 and MafA / AAV gene therapy / Diabetes
    Type 1 DiabetesPreclinicalType 2 DiabetesPreclinical
  • NPRL2 gene therapyNPRL2 / non-viral gene therapy / Oncology
    KRAS/STK11 mutant anti-PD1-resistant NSCLCPreclinical

Cybin Inc.

helus.com
3assets
  • HLP0035-HT2A (and other serotonin receptors) / Deuterated NSA (oral) / Mental Health
    Adjunctive treatment of major depressive disorder (MDD)Phase 3Dosing underway (PARADIGM program); FDA Breakthrough Therapy DesignationUnited StatesEuropeAustralia
  • HLP004Serotonin receptors / Deuterated NSA (intramuscular) / Mental Health
    Generalized anxiety disorder (GAD)Phase 2Positive topline results reportedUnited States
  • HLP005NSA (phenethylamines and tryptamines) / Mental Health
    CNS disordersPreclinical

TuHURA Biosciences, Inc.

tuhurabio.com
3assets
  • IFx-2.0plasmid DNA (innate immune agonist) / Oncology
    Advanced or metastatic Merkel cell carcinoma (first-line, adjunctive to pembrolizumab)Phase 3OngoingUnited StatesMetastatic Merkel cell carcinoma of unknown primary (MCCUP, first-line)Phase 1b/2aOngoingUnited States
  • TBS-2025VISTA / monoclonal antibody / Oncology
    NPM1-mutated relapsed/refractory AML (with menin inhibitor)Phase 1b/2PlannedUnited States
  • DOR bi-specific ADCDelta opioid receptor (DOR) on MDSCs/TAMs / antibody-drug conjugate (ADC) / Oncology
    Acute myeloid leukemia (AML)PreclinicalLead selection

Immunic, Inc.

imux.com
3assets
  • Vidofludimus calciumIMU-838 / DHODH inhibitor and Nurr1 activator / Oral small molecule / Multiple sclerosis
    Relapsing multiple sclerosisPhase 3Ongoing (ENSURE-1/2 fully enrolled; top-line data expected end 2026)GlobalProgressive multiple sclerosisPhase 2Completed (CALLIPER positive; PPMS Phase 3 initiation expected 2026)North AmericaEurope
  • IMU-856IMU-856 / SIRT6 modulator / Oral small molecule / Gastrointestinal diseases
    Celiac diseasePhase 1bCompleted (positive proof-of-concept)Global
  • IMU-381IMU-381 / Nurr1 / Oral small molecule / Autoimmune diseases
    Neurologic, gastrointestinal and other autoimmune diseasesPreclinicalPreclinical

Inventiva S.A.

inventivapharma.com
3assets

Kiniksa Pharmaceuticals International, PLC

kiniksa.com
3assets

Kodiak Sciences Inc.

kodiak.com
3assets
  • tarcocimab tedromerZenkuda / VEGF / Antibody Biopolymer Conjugate (ABC) / Ophthalmology
    Wet Age-Related Macular Degeneration (wet AMD)Diabetic RetinopathyRetinal Vein Occlusion (RVO)
  • KSI-501KSI-501 / IL-6 / VEGF / Bispecific Antibody Biopolymer Conjugate (ABC) / Ophthalmology
    Wet Age-Related Macular Degeneration (wet AMD)Diabetic Macular Edema (DME)
  • KSI-101KSI-101 / IL-6 / VEGF / Bispecific Protein / Ophthalmology
    Macular Edema Secondary to Inflammation (MESI)

Kyverna Therapeutics, Inc.

kyvernatx.com
3assets
  • mivocabtagene autoleucelKYV-101 / CD19 / Autologous CAR T-cell therapy / Autoimmune Diseases
    Stiff Person Syndrome (SPS)Phase 2Completed (Preparing BLA)USGeneralized Myasthenia Gravis (gMG)Phase 3OngoingUSLupus Nephritis (LN)Phase 1/2OngoingUSGermany
  • KYV-102KYV-102 / CD19 / Autologous CAR T-cell therapy / Autoimmune Diseases
    Autoimmune DiseasesPhase 1IND ActiveUS
  • KYV-201KYV-201 / CD19 / Allogeneic CAR T-cell therapy / Autoimmune Diseases
    Autoimmune DiseasesPreclinicalActiveUS

Lexicon Pharmaceuticals, Inc.

lexpharma.com
3assets
  • SotagliflozinINPEFA / ZYNQUISTA / SGLT1 / SGLT2 / Small Molecule / Cardiometabolic
    Heart FailureApprovedactiveUnited StatesHypertrophic Cardiomyopathy (HCM)Phase 3activeGlobalType 1 Diabetes (T1D)RegistrationactiveUnited States
  • PilavapadinLX9211 / AAK1 / Small Molecule / Pain / Neurology
    Diabetic Peripheral Neuropathic Pain (DPNP)Phase 2bactiveUnited StatesPostherpetic Neuralgia (PHN)Phase 2inactiveUnited States
  • LX9851LX9851 / ACSL5 / Small Molecule / Metabolism
    Obesity / Weight ManagementPhase 1activeGlobal

MediWound Ltd.

mediwound.com
3assets

Nuvalent, Inc.

nuvalent.com
3assets

Oculis Holding AG

oculis.com
3assets

Ocular Therapeutix, Inc.

ocutx.com
3assets

Phathom Pharmaceuticals, Inc.

phathompharma.com
3assets

Phio Pharmaceuticals Corp.

phiopharma.com
3assets
  • PH-762PH-762 / PD-1 / INTASYL (sdRNA) / Oncology
    Cutaneous Squamous Cell CarcinomaMelanomaMerkel Cell Carcinoma
  • PH-894PH-894 / BRD4 / INTASYL (sdRNA) / Oncology / Infectious Disease
    Advanced MelanomaMerkel Cell CarcinomaHepatocellular Carcinoma
  • PH-804PH-804 / TIGIT / INTASYL (sdRNA) / Oncology
    Cancer

PolyPid Ltd.

polypid.com
3assets
  • D-PLEX100D-PLEX100 / Bacterial Ribosome / Small Molecule Formulation / Infectious Diseases / Surgical Site Care
    Prevention of surgical site infections (SSIs) following abdominal colorectal surgeryPhase 3OngoingUnited StatesEuropeIsrael
  • PP03APP03A / GLP-1 Receptor / Peptide Formulation / Metabolic Disease
    Obesity and Type 2 DiabetesPreclinicalOngoing
  • PP04APP04A / OncoPLEX / STING / Small Molecule Formulation / Oncology
    Solid TumorsPreclinicalOngoing

Quoin Pharmaceuticals, Ltd.

quoinpharma.com
3assets
  • QRX003QRX003 / Serine protease inhibitor / Small molecule / Dermatology
    Netherton SyndromePhase 3OngoingUnited StatesEuropeMiddle EastPeeling Skin SyndromePhase 2OngoingNew Zealand
  • Topical rapamycinQRX009 / mTOR / Small molecule / Dermatology
    Microcystic Lymphatic MalformationsPreclinicalOngoingGlobalVenous MalformationsPreclinicalOngoingGlobalAngiofibromaPreclinicalOngoingGlobal
  • QRX008QRX008 / VLA-4 / VCAM-1 inhibitor / Small molecule / Dermatology
    SclerodermaPreclinicalOngoingGlobal

Rapport Therapeutics, Inc.

rapportrx.com
3assets
  • RAP-219RAP-219 / TARPγ8 AMPAR / Small molecule / Neurology/Psychiatry
    Focal onset seizuresPrimary generalized tonic-clonic seizuresBipolar mania
  • α6β4 nAChR Agonistα6β4 nAChR / Small molecule / Neurology
    Chronic painMigraine
  • α9α10 nAChR Modulatorα9α10 nAChR / Small molecule / Hearing/Vestibular
    Hearing disordersVestibular disorders

Scinai Immunotherapeutics Ltd.

scinai.com
3assets
  • PC111PC111 / sFasL (soluble Fas Ligand) / Monoclonal Antibody / Immunology / Dermatology
    PemphigusPreclinicalActiveGlobalStevens-Johnson syndrome / toxic epidermal necrolysis (SJS/TEN)PreclinicalActiveGlobal
  • Intradermal IL-17A/F NanoAbIL-17A / IL-17F / VHH Antibody Fragment (NanoAb) / Immunology / Dermatology
    Mild-to-moderate plaque psoriasisPreclinicalActiveGlobal
  • Systemic Bi-Specific IL-17 NanoAbIL-17A / IL-17F and secondary proprietary target / Bi-specific VHH Antibody Fragment (NanoAb) / Immunology / Dermatology
    Moderate-to-severe plaque psoriasisPreclinicalActiveGlobalPsoriatic arthritisPreclinicalActiveGlobal

Sagimet Biosciences Inc. - Series A

sagimet.com
3assets
  • DenifanstatASC40 / FASN / Small molecule / Metabolic disease, Dermatology, Oncology
    MASH (F2/F3)Phase 3ActiveModerate to severe acnePhase 3ActiveRecurrent glioblastoma (GBM)Phase 3Active
  • TVB-3567FASN / Small molecule / Dermatology, Oncology
    AcnePhase 1ActiveSolid tumorsPreclinicalActive
  • FASNi TopicalFASN / Small molecule / Dermatology
    AcnePreclinicalActive

Supernus Pharmaceuticals, Inc.

supernus.com
3assets

Tarsus Pharmaceuticals, Inc.

tarsusrx.com
3assets

Tectonic Therapeutic, Inc.

tectonictx.com
3assets
  • TX45TX-000045 / RXFP1 / Fc-relaxin fusion protein / Cardiopulmonary
    PH-HFpEF (Group 2 Pulmonary Hypertension)PH-HFrEF (Group 2 Pulmonary Hypertension)PH-ILD (Group 3 Pulmonary Hypertension)
  • TX2100TX002100 / GPCR / Biotherapeutic / GPCR Antagonist / Hematology / Rare Diseases
    Hereditary Hemorrhagic Telangiectasia (HHT)
  • Fibrosis ProgramGPCR / Bispecific GPCR Antagonist / Fibrosis
    Fibrosis

Tg Therapeutics, Inc.

tgtherapeutics.com
3assets
  • ublituximabTG-1101 / BRIUMVI / CD20 / Monoclonal Antibody / Autoimmune Diseases
    Relapsing Multiple Sclerosis (RMS)
  • ublituximab subcutaneousCD20 / Monoclonal Antibody / Autoimmune Diseases
    Relapsing Multiple Sclerosis (RMS)
  • azercabtagene zapreleucelazer-cel / CD19 / Allogeneic CAR-T Cell Therapy / Autoimmune Diseases
    Progressive Multiple Sclerosis (PMS)Autoimmune Diseases

Tiziana Life Sciences Ltd. -

tizianalifesciences.com
3assets
  • Intranasal ForalumabTZLS-401 / CD3 epsilon / Monoclonal Antibody / Neurology/Immunology
    Non-Active Secondary Progressive Multiple Sclerosis (SPMS)Multiple System Atrophy (MSA)Mild Alzheimer's Disease
  • Anti IL-6R mAbTZLS-501 / IL-6R / Monoclonal Antibody / Immunology
  • MilciclibTZLS-201 / CDKs / Small Molecule / Oncology
    NSCLC with pan KRAS-positive mutations

Tenaya Therapeutics, Inc.

tenayatherapeutics.com
3assets
  • TN-201TN-201 / MYBPC3 / AAV-based gene therapy / Cardiovascular
    MYBPC3-associated Hypertrophic Cardiomyopathy (HCM)
  • TN-401TN-401 / PKP2 / AAV9-based gene therapy / Cardiovascular
    PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
  • TN-301TN-301 / HDAC6 / Small Molecule / Cardiometabolic / Neuromuscular
    Heart Failure with preserved Ejection Fraction (HFpEF)Duchenne Muscular Dystrophy (DMD)

Travere Therapeutics, Inc.

travere.com
3assets

Tyra Biosciences, Inc.

tyra.bio
3assets
  • dabogratinibTYRA-300 / FGFR3 / Small molecule / Oncology / Skeletal Dysplasia
    Metastatic Urothelial Cancer (mUC)Non-Muscle Invasive Bladder Cancer (IR NMIBC)Achondroplasia
  • TYRA-200TYRA-200 / FGFR1/2/3 / Small molecule / Oncology
    Intrahepatic CholangiocarcinomaAdvanced Solid Tumors
  • TYRA-430TYRA-430 / FGFR4/3 / Small molecule / Oncology
    Hepatocellular Carcinoma (HCC)Advanced Solid Tumors

Vera Therapeutics, Inc.

veratx.com
3assets
  • AtaciceptVT-001 / BAFF and APRIL / Recombinant Fusion Protein / Immunology / Nephrology
    IgA Nephropathy (IgAN)BLA SubmittedPriority Review (PDUFA July 2026)USGlobalLupus NephritisPhase 2OngoingGlobalFocal Segmental Glomerulosclerosis (FSGS)Phase 2OngoingGlobal
  • MAU868MAU868 / BK Virus / Monoclonal Antibody / Infectious Disease / Transplantation
    BK Viremia in Kidney Transplant RecipientsPhase 2Evaluating for future developmentGlobal
  • VT-109VT-109 / BAFF and APRIL / Fusion Protein / Immunology
    B Cell Mediated DiseasesPreclinicalActiveGlobal

Verastem, Inc.

verastem.com
3assets
  • Avutometinib and DefactinibVS-6766 / VS-6063 / AVMAPKI FAKZYNJA CO-PACK / RAF/MEK and FAK / Small Molecule / Oncology
    KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)ApprovedActiveUnited StatesRecurrent low-grade serous ovarian cancer (LGSOC)Phase 3ActiveGlobalMetastatic Pancreatic Cancer (PDAC)Phase 2ActiveGlobal
  • AvutometinibVS-6766 / RAF/MEK / Small Molecule / Oncology
    BRAF, KRAS and NRAS-Mutant Solid TumorsPhase 1ActiveGlobal
  • VS-7375GFH375 / KRAS G12D / Small Molecule / Oncology
    KRAS G12D-Mutated Solid TumorsPhase 1/Phase 2ActiveUnited StatesChina

Zura Bio Limited

zurabio.com
3assets
  • tibulizumabZB-106 / IL-17A and BAFF / Bispecific dual-antagonist antibody / Autoimmune and Inflammatory Diseases
    Hidradenitis suppurativaSystemic sclerosis
  • crebankitugZB-168 / IL-7Rα / Monoclonal antibody / Autoimmune and Inflammatory Diseases
    Autoimmune and inflammatory conditions
  • torudokimabZB-880 / IL-33 / Monoclonal antibody / Autoimmune and Inflammatory Diseases
    Autoimmune and inflammatory conditions

Absci Corporation

absci.com
2assets
  • ABS-201ABS-201 / PRLR / anti-PRLR antibody / Cytokine biology
    Androgenetic alopeciaPhase 1/2aactiveEndometriosisPhase 1active
  • ABS-202ABS-202 / PRLR / anti-PRLR antibody / Immunology & inflammation
    Undisclosed I&I indicationCandidateactive

Arbutus Biopharma

arbutusbio.com
2assets
  • ImdusiranAB-729; IDR / HBV viral antigens/HBV RNA transcripts / GalNAc-conjugated RNAi therapeutic; subcutaneous / Infectious disease; hepatitis B
    Chronic hepatitis B (cHBV); IM-PROVE I: imdusiran + peg-IFNα-2a + NAPhase 2aclinicalChronic hepatitis B (cHBV); IM-PROVE II: imdusiran + nivolumab + NA + VTP-300Phase 2aclinical
  • AB-101AB-101 / PD-L1 / Oral PD-L1 inhibitor / Infectious disease; hepatitis B
    Chronic hepatitis B (cHBV); AB-101-001 in healthy subjects and cHBV patientsPhase 1a/1bclinical; Part 3 dosing in cHBV patients

Adicet Bio

adicetbio.com
2assets
  • Prulacabtagene leucelprula-cel; formerly ADI-001 / CD20 / Allogeneic gamma delta CAR T cell therapy / Autoimmune diseases
    Lupus nephritisPhase 1activeSystemic lupus erythematosusPhase 1activeSystemic sclerosisPhase 1active
  • ADI-212ADI-212 / PSMA / Next-generation gene-edited and armored allogeneic CAR gamma delta T cell therapy / Oncology
    Metastatic castration-resistant prostate cancerPreclinicalactive

Aktis Oncology, Inc.

aktisoncology.com
2assets
  • AKY-1189AKY-1189 / Nectin-4 / miniprotein radioconjugate; 225Ac targeted alpha radiopharmaceutical / Oncology
    Nectin-4 expressing solid tumorsPhase 1bongoingUSLocally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer, cervical cancer, head and neck cancerPhase 1bongoingUS
  • AKY-2519AKY-2519 / B7-H3 (CD276) / miniprotein radioconjugate; 225Ac targeted alpha radiopharmaceutical; 64Cu imaging pair / Oncology
    Metastatic castration-resistant prostate cancerPhase 1bongoingUSB7-H3 expressing solid tumors, including lung and colorectal cancerPhase 1bplannedUS

Akari Therapeutics PLC

akaritx.com
2assets
  • AKTX-101AKTX-101 / TROP2 / Antibody-drug conjugate with PH1 RNA splicing modulator payload / Oncology
    TROP2-expressing solid tumorsPreclinical / IND-enablingPhase 1 planned late 2026 or early 2027
  • AKTX-102AKTX-102 / CEACAM5 / Antibody-drug conjugate with PH1 RNA splicing modulator payload / Oncology
    CEACAM5-expressing solid tumorsDiscoveryAdvancing

ALX Oncology Holdings Inc.

alxoncology.com
2assets
  • evorpaceptALX148 / CD47 / CD47-targeted investigational therapy / Oncology
    ENHERTU-experienced HER2-positive breast cancer; with trastuzumab + chemotherapy (ASPEN-Breast)Phase 2FPI mid-year 2025Relapsed or refractory multiple myeloma; with SARCLISA + dexamethasonePhase 1FPI Q3 2024, currently enrolling2L/3L advanced HER2-overexpressing gastric/GEJ cancer; with trastuzumab, CYRAMZA + paclitaxel (ASPEN-06)Phase 2Completed, established POC, seeking partner ex-US
  • ALX2004ALX2004 / EGFR / ADC / Oncology
    EGFR-expressing solid tumorsPhase 1FPI mid-year 2025

Alzamend Neuro, Inc.

alzamend.com
2assets
  • AL001AL001 / LISPRO / ionic cocrystal of lithium, proline and salicylate / Neurology/Psychiatry
    Alzheimer's diseasePhase 2clinical developmentUSBipolar disorderPhase 2clinical developmentUSMajor depressive disorderPhase 2anticipated initiation in 2026US
  • ALZN002ALZN002 / E22W / beta-amyloid / autologous mutant-peptide sensitized dendritic-cell therapeutic vaccine / Neurology
    Mild to moderate dementia of the Alzheimer's typePhase 1/2apaused in 2024; expected to resume by mid-2026US

AnaptysBio, Inc.

anaptysbio.com
2assets
  • dostarlimabJemperli / PD-1 / antibody / Oncology
    Endometrial cancerApprovedapproveddMMR pan tumorsApprovedapprovedRectal cancerbeing studied
  • imsidolimabIL-36R / antibody / Dermatology/Inflammation
    Generalized pustular psoriasisBLA submitted/acceptedFDA target action date December 12, 2026US

AN2 Therapeutics, Inc.

an2therapeutics.com
2assets
  • EpetraboroleLeucyl-tRNA synthetase / oral boron-based small molecule antibiotic / Hematology; Infectious disease
    Phlebotomy-dependent polycythemia veraPhase 2proof-of-concept studyMycobacterium abscessus complex lung diseasePhase 2IND cleared; investigator-initiated studyU.S.MelioidosisPhase 2 planneddevelopment
  • AN2-502998AN2-502998 / CPSF3 / oral boron-based benzoxaborole small molecule / Infectious disease
    Chagas diseasePhase 1first-in-human trial underway

Ardelyx, Inc.

ardelyx.com
2assets
  • tenapanorIBSRELA / small molecule / Gastrointestinal
    Chronic Idiopathic Constipation (CIC)Phase III
  • RDX10531RDX10531 / NHE3 / small molecule / Multiple therapeutic areas
    UndisclosedPreclinical

Atea Pharmaceuticals, Inc.

ateapharma.com
2assets
  • bemnifosbuvir/ruzasvir fixed-dose combinationBEM/RZR / HCV NS5B polymerase; HCV NS5A / oral small-molecule antiviral regimen / viral hepatitis
    hepatitis C virus (HCV) infectionPhase 3activeglobal
  • AT-587AT-587 / hepatitis E virus (HEV) / oral nucleotide analog / viral hepatitis
    chronic hepatitis E virus (HEV) infection in immunocompromised patientspreclinicalPhase 1 anticipated mid-2026

Bausch Health Companies Inc.

bauschhealth.com
2assets
  • LarsucosterolDUR-928 / Epigenetic modulator / Hepatology
    Alcohol-associated hepatitisPhase 3Registrational Phase 3 initiated in early 2026US
  • AmiselimodMT-1303 / S1P receptor / Oral S1P modulator / Gastroenterology
    Mild-to-moderate ulcerative colitisPhase 2Internal review of opportunity ongoing

Biovie Inc.

bioviepharma.com
2assets
  • BezisterimNE3107 / ERK; NF-κB; TNF-α / oral small molecule anti-inflammatory insulin sensitizer / neurology; neurodegenerative disease
    Alzheimer’s diseasePhase 2/3 conductedclinicalParkinson’s diseasePhase 2SUNRISE-PD last patient evaluation completed; topline targeted Q3 2026USLong COVID neurological symptomsPhase 2ADDRESS-LC enrollingUS
  • BIV201BIV201 / continuous infusion formulation of terlipressin / liver disease
    ascites due to liver cirrhosisPhase 3 planningclinical developmentUSrefractory ascitesPhase 2b completedclinical developmentUS

BioLineRx Ltd.

biolinerx.com
2assets
  • GLIX1GLIX1 / DNA damage response; restores TET2 activity / oral small molecule / Oncology
    GlioblastomaPhase 1Other cancersPreclinical
  • MotixafortideBL-8040 / APHEXDA / CXCR4 / peptide CXCR4 inhibitor / Oncology; rare diseases; stem cell mobilization
    Pancreatic cancerPhase 2Stem cell mobilization in multiple myelomaApprovedApproved in US; bridging study in AsiaUSAsiaSickle cell disease stem cell mobilizationPhase 1/2

Belite Bio, Inc.

belitebio.com
2assets
  • TinlarebantLBS-008 / RBP4 / Oral small-molecule RBP4 antagonist / Ophthalmology / retinal degenerative diseases
    Stargardt disease type 1 (STGD1)Phase 3; Phase 2/3Ongoing clinical evaluation; rolling NDA submission initiated in U.S.U.S.EuropeJapanGeographic atrophy (GA) in advanced dry AMDPhase 3Ongoing clinical evaluation
  • LBS-009LBS-009 / RBP4 / Oral small-molecule RBP4 antagonist / Metabolic disease / liver disease
    Non-alcoholic fatty liver disease (NAFLD)PreclinicalPreclinical developmentNon-alcoholic steatohepatitis (NASH)PreclinicalPreclinical developmentType 2 diabetes (T2D)PreclinicalPreclinical development

Biomea Fusion, Inc.

biomeafusion.com
2assets
  • IcovamenibMenin / Oral small molecule menin inhibitor / Diabetes; metabolic disease
    Type 1 diabetes mellitusPhase IIOngoingInsulin-deficient type 2 diabetesPhase IIEnrollingType 2 diabetes uncontrolled with a GLP-1 RA-based therapyPhase IIEnrolling
  • BMF-650BMF-650 / GLP-1 receptor / Oral small molecule GLP-1 receptor agonist / Obesity; metabolic disease
    Healthy participants / obesity and metabolic disordersPhase IOngoing

Candel Therapeutics, Inc.

candeltx.com
2assets
  • CAN-2409CAN-2409 / Adenovirus platform viral immunotherapy / Oncology
    Borderline resectable pancreatic adenocarcinomaPhase IIFast Track Designation (FDA); enrollment paused subject to additional fundingUSNSCLC + PD-1/PD-(L)1Phase IIFast Track Designation (FDA)USLocalized intermediate/high-risk prostate cancerBLA ReadinessFast Track Designation (FDA); Special Protocol Assessment (FDA)US
  • CAN-3110CAN-3110 / HSV platform viral immunotherapy / Oncology
    Recurrent high-grade glioma / recurrent GBMPhase IFast Track Designation (FDA)US

Celldex Therapeutics, Inc.

celldex.com
2assets
  • BarzolvolimabCDX-0159 / KIT / KIT antagonist mAb / Immunology/inflammation
    Chronic spontaneous urticariaPhase 3ongoingCold urticariaPhase 3ongoingSymptomatic dermographismPhase 3ongoing
  • CDX-622CDX-622 / TSLP; SCF / Bispecific antibody / Immunology/inflammation
    Healthy volunteersPhase 1ongoingAsthma proof of mechanismPhase 1ongoing

Compass Pathways PLC

compasspathways.com
2assets
  • COMP360COMP360 / synthetic psilocybin treatment / Mental health
    Treatment-resistant depressionPhase 3NDA rolling submission underwayUSUKPost-traumatic stress disorderPhase 2b/3IND accepted; trial initiation enabledUSAnorexia nervosaPhase 2
  • Prodrug programmeprodrug programme

Corbus Pharmaceuticals Holdings, Inc.

corbuspharma.com
2assets
  • CRB-701CRB-701 / Nectin-4 / antibody-drug conjugate / Oncology
    Nectin-4 expressing solid tumorsPhase 3 pendingCSPC China: Phase 3 in cervical cancer milestoneChinaHNSCCPhase 1 in progressDose optimization; FDA Fast Track DesignationUSEuropeCervical cancerPhase 1 in progressDose optimization; FDA Fast Track DesignationUSEurope
  • CRB-913CRB-913 / CB1R / peripherally restricted oral CB1 inverse agonist / Obesity/metabolic disease
    Obesity and related conditionsPhase 1 in progress12-week dose-range study in obesity planned mid-2026

Caribou Biosciences, Inc.

cariboubio.com
2assets
  • Vispacabtagene regedleucelCB-010 / vispa-cel / CD19 / Allogeneic anti-CD19 CAR-T cell therapy; PD-1 knockout / Hematologic malignancies
    Relapsed or refractory B cell non-Hodgkin lymphomaPhase 1Ongoing
  • CB-011CB-011 / BCMA / Allogeneic anti-BCMA CAR-T cell therapy; B2M knockout and B2M–HLA-E insertion / Hematologic malignancies
    Relapsed or refractory multiple myelomaPhase 1Ongoing

DBV Technologies S.A.

dbv-technologies.com
2assets
  • VIASKIN® Peanut PatchDBV712 / Peanut allergen extract / Epicutaneous immunotherapy patch; drug-device combination / Food allergy
    Peanut allergy; children 4–7 years oldPhase 3 completed; BLA submission anticipated 1H 2026Primary endpoint met in VITESSE Phase 3USPeanut allergy; toddlers 1–3 years oldPhase 3 / BLA submission anticipated 2H 2026Accelerated Approval pathway; COMFORT Toddlers safety trial ongoingUSPeanut allergy; children 1–7 years oldMAA planningEMA guidance received for circular patchEU
  • VIASKIN® Milk PatchDBV135 / Milk allergen / Epicutaneous immunotherapy patch; drug-device combination / Food allergy / immunology
    Cow’s milk allergy; ages 2–17 yearsPhase 2MILES study referencedMilk-induced eosinophilic esophagitis; ages 4–17 yearsPhase 2SMILEE study referenced

Definium Therapeutics, Inc. -

definiumtx.com
2assets
  • DT120 ODTDT120 / serotonin receptors / Orally disintegrating tablet formulation of lysergide (LSD) D-tartrate / Psychiatry / brain health
    Generalized anxiety disorderPhase 3Two Phase 3 registrational trials ongoing/evaluating efficacy and safetyU.S.EuropeMajor depressive disorderPhase 3Emerge Phase 3 ongoing; Ascend Phase 3 expected to initiate mid-2026U.S.
  • DT402DT402 / serotonergic system / R-enantiomer of MDMA (R(-)-MDMA) / Neurodevelopmental disorders
    Autism spectrum disorderPhase 2aPhase 2a study initiated after completion of Phase 1 single-ascending dose study

DiaMedica Therapeutics Inc.

diamedica.com
2assets
  • DM199 (rinvecalinase alfa)DM199 / KLK1 / Recombinant human tissue kallikrein-1 protein (rhKLK1) / Neurological
    Acute Ischemic StrokePhase 2/3ReMEDy2 Study; in progress
  • DM199 (rinvecalinase alfa)DM199 / KLK1 / Recombinant human tissue kallikrein-1 protein (rhKLK1) / Pregnancy Complications
    PreeclampsiaPhase 2Part 1A Dose-Selection / Part 1B Expansion Cohort; in progressPreeclampsiaPhase 2Parts 2 & 3 Expected Management Study; in progressFetal Growth RestrictionPhase 2Part 3 Fetal Growth Restriction; in progress

Dianthus Therapeutics, Inc.

dianthustx.com
2assets
  • ClaseprubartDNTH103 / active C1s / long-acting monoclonal antibody / autoimmune / neuromuscular disorders
    Generalized Myasthenia Gravis (gMG)Phase IIPhase 2 data reported; Phase 3 trial planned mid-2026Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Phase IIICAPTIVATE; interim responder analysis completed and GO decision announced Q1 2026Multifocal Motor Neuropathy (MMN)Phase IITop-line Phase 2 data expected 2H 2026
  • DNTH212DNTH212 / LBL-047 / BDCA2 and BAFF/APRIL / extended half-life bifunctional fusion protein / autoimmune disorders
    Systemic lupus erythematosus (SLE)Phase ITwo-part Phase 1 study in China ongoing; healthy-volunteer results expected 2H 2026China

Precision BioSciences, Inc.

precisionbiosciences.com
2assets
  • PBGENE-HBVPBGENE-HBV / HBV cccDNA and integrated HBV DNA / in vivo ARCUS gene editing therapy / Infectious disease
    Chronic hepatitis BPhase 1/2aELIMINATE-B trial ongoingGlobalUnited States
  • PBGENE-DMDPBGENE-DMD / Dystrophin gene exons 45-55 region / in vivo ARCUS gene editing therapy / gene excision / Neuromuscular disease
    Duchenne muscular dystrophyPhase 1/2FUNCTION-DMD study; first clinical trial site activated and enrollment begun per company IR overviewUnited States

Emergent BioSolutions Inc.

emergentbiosolutions.com
2assets

Enliven Therapeutics, Inc.

enliventherapeutics.com
2assets

Eupraxia Pharmaceuticals Inc.

eupraxiapharma.com
2assets
  • EP-104GIEP-104GI / long-acting controlled-release fluticasone propionate formulation; intra-esophageal injection / Gastrointestinal / inflammatory disease
    Eosinophilic esophagitis (EoE)Phase 1b/2Ongoing
  • EP-104IAREP-104IAR / long-acting controlled-release fluticasone propionate formulation; intra-articular injection / Pain / osteoarthritis
    Pain due to knee osteoarthritisPhase 2Completed

Evommune, Inc.

evommune.com
2assets
  • EVO756EVO756 / MRGPRX2 / Oral small-molecule antagonist / Chronic inflammatory diseases
    Chronic Spontaneous UrticariaPhase 2Atopic DermatitisPhase 2MigrainePhase 1
  • EVO301EVO301 / IL-18 / Long-acting injectable SAFA-IL-18BP fusion protein / Chronic inflammatory diseases
    Atopic DermatitisPhase 2Ulcerative ColitisPhase 1

EyePoint, Inc.

eyepoint.bio
2assets
  • DURAVYUEYP-1901 / DURAVYU / VEGF receptors; JAK1; PDGFR / vorolanib intravitreal insert; tyrosine kinase inhibitor in Durasert E bioerodible sustained-release insert / Retinal diseases
    Wet age-related macular degenerationPhase 3Trial underway; LUGANO and LUCIA fully enrolled; LUGANO topline data expected mid-2026, LUCIA to closely followGlobalDiabetic macular edemaPhase 3COMO and CAPRI pivotal trials underway; enrollment completion expected 3Q 2026Global
  • Undisclosed candidatesDurasert E programs / Retinal diseases
    Retinal diseasesPre-clinicalIn progress

Fulgent Genetics, Inc.

ir.fulgentgenetics.com
2assets
  • FID-007FID-007 / Cytotoxic / Nanoencapsulated paclitaxel / Oncology
    Head and Neck (H&N) cancer, 2nd linePhase 2Ongoing; interim findings expected June 2026Ampullary or ICI resistant cancerGo/no-go based on H&N study
  • FID-022FID-022 / Cytotoxic / Oncology
    Colon cancerPhase 1Ongoing; dosing for 3rd dose level ongoingPancreatic cancerPhase 1Ongoing; dosing for 3rd dose level ongoingOvarian cancerPhase 1Ongoing; dosing for 3rd dose level ongoing

Fractyl Health, Inc.

ir.fractyl.com
2assets
  • RevitaDuodenal mucosa / Endoscopic hydrothermal ablation / Obesity
    Weight maintenance post-GLP-1 in obesityPivotalREMAIN-1 randomization completed; 6-mo topline expected early Q4 2026US
  • RejuvaRJVA-001 / Pancreatic beta cells / AAV9 gene therapy / Type 2 Diabetes
    Type 2 diabetesPhase 1/2CTA submitted; FIH dosing & preliminary data expected H2 2026 pending approvalEUAustralia

Immunovant, Inc.

immunovant.com
2assets

KalVista Pharmaceuticals, Inc.

kalvista.com
2assets

Kyntra Bio, Inc.

kyntrabio.com
2assets
  • FG-3246FOR46 / CD46 / Antibody-Drug Conjugate (ADC) / Oncology
    Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 2OngoingUnited States
  • roxadustatFG-4592 / HIF-PH / Small Molecule / Rare Disease
    Anemia associated with lower-risk myelodysplastic syndromes (LR-MDS)Phase 3PlannedUnited States

Liquidia Corporation

liquidia.com
2assets
  • YUTREPIAtreprostinil inhalation powder
  • L606liposomal treprostinil inhalation suspension

Lyell Immunopharma, Inc.

lyell.com
2assets
  • rondecabtagene autoleucelLYL314 / Ronde-cel / CD19 / CD20 / CAR T-cell therapy / Oncology
    Relapsed/Refractory Large B-cell Lymphoma (LBCL) - 2LPhase 3ActiveUSRelapsed/Refractory Large B-cell Lymphoma (LBCL) - 3L+PivotalActiveUS
  • LYL273LYL273 / GCC (Guanylyl Cyclase-C) / CD19 / CAR T-cell therapy / Oncology
    Refractory Metastatic Colorectal Cancer (mCRC)Phase 1ActiveUS

Maze Therapeutics, Inc.

mazetx.com
2assets

Marker Therapeutics, Inc.

markertherapeutics.com
2assets
  • MT-601neldaleucel / Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1 / T Cell Therapy (MAR-T cell) / Oncology
    LymphomaPancreatic Cancer
  • MT-401-OTSzelenoleucel / Multi-Tumor Associated Antigens / Allogeneic T Cell Therapy / Oncology
    Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)

NewAmsterdam Pharma Company N.V.

newamsterdampharma.com
2assets
  • ObicetrapibAMG-899 / CETP / Small Molecule / Cardiometabolic
    Primary hypercholesterolemia (HeFH and non-familial or mixed dyslipidemia)RegistrationOngoingGlobalEuropeAtherosclerotic Cardiovascular Disease (ASCVD)Phase 3OngoingGlobal
  • Obicetrapib / Ezetimibe FDCCETP / NPC1L1 / Small Molecule / Cardiometabolic
    Primary hypercholesterolemia (HeFH and non-familial or mixed dyslipidemia)RegistrationOngoingGlobalEurope

NuCana PLC

nucana.com
2assets
  • NUC-3373NUC-3373 / Thymidylate Synthase (TS) / Nucleoside analog (ProTide) / Oncology
    Advanced solid tumorsColorectal cancerLung cancer
  • NUC-7738NUC-7738 / RNA polyadenylation / Nucleoside analog (ProTide) / Oncology
    Advanced solid tumorsMelanoma

Neurogene Inc.

neurogene.com
2assets

NRx Pharmaceuticals, Inc.

nrxpharma.com
2assets
  • NRX-101NMDA and 5-HT2A receptors / Small molecule / Central Nervous System
    Bipolar Depression with Acute Suicidal Ideation and Behavior (ASIB)Phase 3ActiveUnited StatesBipolar Depression with Subacute Suicidal Ideation and Behavior (SSIB)Phase 2/Phase 3ActiveUnited StatesDepression and Suicidality (in association with Transcranial Magnetic Stimulation)Phase 3ActiveUnited States
  • NRX-100KETAFREE / NMDA receptor / Small molecule / Central Nervous System
    Acute Suicidal Depression / Suicidal Ideation in DepressionRegistrationActiveUnited States

NextCure, Inc.

nextcure.com
2assets
  • SIM0505SIM0505 / CDH6 / Antibody-drug conjugate (ADC) / Oncology
    Solid tumorsOvarian cancerLung cancer
  • LNCB74LNCB74 / B7-H4 / Antibody-drug conjugate (ADC) / Oncology
    Solid tumorsBreast cancerOvarian cancer

OnKure Therapeutics, Inc.

onkuretherapeutics.com
2assets

Olema Pharmaceuticals, Inc.

olema.com
2assets

ORIC Pharmaceuticals, Inc.

oricpharma.com
2assets
  • RinzimetostatORIC-944 / PRC2 (EED subunit) / Small molecule / Oncology
    Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 1bActiveGlobal
  • EnozertinibORIC-114 / EGFR / HER2 (exon 20 and PACC/atypical mutations) / Small molecule / Oncology
    Non-Small Cell Lung Cancer (NSCLC)Phase 1bActiveUnited StatesAustraliaCanadaHong KongMalaysiaPolandSouth KoreaSpainTaiwanUnited Kingdom

Oruka Therapeutics, Inc.

orukatx.com
2assets
  • ORKA-001ORKA-001 / IL-23p19 / Monoclonal Antibody / Dermatology / Immunology
    Plaque PsoriasisPhase 2ActiveUnited States
  • ORKA-002ORKA-002 / IL-17A/F / Monoclonal Antibody / Dermatology / Immunology
    Plaque PsoriasisPhase 1ActiveUnited StatesHidradenitis SuppurativaPhase 1ActiveUnited States

Puma Biotechnology Inc.

pumabiotechnology.com
2assets

Plus Therapeutics, Inc.

plustherapeutics.com
2assets

Pyxis Oncology, Inc.

pyxisoncology.com
2assets
  • Micvotabart pelidotinMICVO, PYX-201 / EDB+FN / Antibody-Drug Conjugate (ADC) / Oncology
    Solid TumorsRecurrent and Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
  • PYX-106PYX-106 / Siglec-15 / Monoclonal Antibody (mAb) / Oncology
    Solid Tumors

Quantum Biopharma Ltd.

quantumbiopharma.com
2assets
  • Lucid-MSLucid-21-302 / Demyelination / Small Molecule (NCE) / Neurology
    Multiple Sclerosis
  • FSD202FSD-202 / Mast cell activation / Small Molecule / Immunology / Pain
    Idiopathic Mast Cell Activation Syndrome (MCAS)

Q32 Bio Inc.

q32bio.com
2assets

Replimune Group, Inc.

replimune.com
2assets
  • vusolimogene oderparepvecRP1 / HSV-1 oncolytic virus encoding GALV-GP R-protein and GM-CSF / Oncolytic Virus / Oncology
    Advanced MelanomaPhase 3Complete Response LetterUSNon-melanoma Skin Cancers (CSCC, MCC, BCC, Angiosarcoma)Phase 2ActiveUS
  • RP2RP2 / Oncolytic virus / Oncolytic Virus / Oncology
    Metastatic Uveal MelanomaPhase 2ActiveUSHepatocellular CarcinomaPhase 2ActiveUS

Relmada Therapeutics, Inc.

relmada.com
2assets

RenovoRx, Inc.

renovorx.com
2assets

Rezolute, Inc.

rezolutebio.com
2assets
  • ErsodetugRZ358 / Insulin receptor / Monoclonal antibody / Endocrinology/Rare Diseases
    Congenital hyperinsulinismTumor hyperinsulinism
  • RZ402RZ402 / Plasma kallikrein / Small molecule / Ophthalmology
    Diabetic macular edema (DME)Diabetic retinopathy (DR)

Sana Biotechnology, Inc.

sana.com
2assets
  • SC451SC451 / Pancreatic islet cell replacement / HIP-modified stem-cell-derived pancreatic islet cell therapy / Endocrinology / Autoimmune
    Type 1 diabetes
  • SG293SG293 / B-cells / In vivo CAR-T therapy / Oncology / Autoimmune
    B-cell cancersB-cell mediated autoimmune diseases

SpyGlass Pharma, Inc.

spyglasspharma.com
2assets

Sellas Life Sciences Group, Inc.

sellaslifesciences.com
2assets

Syndax Pharmaceuticals, Inc.

syndax.com
2assets
  • RevumenibSNDX-5613 / Revuforj / Menin / Small Molecule / Oncology
    R/R acute leukemia with KMT2A translocation (AUGMENT-101-2A)ApprovedApprovedUSR/R NPM1m AML (AUGMENT-101-2C)ApprovedApprovedUSFrontline unfit NPM1m and KMT2Ar acute leukemias (EVOLVE-2)Phase 3ActiveUS
  • AxatilimabSNDX-6352 / Niktimvo / CSF-1R / Monoclonal Antibody / Oncology / Immunology
    Refractory Chronic GVHD (AGAVE-201)ApprovedApprovedUSFrontline Chronic GVHD (corticosteroids combination)Phase 3ActiveUSFrontline Chronic GVHD (ruxolitinib combination)Phase 2ActiveUS

Spruce Biosciences, Inc.

sprucebio.com
2assets
  • Tralesinidase AlfaTA-ERT / Alpha-N-acetylglucosaminidase (NAGLU) / Enzyme Replacement Therapy / Neurology / Rare Disease
    Mucopolysaccharidosis Type IIIB (MPS IIIB) / Sanfilippo Syndrome Type BPhase 3ActiveGlobal
  • TildacerfontCorticotropin-releasing factor type-1 (CRF1) receptor / Small Molecule / Neurology / Psychiatry
    Major Depressive Disorder (MDD)Phase 2ActiveEurope

Stoke Therapeutics, Inc.

stoketherapeutics.com
2assets

Shattuck Labs, Inc.

shattucklabs.com
2assets
  • SL-325SL-325 / DR3 (Death Receptor 3) / Monoclonal Antibody / Inflammatory and Immune-Mediated Diseases
    Inflammatory Bowel Disease (IBD)Crohn's DiseaseUlcerative Colitis
  • SL-425SL-425 / DR3 (Death Receptor 3) / Monoclonal Antibody / Inflammatory and Immune-Mediated Diseases
    Inflammatory Bowel Disease (IBD)

Protara Therapeutics, Inc.

protaratx.com
2assets
  • TARA-002TARA-002 / Broad immunopotentiator / Cell therapy / Oncology / Rare Diseases
    Non-Muscle Invasive Bladder Cancer (NMIBC)Phase 2ActiveUnited StatesLymphatic Malformations (LMs)Phase 2ActiveUnited States
  • IV Choline ChloridePhospholipid substrate replacement / Small molecule / Intravenous replacement therapy / Rare Diseases
    Patients dependent on long-term parenteral support (PS) / Choline deficiencyPhase 3ActiveUnited States

Theravance Biopharma, Inc.

theravance.com
2assets

Tenax Therapeutics, Inc.

tenaxthera.com
2assets

Unicycive Therapeutics, Inc.

unicycive.com
2assets
  • Oxylanthanum CarbonateOLC / Renazorb / Phosphate / Small molecule / Nephrology
    Hyperphosphatemia in chronic kidney disease (CKD) on dialysisNDAResubmittedUnited States
  • UNI-494UNI-494 / KATP channel / Nitric oxide (nicorandil prodrug) / Small molecule / Nephrology
    Acute Kidney Injury (AKI)Phase 1CompletedUnited KingdomUnited StatesPrevention of Delayed Graft Function (DGF) in kidney transplant patientsPhase 1ActiveUnited States

Veru Inc.

verupharma.com
2assets

Verrica Pharmaceuticals Inc.

verrica.com
2assets
  • cantharidinVP-102 / YCANTH / Unknown / Small Molecule / Dermatology
    Molluscum ContagiosumApprovedActiveCommon WartsPhase 3ActiveExternal Genital WartsPhase 2Active
  • VP-315VP-315 / Oncolytic peptide / Peptide / Dermatologic Oncology
    Basal Cell CarcinomaPhase 2ActiveSquamous Cell CarcinomaPhase 1/2Active

ZyVersa Therapeutics, Inc.

zyversa.com
2assets
  • VAR 200Cholesterol Efflux Pathway (ABCA1 and ABCG1) / Cholesterol Efflux Mediator / Renal Diseases
    Focal Segmental Glomerulosclerosis (FSGS)Phase 2activeUnited StatesDiabetic Kidney Disease (DKD)Phase 2activeUnited StatesAlport SyndromePreclinicalactiveUnited States
  • IC 100Inflammasome ASC / Monoclonal Antibody / Inflammatory Diseases
    Cardiometabolic Conditions (Obesity-associated)PreclinicalactiveUnited StatesParkinson's DiseasePreclinicalactiveUnited StatesOrphan Renal DiseasesPreclinicalactiveUnited States

Abivax S.A.

abivax.com
1assets
  • ObefazimodABX464 / microRNA-124 (miR-124) enhancer / Oral small molecule / Inflammatory diseases
    Moderately to severely active ulcerative colitisPhase 3ABTECT induction data readout completed July 2025; maintenance data expected Q2 2026Crohn's diseasePhase 2bENHANCE-CD initiated; 12-week induction data expected Q4 2026Moderately to severely active ulcerative colitis, combination therapyPreclinicalEvaluation of obefazimod combined with other agents; decision on combination agent expected in 2026

Achieve Life Sciences

achievelifesciences.com
1assets
  • cytisiniclinenicotinic acetylcholine receptor / plant-derived alkaloid; partial agonist / nicotine dependence
    smoking cessation in adultsNDA accepted; PDUFA June 20, 2026under FDA reviewUSe-cigarette or vaping cessationPhase 2 completed; Phase 3 design agreedBreakthrough Therapy designation; FDA CNPVUS

Actuate Therapeutics, Inc.

actuatetherapeutics.com
1assets
  • elraglusib9-ING-41 / GSK-3β / small molecule inhibitor / Oncology
    1L metastatic pancreatic cancer with gemcitabine/nab-paclitaxelPhase 2ongoing; Actuate-1801 Part 3BUSEUCanada1L metastatic pancreatic cancer with gemcitabine/nab-paclitaxelPhase 3in planning; registration trial contingent on funding1L metastatic pancreatic cancer with FOLFIRINOXPhase 2investigator-initiated; closed to enrollment

ADC Therapeutics S.A.

adctherapeutics.com
1assets
  • loncastuximab tesirine-lpylZYNLONTA / CD19 / antibody-drug conjugate / Oncology
    LOTIS-2 in 3L+ r/r DLBCLPhase 3/ConfirmatoryLOTIS-5 in r/r DLBCLPhase 3/ConfirmatoryLOTIS-7 in r/r B-NHLPhase 1b

AEON Biopharma, Inc.

aeonbiopharma.com
1assets
  • ABP-450ABP-450 / Acetylcholine release / 900 kDa botulinum toxin type A complex; biosimilar biologic / Neurology; neuromuscular disorders
    Episodic migrainePhase 2United StatesChronic migrainePhase 2United StatesCervical dystoniaPhase 2United States

AIM ImmunoTech Inc.

aimimmuno.com
1assets
  • Ampligenrintatolimod / Ampligen / TLR3 / dsRNA immuno-modulator / Oncology; immune disorders; viral diseases
    Metastatic pancreatic ductal adenocarcinomaPhase 1b/2DURIPANCAdvanced, recurrent ovarian cancerPhase 2Refractory melanomaPhase 2

Altimmune, Inc.

ir.altimmune.com
1assets
  • pemvidutideALT-801 / glucagon and GLP-1 receptors / balanced 1:1 glucagon/GLP-1 dual receptor agonist peptide / serious liver diseases
    Metabolic dysfunction-associated steatohepatitis (MASH)Phase 3 plannedPERFORMA Phase 3 initiation planned 2H 2026; FDA Fast Track and Breakthrough Therapy DesignationsU.S.Alcohol use disorder (AUD)Phase 2RECLAIM Phase 2 enrollment complete; topline data expected 3Q 2026; FDA Fast Track DesignationU.S.Alcohol-associated liver disease (ALD)Phase 2RESTORE Phase 2 enrolling; enrollment completion expected 3Q 2026U.S.

Atossa Therapeutics, Inc.

atossatherapeutics.com
1assets
  • (Z)-endoxifenestrogen receptor / oral small molecule SERM/D / Oncology; rare diseases
    Metastatic breast cancerPhase 1/2FDA pathway discussions; IND study may proceed reportedUSAdjuvant breast cancerFDA pathway discussionsUSNeoadjuvant breast cancerongoing clinical studies: EVANGELINE and I-SPY2

Aura Biosciences, Inc.

aurabiosciences.com
1assets
  • belzupacap sarotalocanbel-sar; AU-011 / tumor-associated GAGs/HSPGs / virus-like drug conjugate (VDC) / oncology
    early-stage choroidal melanomaPhase 3ongoing CoMpass trialUSEuropemetastases to the choroidPhase 2ongoingUSEuropecancers of the ocular surfacePhase 1initiating proof-of-concept trialUSEurope

Avalo Therapeutics, Inc.

avalotx.com
1assets
  • AbdakibartAVTX-009 / IL-1β / Humanized IgG4 monoclonal antibody / Immune-mediated inflammatory diseases
    Hidradenitis suppurativaPhase 2 completed; registrational Phase 3 plannedPositive topline Phase 2 LOTUS results reported May 5, 2026

Bicara Therapeutics Inc.

ir.bicara.com
1assets
  • ficerafusp alfaBCA101 / EGFR/TGF-β / bifunctional EGFR-directed monoclonal antibody bound to a human TGF-β ligand trap / Oncology
    1L recurrent/metastatic HPV-negative head and neck squamous cell carcinomaPhase 2/3ongoinggloballate-line MSS RAS wild-type metastatic colorectal cancerPhase 1/1benrolling expansion cohort

Biofrontera Inc.

biofrontera-us.com
1assets
  • AMELUZ®AMELUZ® / aminolevulinic acid HCl topical gel; photodynamic therapy / Dermatology
    New formulationMild to moderate actinic keratosis: face & scalp larger treatment area (3 tubes)Superficial basal cell carcinomaPhase 3database lockedUS

Benitec Biopharma Inc.

benitec.com
1assets
  • BB-301BB-301 / PABPN1 / AAV ddRNAi silence-and-replace genetic medicine / Rare disease; neuromuscular
    Oculopharyngeal muscular dystrophy (OPMD)Phase 1b/2aClinical-stage

Cabaletta Bio, Inc.

cabalettabio.com
1assets
  • rese-celCABA-201 / CD19 / Autologous fully human 4-1BB CD19-CAR T cell therapy / Autoimmune disease
    DermatomyositisRegistrationalrecruitingUSAntisynthetase syndromeRegistrationalrecruitingUSImmune-mediated necrotizing myopathyPhase 1/2recruitingUS

Celcuity Inc.

celcuity.com
1assets
  • gedatolisibPI3K/AKT/mTOR pathway; class I PI3K isoforms; mTORC1/2 / small molecule kinase inhibitor / Oncology
    HR+/HER2- advanced breast cancer, 2nd linePhase 3; NDA accepted/Priority Review for PIK3CA WTVIKTORIA-1 reported results; PDUFA July 17, 2026GlobalHR+/HER2- locally advanced or metastatic breast cancer, 1st linePhase 3VIKTORIA-2 ongoingNorth AmericaEuropeLatin AmericaAsiaMetastatic castration-resistant prostate cancerPhase 1/2CELC-G-201 ongoingUnited StatesEurope

Cg Oncology, Inc.

cgoncology.com
1assets
  • Cretostimogene grenadenorepvecCG0070 / Intravesical oncolytic immunotherapy / Bladder cancer
    High-risk BCG-unresponsive NMIBC with CIS with or without high-grade Ta/T1 disease; monotherapy; BOND-003 Cohort CPhase 3Enrollment complete; data presented at AUA 2025High-risk BCG-unresponsive NMIBC with high-grade Ta/T1; monotherapy; BOND-003 Cohort PPhase 2Enrollment complete; topline results at SUO 2025Intermediate-risk NMIBC; monotherapy; PIVOT-006Phase 3Enrollment complete; topline data expected 1H 2026

Connect Biopharma Holdings Limited

connectbiopharma.com
1assets
  • RademikibartCBP-201 / IL-4Rα / human monoclonal antibody / Inflammatory diseases
    Acute exacerbations of COPDPhase 2ongoingGlobalAcute exacerbations of asthmaPhase 2ongoingGlobalChronic asthmaongoing studies by SimcereChina

Cardiff Oncology, Inc.

cardiffoncology.com
1assets
  • onvansertibPLK1 / oral small-molecule PLK1 inhibitor / Oncology
    1L RAS-mutated metastatic colorectal cancerPhase 2randomized CRDF-0042L KRAS-mutated metastatic colorectal cancerPhase 1b/2completed2L metastatic colorectal cancerPhase 3ONSEMBLE/CRDF-003 randomized

Editas Medicine, Inc.

editasmedicine.com
1assets
  • EDIT-401EDIT-401 / LDLR / in vivo CRISPR gene editing medicine / Cardiovascular diseases
    Hyperlipidemia / LDL-C reductionPreclinicalIND/CTA submission planned by mid-2026; human proof-of-concept targeted by end of 2026Atherosclerotic cardiovascular disease (ASCVD)PreclinicalIn developmentHeterozygous familial hypercholesterolemia (HeFH)PreclinicalFirst-in-human trial planned in 2026

Forte Biosciences, Inc.

fortebiorx.com
1assets
  • FB102FB102 / CD122 / monoclonal antibody / Autoimmune and autoimmune-related diseases
    Celiac diseasePhase 2Topline results expected in 2026; U.S. arm included after FDA IND approvalUnited StatesVitiligoPhase 1bTopline results expected in 1H 2026Alopecia areataPhase 1bData readout expected in 2026

Fennec Pharmaceuticals Inc.

investors.fennecpharma.com
1assets
  • PEDMARKPEDMARK / PEDMARQSI / cisplatin-induced ototoxicity / small molecule; sodium thiosulfate injection / oncology supportive care
    Reduce risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumorsApprovedMarketed; ongoing evidence generationUSEUUKCisplatin-induced ototoxicity in pediatric and AYA patients with non-metastatic solid tumorsPhase 2/3Positive topline results; pursuing registrationJapanOtoprotection in adults receiving cisplatin chemotherapy, including head and neck and testicular cancersPhase I/IIInvestigator-sponsored study initiatedUS

Fulcrum Therapeutics, Inc.

fulcrumtx.com
1assets
  • pociredirFTX-6058 / EED / PRC2; HbF induction / oral small molecule / Hematology
    Sickle cell diseasePhase 1bactive; potential registration-enabling trial planned for 2H 2026United States

Geron Corporation

geron.com
1assets
  • imetelstatRYTELO / telomerase / telomerase inhibitor / Hematologic malignancies
    JAK inhibitor relapsed/refractory myelofibrosisPhase 3open for screening and enrollmentfrontline myelofibrosis, intermediate-1/intermediate-2/high-risk; combination with ruxolitinibPhase 1open for screening and enrollmentrelapsed/refractory/intolerant acute myeloid leukemia or high-risk MDS after hypomethylating agentsPhase 2investigator-led; open for screening and enrollment

Greenwich LifeSciences, Inc.

greenwichlifesciences.com
1assets
  • GLSI-100GP2 + GM-CSF / HER2/neu / peptide immunotherapy vaccine / Oncology
    Prevention of recurrence in HER2/neu-positive breast cancer after surgery and trastuzumab-based therapyPhase 3Ongoing; Fast Track designated; FLAMINGO-01United StatesEurope

Genelux Corporation

genelux.com
1assets
  • Olvi-Vecolvimulogene nanivacirepvec / Oncolytic vaccinia virus immunotherapy / Oncology
    Platinum-resistant/refractory ovarian cancer (PRROC)Phase 3Enrolling; topline data expected 2H 2026 (OnPrime/GOG-3076; NCT05281471)USNon-small cell lung cancer (NSCLC), advanced/metastatic recurrentPhase 2Dose-escalation ongoing (VIRO-25; NCT06463665); systemic IV Olvi-Vec + platinum-doublet + ICI vs docetaxelUSSmall cell lung cancer (SCLC), platinum-relapsed/refractoryPhase 1b/2Dose selection ongoing (OLVI-VEC-SCLC-202; NCT07136285); Olvi-Vec + platinum + etoposideChinaUS

Immix Biopharma, Inc.

immixbio.com
1assets
  • NXC-201NXC-201 / BCMA / sterically-optimized autologous CAR-T / Hematology
    Relapsed/refractory AL AmyloidosisPhase 2BLA-enabling; enrollment completedUSIsraelSelect immune-mediated diseasesExpanding

Kalaris Therapeutics, Inc.

kalaristx.com
1assets
  • TH103TH103 / VEGF / HSPG / Recombinant fusion protein / Retinal Diseases
    Neovascular age-related macular degeneration (nAMD)Phase 1b/2OngoingDiabetic eye diseasePlannedPlannedRetinal vein occlusionPlannedPlanned

Lb Pharmaceuticals Inc.

lbpharma.us
1assets

Longeveron Inc.

longeveron.com
1assets

Lixte Biotechnology Holdings, Inc.

lixte.com
1assets
  • LB-100LB-100 / Protein Phosphatase 2A (PP2A) / Small Molecule / Oncology
    Ovarian Clear Cell CarcinomaPhase 2ActiveUnited StatesMetastatic Colon CancerPhase 1bActiveGlobalAdvanced Soft Tissue SarcomaPhase 1/2PausedEurope

Larimar Therapeutics, Inc.

larimartx.com
1assets

MoonLake Immunotherapeutics

moonlaketx.com
1assets
  • SonelokimabM1095 / IL-17A and IL-17F (tri-specific Nanobody) / Nanobody (VHH) / Immunology (Dermatology and Rheumatology)
    Hidradenitis Suppurativa (HS)Phase 3OngoingGlobalAdolescent Hidradenitis Suppurativa (Teen HS)Phase 3OngoingGlobalPsoriatic Arthritis (PsA)Phase 3OngoingGlobal

Mineralys Therapeutics, Inc.

mineralystx.com
1assets
  • lorundrostatMLS-101 / Aldosterone synthase (CYP11B2) / Small molecule / Cardio-Renal-Metabolic Syndrome
    Uncontrolled and treatment-resistant hypertensionPhase 3CompletedGlobalObstructive Sleep Apnea (OSA) and HypertensionPhase 2OngoingGlobalChronic Kidney Disease (CKD)Phase 2OngoingGlobal

Nanobiotix S.A. - ADSs

nanobiotix.com
1assets
  • NBTXR3JNJ-1900 / Hensify / Tumor cell (Radioenhancer) / Functionalized hafnium oxide (HfO2) nanoparticles / Oncology
    Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) - Platinum-ineligiblePhase 3OngoingGlobalRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)Phase 1/2OngoingGlobalSoft Tissue SarcomaApprovedMarketedEurope

Nkarta, Inc.

nkartatx.com
1assets
  • NKX019NKX019 / CD19 / Allogeneic CAR-NK Cell Therapy / Autoimmune Diseases
    Lupus NephritisSystemic SclerosisInflammatory Myopathy

NovoCure Limited

novocure.com
1assets
  • Tumor Treating FieldsTTFields / Optune Gio, Optune Lua, Optune Pax, Optune Mya / Mitotic spindle / Electric Field Therapy / Oncology
    Glioblastoma (GBM)ApprovedMarketedUnited StatesEuropeJapanGlioblastoma (GBM) - Earlier use (TRIDENT)Phase 3ActiveGlobalNon-Small Cell Lung Cancer (NSCLC)ApprovedMarketedUnited StatesJapanEurope

Palisade Bio, Inc.

palisadebio.com
1assets
  • PALI-2108PALI-2108 / PDE4 / Small Molecule Prodrug / Gastroenterology
    Ulcerative Colitis (UC)Phase 2ActiveGlobalCrohn's Disease (CD)Phase 2ActiveGlobal

Pharvaris N.V.

pharvaris.com
1assets

PMV Pharmaceuticals, Inc.

pmvpharma.com
1assets

ProKidney Corp.

prokidney.com
1assets

Skye Bioscience, Inc.

skyebioscience.com
1assets
  • NimacimabCB1 / Monoclonal antibody / Metabolic Diseases
    ObesityPhase 2activeUnited States

Soleno Therapeutics Inc.

soleno.life
1assets

Summit Therapeutics Inc.

smmttx.com
1assets

ARS Pharmaceuticals, Inc.

ars-pharma.com
1assets
  • Epinephrine nasal sprayARS-1 / neffy / Alpha and beta-adrenergic receptors / Small Molecule / Immunology & Allergy
    Type I Allergic Reactions (including Anaphylaxis)ApprovedActiveUnited StatesEuropean UnionCanadaUrticaria (Acute Flares of Chronic Spontaneous Urticaria)Phase 2ActiveUnited States

Savara, Inc.

savarapharma.com
1assets
  • MolgramostimMolbreevi / GM-CSF receptor / Recombinant protein (rhGM-CSF) / Respiratory / Rare Lung Diseases
    Autoimmune Pulmonary Alveolar Proteinosis (aPAP)SubmissionRegulatory SubmissionUSUKEU

Terns Pharmaceuticals, Inc.

ternspharma.com
1assets
  • TERN-701TERN-701 / BCR::ABL1 / Small Molecule / Oncology
    Chronic Myeloid Leukemia (CML)Phase 1/2ActiveGlobal

Tourmaline Bio, Inc.

tourmalinebio.com
1assets
  • pacibekitugTOUR006 / IL-6 / Monoclonal Antibody / Cardiovascular and Immune Diseases
    Atherosclerotic Cardiovascular Disease (ASCVD)Phase 2ActiveGlobalThyroid Eye Disease (TED)Phase 2ActiveGlobalAbdominal Aortic Aneurysm (AAA)Phase 2PlannedGlobal

Taysha Gene Therapies, Inc.

tayshagtx.com
1assets

2seventy bio, Inc.

2seventybio.com
1assets
  • idecabtagene vicleucelAbecma / BCMA / CAR-T Cell Therapy / Oncology
    Relapsed or refractory multiple myelomaMarketedApprovedUSEU

Upstream Bio, Inc.

upstreambio.com
1assets
  • verekitugUPB-101 / TSLP receptor (TSLPR) / Monoclonal antibody / Respiratory/Inflammatory Diseases
    Severe AsthmaChronic rhinosinusitis with nasal polyps (CRSwNP)Chronic obstructive pulmonary disease (COPD)

Vor Biopharma Inc.

vorbio.com
1assets
  • TelitaciceptRC18 / Taiai / BAFF/APRIL (BLyS/APRIL) / Recombinant Fusion Protein / Autoimmune Diseases
    Generalized Myasthenia Gravis (gMG)Phase 3Active / Approved in ChinaGlobalChinaSystemic Lupus Erythematosus (SLE)Phase 3Active / Approved in ChinaGlobalChinaRheumatoid Arthritis (RA)Phase 3Active / Approved in ChinaGlobalChina

vTv Therapeutics Inc.

vtvtherapeutics.com
1assets
  • CadisegliatinTTP399 / Liver-selective glucokinase / Small molecule / Endocrinology
    Type 1 Diabetes (adjunctive to insulin)Phase 3OngoingUnited StatesType 2 DiabetesPhase 2PlannedUnited Arab Emirates

Zentalis Pharmaceuticals, Inc.

zentalis.com
1assets
  • AzenosertibZN-c3 / WEE1 / Small Molecule / Oncology
    Cyclin E1-positive platinum-resistant ovarian cancer (PROC)Advanced solid tumors

Adaptive Biotechnologies Corporation

No pipeline
sec.gov
0assets

No disclosed assets in this row.